Keep Abreast of Innovation

Paths

Keeping up with the latest advancements in medicine can seem daunting at times. It’s not enough to practice the latest, but you also need to have an eye on the horizon.

This learning path is one way to help you keep up with innovations and provide the practical guidance on how to effectively apply these advancements to group and laboratory practices.

Be sure to review our full agenda for more ways to help you keep abreast of innovation.

I find the topics to be very useful. They offer me ideas I can directly use in my daily practice. It is not just theoretical or cases I am never going to see, but cases I see every day and I really appreciate that.

Michelle M. Hebert, MD, FCAP

Educational Courses

Events

Networking

Educational Courses

Stay Abreast of Ongoing Diagnostic Learning and Advances in Pathology

Path	Category
Path	Category	List	Code	Title	CreditHours	Description	SpeakersList	Pass Type	FilterByDate	Date	Start Time	DateStartTime	End Time	Time	DateTime	Competency	Faculty 1	Faculty 2	Faculty 3	Faculty 4	Details	F1ID	F2ID	F3ID	F4ID
Keep Abreast of Innovation	KAI2	Sunday, October 9, 2022, 7:30 AM - 8:30 AM \| In-Person How Many Pathologists do We Really Have in the US? Threats, Opportunities, and Implications for Future Practice A2261 \| Advocacy \| 0.00 CME Credit	A2261	How Many Pathologists do We Really Have in the US? Threats, Opportunities, and Implications for Future Practice	0.00 CME Credit	Recent research by the CAP and the Association of American Medical Colleges (AAMC) has revealed, in its Physician Specialty Data Reports – one of the most important data sources on physician supply in the US, that the AAMC has been dramatically undercounting the number of pathologists. This undercount has been increasing each year since 2004 and reached nearly 40% in 2020. In this session, faculty will discuss the research that led to this important finding; show how the discovery of this shortfall changes what we know about the rate of growth in pathologist supply, the distribution of pathologists by whether or not they specialize, and the gender, age distribution, and racial/ethnic mix of pathologists. The faculty will also discuss what the data tells us about threats, opportunities, and implications for the future of pathology practice.	W. Stephen Black-Schaffer, MD, FCAP Kalisha A. Hill, MD, MBA, FCAP Thomas M. Wheeler, MD, FCAP Kalisha A. Hill, MD, MBA, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	08:30 AM		Sunday, October 9, 2022, 7:30 AM - 8:30 AM	Advocacy	W. Stephen Black-Schaffer, MD, FCAP	Kalisha A. Hill, MD, MBA, FCAP	Thomas M. Wheeler, MD, FCAP	Kalisha A. Hill, MD, MBA, FCAP		w. -fer	kal-ill	tho-ler	kal-ill
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 3:30 PM \| In-Person CPT Coding…You Can’t Practice Without It! Why Pathologists Need to Understand CPT Coding A2276 \| Dermatopathology \| 0.00 CME Credit	A2276	CPT Coding…You Can’t Practice Without It! Why Pathologists Need to Understand CPT Coding	0.00 CME Credit	Is understanding current procedural terminology (CPT) coding and its impact on your practice making your head spin? Get an insider expert’s insights and examples of current CPT coding practices and relevant payment policies for pathology and laboratory medicine. This workshop is designed to provide a comprehensive review of concepts as well as recent and anticipated changes in CPT coding that pathologists use to report their services. Faculty also will address your CPT coding problems and direct you to additional resources for answering your coding and related payment policy questions.	Mark S. Synovec, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	03:30 PM		Sunday, October 9, 2022, 2:30 PM - 3:30 PM	Dermatopathology	Mark S. Synovec, MD, FCAP					mar-vec
		Monday, October 10, 2022, 11:00 AM - 12:30 PM \| In-Person, Virtual Advocacy Town Hall A2260 \| Advocacy \| 0.00 CME Credit	A2260	Advocacy Town Hall	0.00 CME Credit	This session will provide members with a better understanding of the scope of our advocacy agenda. The CAP continually works to expand the public policy impact of pathology at the federal and state levels of government by engaging members in advocacy efforts. By combining grassroots advocacy with events like our annual policy meeting, town hall meetings, and other forums, engaged members help strengthen the profession's influence with policymakers.	Kalisha A. Hill, MD, MBA, FCAP Jonathan L. Myles, MD, FCAP Emily Volk, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	11:00 AM	10/10/2022 11:00 AM	12:30 PM		Monday, October 10, 2022, 11:00 AM - 12:30 PM	Advocacy	Kalisha A. Hill, MD, MBA, FCAP	Jonathan L. Myles, MD, FCAP	Emily Volk, MD, FCAP			kal-ill	jon-les	emi-olk
Get a Strong Start	GASS2	Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Current Payment Policy Challenges in Pathology Practice A2275 \| Advocacy \| 0.00 CME Credit	A2275	Current Payment Policy Challenges in Pathology Practice	0.00 CME Credit	Pathologists are often challenged by payment policy-related issues regarding the services they provide. It is important that pathologists better understand how Advocacy seeks to influence payment policies, why changes in reimbursement occur, and how to adapt within their practices. Workshop participants will gain knowledge and insight into the engagement opportunities available. The faculty will present payment policy information associated with Physician Fee Schedule valuation (that can influence payment policy development), Clinical Laboratory Fee Schedule Payment Reform (PAMA), emerging payment models, and other payment challenges and possible solutions.	Jonathan L. Myles, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Advocacy	Jonathan L. Myles, MD, FCAP					jon-les
Get a Strong Start	GASS2	Tuesday, October 11, 2022, 7:30 AM - 9:30 AM \| In-Person Negative Autopsies: When Routine Gross Dissection and Histology Come Up Empty H2144 \| Autopsy \| 2.00 CME Credits	H2144	Negative Autopsies: When Routine Gross Dissection and Histology Come Up Empty	2.00 CME Credits	Join us for discussion and hands-on dissection with esteemed faculty Dr. Fyfe-Kirschner and Dr. Sanchez to discover and practice vitreous humor extraction for electrolytes and toxicology and cardiac conduction system dissection. In most hospital autopsies, a routine dissection and histology will provide a cause of death. However, no cause of death will be apparent in some cases, a dissatisfying result for the pathologist, clinician, and family. This hands-on lab will provide a practical guide to approaching such cases. Interactive case presentations will be used to illustrate some of the most common causes of death in the absence of gross and histologic findings and when to suspect those diagnoses. The lecture will also cover the special testing needed to make those diagnoses, including special dissections, clinical laboratory testing, toxicology, genetic testing, and molecular testing. The participants will have the opportunity to practice several unique techniques, including a dissection of the conducting system and aspiration of the vitreous humor. The session will provide participants with a rational, cost-effective approach to diagnosing fewer common causes of a sudden unexpected death at all stages of their careers.	Meagan Chambers, MD Billie S. Fyfe-Kirschner, MD, FCAP Dylan V. Miller, MD, FCAP Harold Sanchez, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:30 AM		Tuesday, October 11, 2022, 7:30 AM - 9:30 AM	Autopsy	Meagan Chambers, MD	Billie S. Fyfe-Kirschner, MD, FCAP	Dylan V. Miller, MD, FCAP	Harold Sanchez, MD, FCAP		mea-ers	bil-ner	dyl-ler	har-hez
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Cutting Edge Pathology: Emerging Disease and Advancement of Molecular Research in Autopsy Investigation (On-Demand) S2041 \| Autopsy \| 1.50 CME Credits	S2041	Cutting Edge Pathology: Emerging Disease and Advancement of Molecular Research in Autopsy Investigation (On-Demand)	1.50 CME Credits	Autopsies remain the gold standard for cause of death; their use to educate clinicians can reduce discrepancies by half. Furthermore, large institutions benefit from rapid autopsies because of unlimited access to tissue and the opportunity to capture the biology of both normal and diseased states. Studies using autopsy tissue have greatly advanced our understanding of neurodevelopment, neurodegeneration, the pathophysiology of emerging infectious agents, and the molecular alterations responsible for disease recurrence and progression after treatment. Next-generation genomics brings new opportunities in pathology to utilize fresh tissue for the molecular advancement of neoplastic and infectious human disease, with unprecedented single cell resolution. This course will provide simple tips on how to educate administrators/clinicians on the value of autopsies. The faculty will highlight the advantages of rapid autopsies for the pathologist and the researcher, using specific case examples including their own experience gained during the COVID-19 pandemic. Finally, they will provide practical guidelines on techniques for fresh tissue procurement, including collection, single-cell dissociation, and culture.	Clare H. Bryce, MD, FCAP Nadejda Tsankova, MD, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Autopsy	Clare H. Bryce, MD, FCAP	Nadejda Tsankova, MD, PhD				cla-yce	nad-ova
		Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Book Club: Deceit and Denial: The Deadly Politics of Industrial Pollution N2204 \| Book Club \| 0.00 CME Credit	N2204	Book Club: Deceit and Denial: The Deadly Politics of Industrial Pollution	0.00 CME Credit	CAP22 will feature a book club, which offers discussion of literature topics related to pathology in an intimate, small group setting. Join Julie W. Lemmon, MD, FCAP as she facilitates a conversation about Deceit and Denial The Deadly Politics of Industrial Pollution by authors Gerald Markowitz and David Rosner. Through the lens of public health, historians Gerald Markowitz and David Rosner explore how the lead and plastic industries prioritized progress and profit at the expense of human health and the environment. They use primary sources to illustrate the complicity of industry executives, government agencies, scientists, and lobbyists in perpetuating harm against workers and the environment. Key Talking Points: •How did industries promote the benefits of lead to consumers •What were the catalysts that resulted in diminished use of lead in household products •How can relationships between industries and governments compound detrimental environmental effects that disproportionately affect marginalized communities •What types of advocacy efforts were successful at promoting improvements in safety and environmental reforms Attendees will read the book prior to the session and then engage in discussion.	Julie W. Lemmon, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Book Club	Julie W. Lemmon, MD, FCAP					jul-mon
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Roadmap Towards the “Perfect” Pathology Report of Post Neoadjuvant Therapy Breast Resections M2116 \| Breast Pathology \| 1.00 CME Credit	M2116	Roadmap Towards the “Perfect” Pathology Report of Post Neoadjuvant Therapy Breast Resections	1.00 CME Credit	Neoadjuvant therapy (NAT) is used increasingly in breast carcinoma (BC). The faculty will discuss the indications of NAT and important chemotherapeutic regimes. Additionally, faculty will cover the recommendations of the Breast International Group-North American Breast Cancer Group (BIG-NABCG) for assessing post-NAT resection specimens with emphasis on: the proper sampling of post-NAT specimens, the estimation of tumor size and residual cancer burden, post-therapy staging issues, and essential components to include in the pathology report.	Uma Krishnamurti, MD, PhD, FCAP Marina Mosunjac, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Breast Pathology	Uma Krishnamurti, MD, PhD, FCAP	Marina Mosunjac, MD, FCAP				uma-rti	mar-jac
Grow as a Leader	GAL2	Sunday, October 9, 2022, 9:00 AM - 5:00 PM \| In-Person Difficult Diagnoses in Breast Pathology and Management Challenges L2299 \| Breast Pathology \| 5.00 CME Credits	L2299	Difficult Diagnoses in Breast Pathology and Management Challenges	5.00 CME Credits	Join our team of renowned experts on Sunday, October 9, for an immersive review of challenging entities commonly seen in breast pathology practice. Faculty will help you navigate these diagnostic challenges using didactic, case-based, and interactive approaches to facilitate learning. This full-day course will cover an abundance of topics that will assist in your daily practice. Topics include diagnostic features and clinical significance of intraductal proliferative breast lesions, developing strategies for reporting papillary carcinomas, and recognizing the importance of radiologic correlation with nonneoplastic lesions. Fibroepithelial lesions will be highlighted by summarizing diagnostic features and clinical significance regarding the challenges for a core needle biopsy specimen. Attendees will learn to evaluate diagnostic criteria and clinical importance of classic and variant forms of LCIS, and classify morphologic and molecular features of special subtypes of invasive breast cancer. The faculty will also explore the role and limitations of prognostic and predictive markers, ER, PR, HER2, newer molecular assays, and PD-L1 testing in patients with breast cancer. This advanced course also includes interactive exercises illustrating the diagnostic and clinical features and management implications of several uncommon breast lesions. It will target general surgical pathologists with practical experience in diagnosing and signing out breast pathology.	Kimberly Allison, MD, FCAP Laura C. Collins, MD, FCAP Hannah L. Gilmore, MD Hannah Y. Wen, MD, PhD	In-Person	Sunday, October 9, 2022	10/09/2022	09:00 AM	10/09/2022 09:00 AM	05:00 PM		Sunday, October 9, 2022, 9:00 AM - 5:00 PM	Breast Pathology	Kimberly Allison, MD, FCAP	Laura C. Collins, MD, FCAP	Hannah L. Gilmore, MD	Hannah Y. Wen, MD, PhD		kim-son	lau-ins	han-ore	han-wen
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Hereditary Breast Cancers: What do We Know Beyond BRCA? S2149 \| Breast Pathology \| 1.50 CME Credits	S2149	Hereditary Breast Cancers: What do We Know Beyond BRCA?	1.50 CME Credits	Advances in the application of next-generation sequencing have led to the identification of germline mutations in cancer susceptibility genes other than BRCA1/2 that significantly increase risk for developing breast cancer. Guidelines for genetic testing in breast cancer patients are limited by the tedious process of extracting family history and are notorious at missing a significant proportion of patients otherwise suitable for testing. We, as pathologists, could ease this process by identifying distinct histomorphologic and immunophenotypic features associated with these mutations. Furthermore, recent approval of PARP-inhibitors for treatment of breast cancer patients with BRCA1/2 mutations has substantiated a need for embracing new tests for predicting response to therapy. The faculty will highlight the most up-to-date information related to hereditary breast cancers and will emphasize the important role the pathologist plays in their identification. This course is suitable for general surgical pathologists, subspecialized pathologists, and pathologists in training.	Rania Bakkar MD, FCAP Anupma Nayak, MD	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Breast Pathology	Rania Bakkar MD, FCAP	Anupma Nayak, MD				ran- md	anu-yak
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation using Morphology and IHC S2276 \| Breast Pathology \| 1.50 CME Credits	S2276	Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation using Morphology and IHC	1.50 CME Credits	Evaluation of spindle cell lesions of the breast is challenging and can be even more so on core needle biopsy specimens. Malignant mimics of benign lesions abound and vice versa. The diagnostic considerations are broad as some malignant lesions, such as metaplastic carcinomas, can be deceptively bland. A targeted IHC panel is often critical in evaluating these lesions, but there are important pitfalls to be aware of when evaluating IHC. The faculty will review common and unusual spindle cell lesions of the breast, considerations that should be included in the differential diagnosis, and when and how to utilize IHC to support a morphologic diagnosis. In some cases, a definitive diagnosis is not possible on core needle biopsy. The faculty will discuss how best to convey sufficient pathologic information to the clinical team so that the patient receives appropriate care. This course is appropriate for all pathologists who review breast specimens.	Laura C. Collins, MD, FCAP Liza Quintana, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Breast Pathology	Laura C. Collins, MD, FCAP	Liza Quintana, MD, FCAP				lau-ins	liz-ana
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person Spindle Cell Lesions of the Breast: A Spectrum of Cases and Their Differential Diagnoses V2293 \| Breast Pathology \| 1.50 CME Credits	V2293	Spindle Cell Lesions of the Breast: A Spectrum of Cases and Their Differential Diagnoses	1.50 CME Credits	This video microscopy course will expand on the companion course Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation Using Morphology and IHC. The differential diagnosis for spindle cell lesions is broad and the evaluation and categorization of these lesions is challenging. The faculty will review common and rare spindle cell lesions with an emphasis on how to work them up, order and interpret relevant IHC, and report them.	Laura C. Collins, MD, FCAP Liza Quintana, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Breast Pathology	Laura C. Collins, MD, FCAP	Liza Quintana, MD, FCAP				lau-ins	liz-ana
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Common Yet Challenging Diagnoses in Breast Core Biopsies: How to Recognize and Avoid the Pitfalls (On-Demand) S2148 \| Breast Pathology \| 1.50 CME Credits	S2148	Common Yet Challenging Diagnoses in Breast Core Biopsies: How to Recognize and Avoid the Pitfalls (On-Demand)	1.50 CME Credits	With the wide practice of breast cancer screening programs, breast core biopsies are among the most common specimens in academic and private pathology practice. It can be challenging to render an accurate diagnosis with limited sampling from core biopsies. Common but challenging cases in breast core biopsies include: 1) usual ductal hyperplasia versus atypical ductal hyperplasia versus low-grade ductal carcinoma in situ; 2) sclerosing lesions including benign and malignant entities; 3) papillary lesions including papilloma with uncommon features, atypical papilloma, and papillary carcinoma; and 4) fibroepithelial lesions including benign and malignant entities. The faculty will present information to help pathologists become familiar with the morphological features of these common but challenging entities, and how to order and interpret appropriate ancillary IHC studies. Faculty will also update pathologists on current recommendations on management and molecular features of these lesions.	Benjamin C. Calhoun, MD, PhD, FCAP Xiaoxian (Bill) Li, MD, PhD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Breast Pathology	Benjamin C. Calhoun, MD, PhD, FCAP	Xiaoxian (Bill) Li, MD, PhD, FCAP				ben-oun	xia- li
Keep Abreast of Innovation	KAI3	Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Point-of-Care and Rapid Tests for COVID-19, the Mayo Clinic Experience R1935 \| Chemistry \| 1.00 CME Credit	R1935	Point-of-Care and Rapid Tests for COVID-19, the Mayo Clinic Experience	1.00 CME Credit	Join the experts for lunch! Exchange information and share solutions in a relaxed setting with your peers. Learn to improve your ability to identify solutions to common problems through interactive sessions.	Bradley S. Karon, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Chemistry	Bradley S. Karon, MD, PhD, FCAP					bra-ron
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person Tips for Ensuring Quality in Your Point-of-Care Program M2221 \| Communication \| 1.00 CME Credit	M2221	Tips for Ensuring Quality in Your Point-of-Care Program	1.00 CME Credit	The rapid growth of point-of-care testing (POCT) adoption is reflective of the vital role POCT plays in patient management. With correct implementation, POCT can improve outcomes, decrease overall turnaround time, increase access to care, reduce costs, and enhance patient satisfaction. It is therefore imperative to ensure quality in POCT, however, managing this is a continuous challenge. During this course, the faculty will review the total testing process in POCT and the challenges associated with ensuring quality at each phase of testing. Using case examples, the faculty will describe strategies to overcome challenges at the preanalytic, analytic, and postanalytic phases of testing. They will also share tips on identifying quality indicators, monitoring performance, engaging personnel, reducing errors, and implementing processes that ensure quality will be described. This course is intended for pathologists, lab directors, lab managers, POCT coordinators, and pathology trainees practicing in hospital or outpatient settings. This course is cosponsored by the American Association for Clinical Chemistry.	Brenda Suh-Lailam, PhD, DABCC	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Communication	Brenda Suh-Lailam, PhD, DABCC					bre-lam
		Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual How to Avoid Death by PowerPoint and Zoom: A Field Guide to Creating More Impactful Presentations M2217 \| Communication \| 1.00 CME Credit	M2217	How to Avoid Death by PowerPoint and Zoom: A Field Guide to Creating More Impactful Presentations	1.00 CME Credit	Pathologists are the visual artists of medicine. We diagnose images and craft diagnostic stories that start patients on their treatment journeys. How do we leverage those visual skills to become a more compelling storyteller? This presentation will help you do that. It is a talk about talks—a how-to guide for presenters. During the first half the faculty will focus on live presentations, constructing a talk that engages and inspires. What are the hidden features of PowerPoint that will make your presentation stand out? The faculty will discuss graphic design principles for creating slides with the right mix of images and text. The second half of the talk will focus on virtual presentations, using Zoom, Teams, etc. What software will maximize impact? How do the interplay of lighting, sound, and virtual backgrounds lead to a better virtual experience? It’s time to unmute yourself and unleash your inner visual storyteller.	Eric F. Glassy, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Communication	Eric F. Glassy, MD, FCAP					eri-ssy
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Diagnostic Reporting Systems in Cytopathology: Updates, Aftermaths and Controversies S2164 \| Cytopathology \| 1.50 CME Credits	S2164	Diagnostic Reporting Systems in Cytopathology: Updates, Aftermaths and Controversies	1.50 CME Credits	The Diagnostic Reporting Systems in Cytopathology (DRSC) were created to meet general and specific needs. All systems address problematic terminologies and attempt to streamline patient management. Common standards improve communication between cytopathologists and their clinical colleagues. Specifically, The Bethesda System for Reporting Cervical Cytology (TBS) was born in response to problematic practices and the creation of CLIA 88. Bethesda-Thyroid and Serous Fluid Systems were created due to a need for clarification of diagnostic tiers and risks of malignancy. Paris was needed because of poor performance of low-grade urinary cytology and clarification of what urinary cytology does well. The Milan System for Salivary Gland came about because of diagnostic inconsistencies in dealing with a very difficult area. All DRSCs have been modeled after TBS. In this session, faculty will describe four DRSCs, discuss real-world implications of the proposed nomenclature, and provide updates of each reporting scheme. This course is cosponsored by the American Society of Cytopathology.	Zubair W. Baloch, MD, PhD, FCAP Guliz A. Barkan, MD, FCAP Daniel F.I. Kurtycz, MD, FCAP Ritu Nayar, MD, MBBS, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Cytopathology	Zubair W. Baloch, MD, PhD, FCAP	Guliz A. Barkan, MD, FCAP	Daniel F.I. Kurtycz, MD, FCAP	Ritu Nayar, MD, MBBS, FCAP		zub-och	gul-kan	dan-ycz	rit-yar
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Common Pitfalls and Mimickers in Dermatopathology S2259 \| Dermatopathology \| 1.50 CME Credits	S2259	Common Pitfalls and Mimickers in Dermatopathology	1.50 CME Credits	This course is tailored for general surgical pathologists with a focus on key aspects of IHC and molecular studies, and traditional clinical and histophenotypic features of difficult benign and malignant skin lesions. The faculty will use their extensive experience in a large tertiary referral cancer center to discuss and illustrate differential diagnoses. Early and correct recognition of these lesions is of utmost importance to reduce incorrect or nondefinitive diagnoses and costs for unnecessary studies, as well as streamline time to results for patients and management. The faculty will summarize the key features and algorithmic approach, and review cases with interactive discussion of this practical approach. Highlighted situations include: digital papillary adenocarcinoma versus acral hidradenoma; primary adnexal neoplasm versus metastatic adenocarcinoma to skin; cutaneous lymphoproliferative disorders such as gamma-delta T-cell lymphoma versus mycosis fungoides with CD8 expression; capsular nevus versus metastatic melanoma in sentinel lymph node of patients with melanoma; spindle melanocytic lesion (benign/malignant) versus neural tumor such as MPNST; Merkel cell carcinoma versus basal cell carcinoma; squamous cell carcinoma versus psedoepitheliomatous hyperplasia due to syphilis.	Phyu P. Aung, MD, PhD, FCAP Victor G. Prieto, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Dermatopathology	Phyu P. Aung, MD, PhD, FCAP	Victor G. Prieto, MD, PhD, FCAP				phy-ung	vic-eto
Keep Abreast of Innovation	KAI3	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Expert Testimony: What Happens After You Receive the Subpoena? M2219 \| Forensic Pathology \| 1.00 CME Credit	M2219	Expert Testimony: What Happens After You Receive the Subpoena?	1.00 CME Credit	You just get handed a subpoena, now what? This course will prepare hospital-based and forensic pathologists (residents to 10 years in practice) for a variety of interactions in the medicolegal arena. The faculty will provide an overview of the judicial system including common terminology, procedures, decorum in the witness box, and various legal orders. Further, the faculty will explain deposition and trial testimony, including how they differ and what can go wrong. Finally, they will describe common pitfalls and “trick” questions (and some answers). The goal of the course is to remove some of the mystery and trepidation around testimony and provide a solid understanding of what to expect and how to react in these proceedings.	Beth E. Frost, DO, FCAP James R. Gill, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Forensic Pathology	Beth E. Frost, DO, FCAP	James R. Gill, MD, FCAP				bet-ost	jam-ill
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person, Virtual Before the Cancer Diagnosis: Navigating Inflammatory and Pre-malignant Pathology of the Esophagus S2262 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2262	Before the Cancer Diagnosis: Navigating Inflammatory and Pre-malignant Pathology of the Esophagus	1.50 CME Credits	Premalignant and non-infectious inflammatory diseases of the esophagus are entities that present diagnostic challenges, especially when there is limited clinical information and overlapping histologic features. Proper identification is imperative in ensuring appropriate patient management. The faculty will address two compelling issues faced by pathologists in academic, private, and community practice as well as pathologists in training. First, faculty will focus on identifying and grading squamous and glandular esophageal dysplasia (Barrett mucosa). Secondly, developing a methodical approach for evaluating non-infectious inflammatory conditions (eosinophilic esophagitis, lichenoid esophagitis). Participants will gain proficiency in how to formulate diagnoses for dysplastic and inflammatory esophageal pathologies. The audience will be engaged through a series of case studies and polling questions to enhance key learning objectives.	Safia N. Salaria, MD, FCAP Annika L. Windon, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Gastrointestinal Pathology	Safia N. Salaria, MD, FCAP	Annika L. Windon, MD, FCAP				saf-ria	ann-don
		Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Inflammatory Bowel Disease: Challenges and Controversies S2263 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2263	Inflammatory Bowel Disease: Challenges and Controversies	1.50 CME Credits	During this course, the faculty will focus on the challenges and controversies in the histologic examination of specimens from patients with inflammatory bowel disease (IBD). They will discuss topics such as unusual forms of dysplasia, reporting of dysplasia are SCENIC, serrated epithelial change, Crohn's colitis, indeterminate colitis, backwash ileitis, and reporting pouch specimens, among other topics. The faculty will address emerging topics in IBD, and their relevance to the practice of GI pathology. The course is intended for practicing pathologists with at least some experience or interest in GI pathology who want to deepen their knowledge in IBD, including pathology residents and fellows in GI pathology. This course is cosponsored by the Rodger C. Haggitt Gastrointestinal Pathology Society.	Won-tak Choi MD, PhD Joseph Misdraji, MD, FCAP Bita V. Naini, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Gastrointestinal Pathology	Won-tak Choi MD, PhD	Joseph Misdraji, MD, FCAP	Bita V. Naini, MD, FCAP			won- md	jos-aji	bit-ini
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Keeping Up With the Advances in Gastric Neoplasms S2153 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2153	Keeping Up With the Advances in Gastric Neoplasms	1.50 CME Credits	In the current era of evolving integration between traditional pathology and molecular advances, this course offers a practical review of neoplastic gastric pathology combining updated morphologic classification and advanced techniques. Faculty will use case-based illustrations to cover updated information on the classification of gastric polyps, dysplasia, and cancer based on morphologic assessment, IHC studies, and molecular techniques. Additionally, faculty will present a combination of succinct up-to-date summaries and real practice examples to explain the updates relevant to routine practice such as novel World Health Organiazation classification, the value of gastric intestinal metaplasia subtyping, and evaluation of HER2/neu and PD-L1 expression in gastric cancer. Examples of molecularly defined subtypes of gastric neoplasms that may direct therapy will also be discussed. The course is designed for academic and community pathologists.	Gregory Lauwers, MD, FCAP Namrata Setia, MD, MBBS	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Gastrointestinal Pathology	Gregory Lauwers, MD, FCAP	Namrata Setia, MD, MBBS				gre-ers	nam-tia
Keep Abreast of Innovation	KAI3	Monday, October 10, 2022, 9:30 AM - 11:00 AM \| In-Person, Virtual Appendix Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis S2172 \| Gastrointestinal Pathology \| 1.50 CME Credit	S2172	Appendix Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis	1.50 CME Credit	This course will provide an update on the classification, nomenclature, and staging of commonly encountered and newly described lesions of the appendix. This course features a case-based discussion from two gastrointestinal pathology experts who will emphasize practical diagnostic pearls and pitfalls and reporting strategies. The faculty will present the latest guidelines and recent changes to nomenclature and staging. An interactive quiz component will emphasize key learning points and allow the audience to practice applying the course content with real-time feedback. There will be ample time for questions and discussion between the faculty and participants. The course is intended for practicing surgical pathologists, gastrointestinal subspecialized pathologists, as well as residents and fellows.	Jacqueline E. Birkness-Gartman, MD Maryam K. Pezhouh, MD, MSc, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	11:00 AM		Monday, October 10, 2022, 9:30 AM - 11:00 AM	Gastrointestinal Pathology	Jacqueline E. Birkness-Gartman, MD	Maryam K. Pezhouh, MD, MSc, FCAP				jac-man	mar-ouh
Keep Abreast of Innovation	KAI3	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual EUS-guided and 'SpyBite' Biopsies of Pancreatic and Biliary Tract Lesions (FNA vs Biopsy) S2178 \| Gastrointestinal Pathology \| 1.50 CME Credit	S2178	EUS-guided and 'SpyBite' Biopsies of Pancreatic and Biliary Tract Lesions (FNA vs Biopsy)	1.50 CME Credit	This course is presented by the Pancreatobiliary Pathology Society and will provide an overview and step-wise, algorithmic approach to the evaluation of “SpyBite” biopsies and cytologic samples (including endoscopic ultrasound (EUS)-guided fine-needle aspirations and bile duct brushings) from cystic/solid lesions/strictures of pancreas and biliary tract. The faculty include a cytopathologist and gastrointestinal pathologist who subspecialize in pancreatobiliary pathology. These faculty will outline practical diagnostic pearls and reporting strategies as well as judicious utility of ancillary IHC/molecular studies. Additionally, the faculty will emphasize changes in terminology, classification, and diagnosis/grading of classical and newly described site-specific entities (intraductal papillary mucinous (IPMN), oncocytic (IOPN) and tubulopapillary (ITPN) neoplasm, flat (Bil-IN) and tumoral intraepithelial biliary tract neoplasms (IPN-B), and neuroendocrine neoplasms). This course is intended for surgical, gastrointestinal, and cytopathologists in community/academic practice as well as pathologists in training. An interactive quiz will emphasize key learning points and allow the audience to practice/apply course content with real-time feedback. This course is sponsored by the Pancreatobiliary Pathology Society.	Olca Basturk, MD Michelle Reid, MD, MS, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Gastrointestinal Pathology	Olca Basturk, MD	Michelle Reid, MD, MS, FCAP				olc-urk	mic-eid
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual When is Enough Enough? Making Sense of the Small Changes in GI Biopsies S2011 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2011	When is Enough Enough? Making Sense of the Small Changes in GI Biopsies	1.50 CME Credits	This course will examine fundamental concepts of histology in upper and lower gastrointestinal biopsies with a focus on intraepithelial lymphocytosis and dysplastic epithelial changes in an ever-increasing, complex patient environment. The faculty will use a case-based approach to provide practical examples of how to sign out cases from different sites, and highlight subtle histologic details to aid recognition of key features. In addition, faculty will review recent literature and the American Joint Committee on Cancer and World Health Organization updates to clarify diagnostic criteria, ensure consistency in reporting, and optimize patient care. These discussions will help both practicing pathologists as well as trainees. This course is cosponsored by the Rodger C. Haggitt Gastrointestinal Pathology Society.	Stephen M. Lagana, MD, FCAP David F. Schaeffer, MD, FRCPC	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Gastrointestinal Pathology	Stephen M. Lagana, MD, FCAP	David F. Schaeffer, MD, FRCPC				ste-ana	dav-fer
Get a Strong Start	GASS2	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21) S2274 \| Genitourinary Pathology \| 1.50 CME Credits	S2274	Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21)	1.50 CME Credits	The classification of genitourinary cancers has significantly advanced due to the rapidly evolving understanding of the molecular underpinnings of cancer with excellent clinical and pathologic correlation. The faculty have designed this course to concisely summarize new diagnostic entities in genitourinary pathology. They have incorporated critical changes in diagnostic nomenclature from the upcoming World Health Organization 2021 (WHO-21) book and will cover all areas of the genitourinary system, including the kidney, prostate, penis, testis, and urinary tract. The faculty will: 1) describe the overarching, evolving paradigm of urologic tumor classification based on morphologic, clinical, and molecular correlations; 2) present new and emerging entities in genitourinary pathology in the context of existing classification schema; 3) highlight molecular testing as relevant to genitourinary diagnostic categories; and 4) discuss the impact of these new modalities and diagnoses on clinical management.	Mahul B. Amin, MD, FCAP Donna E. Hansel, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Genitourinary Pathology	Mahul B. Amin, MD, FCAP	Donna E. Hansel, MD, PhD, FCAP				mah-min	don-sel
Get a Strong Start	GASS3	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Identifying New and Emerging Entities in Genitourinary Pathology V2245 \| Genitourinary Pathology \| 1.50 CME Credits	V2245	Identifying New and Emerging Entities in Genitourinary Pathology	1.50 CME Credits	This video microscopy course will expand upon the companion course on updates in the morphological and molecular classification of urologic malignancies Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21). The faculty will identify critical changes in diagnostic nomenclature from the upcoming World Health Organization 2021 book and cover all areas of the genitourinary system. The faculty will also cover new and emerging entities in genitourinary pathology and discuss the impact of these new modalities and diagnoses on clinical management.	Mahul B. Amin, MD, FCAP Donna E. Hansel, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Genitourinary Pathology	Mahul B. Amin, MD, FCAP	Donna E. Hansel, MD, PhD, FCAP				mah-min	don-sel
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Difficult Differential Diagnoses in Genitourinary Pathology: Mimickers and Beyond S2291 \| Genitourinary Pathology \| 1.50 CME Credits	S2291	Difficult Differential Diagnoses in Genitourinary Pathology: Mimickers and Beyond	1.50 CME Credits	This course focuses on addressing challenging scenarios and contemporary differential diagnosis for a broad array of genitourinary specimens relevant to pathologists in practice and in training. Using a case presentation with an organ-based approach, the faculty will address evolving concepts in old and emerging entities, diagnostic pitfalls, and controversies in numerous genitourinary cancer subtypes. A large number of images in a tumor board format will expose the audience to a wide spectrum of lesions. Faculty will place significant emphasis on contemporary updates, interpretation of diagnostic pitfalls, exclusion of benign mimickers, and application of ancillary studies. Additionally, the faculty will emphasize key pathologic reporting parameters that are of greatest value to clinicians in the context of clinical application and management.	Giovanna A. Giannico, MD, FCAP Sean R. Williamson, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Genitourinary Pathology	Giovanna A. Giannico, MD, FCAP	Sean R. Williamson, MD, FCAP				gio-ico	sea-son
		Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Embracing Diversity in Bladder Cancer: Variants, Divergence, and Molecular Findings in Urothelial Carcinoma M2270 \| Genitourinary Pathology \| 1.00 CME Credit	M2270	Embracing Diversity in Bladder Cancer: Variants, Divergence, and Molecular Findings in Urothelial Carcinoma	1.00 CME Credit	Urothelial carcinomas with variant/divergent differentiation convey a worse prognosis than pure high-grade urothelial carcinoma. They remain unrecognized and underreported, despite their clinical and prognostic importance. They usually present with high pT stage and nodal metastasis. Treatment guidelines may also differ with aggressive multimodal therapy recommended in this setting. The faculty will present the morphologic features of clinically significant divergent histology in the urothelial tract and the need to consistently report them due to their prognostic and therapeutic impact. They will also discuss the differential diagnosis including the preneoplastic lesions and mimickers to ensure accurate recognition. Finally, the faculty will focus on the role of molecular advances in the diagnosis, classification, and management of urothelial carcinoma, including when and how to fully integrate such advances in routine diagnostic practice. This course is suitable for pathologists in training and in practice, irrespective of years of practice, in both academic and community settings.	Hikmat A. Al-Ahmadie, MD Lara R. Harik, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Genitourinary Pathology	Hikmat A. Al-Ahmadie, MD	Lara R. Harik, MD, FCAP				hik-die	lar-rik
Keep Abreast of Innovation	KAI1	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Big Results From Small Specimens: Maximizing the Impact of Renal Mass Biopsy for Best Clinical Outcomes S2246 \| Genitourinary Pathology \| 1.50 CME Credits	S2246	Big Results From Small Specimens: Maximizing the Impact of Renal Mass Biopsy for Best Clinical Outcomes	1.50 CME Credits	Renal mass biopsies are increasingly utilized in the workup of renal masses, especially those that are found incidentally. Simultaneously, the classification of renal neoplasms is expanding with numerous new entities being introduced into the literature. The faculty will focus on the utility and limitations of renal mass biopsies, providing numerous case-based examples of how to effectively approach these small specimens. Video microscopy will be used to review cases in real time with genitourinary pathologists from academic and private settings. The course will be interactive with questions from the audience as well as polling questions. As renal mass biopsies may be seen in any practice setting, this course is geared to pathologists at any stage of their career who are interested in gaining practical insight into the diagnosis of renal mass biopsies.	Ankur R. Sangoi, MD, FCAP Sara E. Wobker, MD, MPH, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Genitourinary Pathology	Ankur R. Sangoi, MD, FCAP	Sara E. Wobker, MD, MPH, FCAP				ank-goi	sar-ker
Get a Strong Start	GASS4	Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Money is in the LAST Detail: Diagnosis and Management of Human Papillomavirus Infection-Associated Lesions S2155 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2155	Money is in the LAST Detail: Diagnosis and Management of Human Papillomavirus Infection-Associated Lesions	1.50 CME Credits	The human papillomavirus (HPV) is mainly responsible for malignancies of the lower anogenital tract and oropharynx. The faculty will review the epidemiology and life cycle of HPV, and the steps in HPV-related carcinogenesis. They will emphasize criteria to accurately identify and classify HPV-driven preneoplastic and neoplastic lesions in both cytology and histologic specimens following the recommendations of the Lower Anogenital Squamous Terminology (LAST) project. There are challenges in the proper implementation of p16 IHC, recommended by the LAST project as a biomarker to identify high-grade squamous intraepithelial lesion. The faculty will discuss sources of error and present solutions to correctly apply and interpret p16 IHC, and will also review the American Society for Colposcopy and Cervical Pathology guidelines for management of women with abnormal Pap test, screening guidelines for various HPV-related cancers, and will conclude by reviewing the HPV vaccine. A case-based approach with live audience response will be used to cover these topics.	Krisztina Z. Hanley, MD Uma Krishnamurti, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Gynecologic/Obstetric Pathology	Krisztina Z. Hanley, MD	Uma Krishnamurti, MD, PhD, FCAP				kri-ley	uma-rti
Grow as a Leader	GAL3	Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Clinically Relevant, Pattern-Based Approach to Diagnosing Uterine Mesenchymal Tumors (On-Demand) S2156 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2156	Clinically Relevant, Pattern-Based Approach to Diagnosing Uterine Mesenchymal Tumors (On-Demand)	1.50 CME Credits	This course will use a pattern-based approach (spindled, epithelioid, rhabdoid, myxoid patterns; low-grade versus high-grade atypia) to build differential diagnoses and emphasize selection and interpretion of the most useful, current IHC and molecular tests for each diagnostic scenario of uterine mesenchymal tumors. The faculty will highlight common pitfalls, new diagnostic tools, and features that predict response to targeted therapy; and the novel role of the pathologist in recognizing morphologic features associated with risk of a hereditary syndrome. Special issues in the diagnosis and reporting of mesenchymal tumors in endometrial biopsy, curettage, and polypectomy and their unique challenges will be addressed. Updates from the new World Health Organization (WHO) Classification System of Tumors (“blue book”), of which both faculty are authors, will also be discussed.	Amy S. Joehlin-Price, MD, MS, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Gynecologic/Obstetric Pathology	Amy S. Joehlin-Price, MD, MS, FCAP					amy-ice
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual What’s in a Name? Serous Neoplasms of the Ovary and Fallopian Tube: Classification Updates, Common Conundrums, and Outcomes (On-Demand) S2169 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2169	What’s in a Name? Serous Neoplasms of the Ovary and Fallopian Tube: Classification Updates, Common Conundrums, and Outcomes (On-Demand)	1.50 CME Credits	The practicing pathologist, whether in a community or academic setting, commonly encounters serous neoplasms of the ovary and fallopian tube. However, correct application of updated nomenclature which can alter patient management can be challenging. The faculty will cover diagnostic dilemmas using a case study method with audience interaction, starting at frozen section/case presentation and ending with the final diagnosis. The course will cover areas such as serous cystadenomas with proliferation versus borderline tumors, sampling and diagnosis of tumors with micropapillary architecture, and features of low-grade carcinoma including implant classification. The faculty will review problematic cases of high-grade serous carcinoma, including diagnosis and reporting of post-neoadjuvant high-grade serous carcinoma, overlap with low-grade carcinoma, and diagnostic features of serous tubal intraepithelial carcinoma. The faculty will use each case to instruct attendees about recent updates to the World Health Organization classification, molecular characteristics which can be exploited in routine practice for diagnosis and clinical management, and implications of diagnosis for patient outcomes and treatment.	Jennifer Bennett, MD Joseph Rabban, MD, MPH, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Jennifer Bennett, MD	Joseph Rabban, MD, MPH, FCAP				jen-ett	jos-ban
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Beyond the Correct Diagnosis: Ancillary Testing in Gynecologic Pathology – Things Your Gynecologic Oncologist Do Not Want You to Miss S2252 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2252	Beyond the Correct Diagnosis: Ancillary Testing in Gynecologic Pathology – Things Your Gynecologic Oncologist Do Not Want You to Miss	1.50 CME Credits	With the inclusion of molecular classification of endometrioid carcinoma in the 2020 World Health Organization Female Genital Tumors, the necessity of ancillary techniques such as next-generation sequencing and/or IHC staining will likely become routine for subclassification of these and other tumor types. Additionally, criteria for clinical trials and emerging therapies for gynecolgic tract malignancies often require results of mismatch repair testing, p53, or HER2 IHC. In this context, the signing pathologist, must understand not only the significance of these ancillary tests, but also when they are required. The faculty will use a case-based presentation to review various entities of the gynecolgic tract with a focus on the clinical and therapeutic implications from the viewpoint of a gynecologic oncologist.	Natalie Banet, MD, FCAP Deyin Xing, MS, BM, MBBS, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Natalie Banet, MD, FCAP	Deyin Xing, MS, BM, MBBS, PhD				nat-net	dey-ing
Keep Abreast of Innovation	KAI2	Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual We Can Do Better Than Hyperkeratosis: Approaches for the Differential Diagnosis of Oral Pathology Lesions M2190 \| Gynecologic/Obstetric Pathology \| 1.00 CME Credits	M2190	We Can Do Better Than Hyperkeratosis: Approaches for the Differential Diagnosis of Oral Pathology Lesions	1.00 CME Credits	Do you have an interest in oral pathology and the diagnosis of oral keratotic lesions? If so, this course will provide specific diagnostic criteria in this area for attendees, including residents, general and even specialist pathologists. These diagnoses range from keratoses caused by friction such as from parafunctional habits, oral lichen simplex chronicus, and inflammatory conditions. The faculty will focus on the architectural, organizational, and cytologic features of oral epithelial dysplasia. Current data suggest that most, if not all leukoplakia’s, are precancerous whether they show cytologic evidence of dysplasia or not. At this time, too much emphasis has been placed on cytologic atypia so that many dysplastic lesions that show organization and architectural atypia have not been correctly diagnosed as such with serious consequences for patients. The faculty will show the clinical lesions and the corresponding histopathology which may look innocuous, and will also provide specific sign-out phrases that may be helpful.	Natalie Banet, MD, FCAP Deyin Xing, MS, BM, MBBS, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Natalie Banet, MD, FCAP	Deyin Xing, MS, BM, MBBS, PhD				nat-net	dey-ing
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Lessons Learned From the New WHO Classification of Head and Neck Tumors M2222 \| Gynecologic/Obstetric Pathology \| 1.00 CME Credit	M2222	Lessons Learned From the New WHO Classification of Head and Neck Tumors	1.00 CME Credit	The fifth edition of the World Health Organization Classification of Head and Neck Tumors presents several advancements and developments in our understanding of tumors and tumor-like lesions that affect the upper aerodigestive tract and salivary glands. The faculty will emphasize emerging diagnostic concepts and key nomenclature changes that were incorporated in the new 2022 “blue book.” The faculty will use a case-based approach to discuss how histopathology, IHC, and molecular testing can be integrated in the daily practice of head and neck pathology.	Leslie Randall, MD Sadia Sayeed, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Gynecologic/Obstetric Pathology	Leslie Randall, MD	Sadia Sayeed, MD, FCAP				les-all	sad-eed
Get a Strong Start	GASS3	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Emerging Diagnostic Concepts of the New WHO Classification of Head and Neck Tumours V2294 \| Head and Neck Pathology \| 1.50 CME Credits	V2294	Emerging Diagnostic Concepts of the New WHO Classification of Head and Neck Tumours	1.50 CME Credits	This video microscopy course will expand upon the complimentary course on the new WHO Classification of Head and Neck Tumours. This 5th edition presents several advancements and developments in our understanding tumors and tumor-like lesions that affect the upper aerodigestive tract and salivary glands. The faculty will emphasize emerging diagnostic concepts and key nomenclature changes that were incorporated in the new 2022 “blue book.”	Sook-Bin Woo, MD, DMD	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Head and Neck Pathology	Sook-Bin Woo, MD, DMD					soo-woo
		Saturday, October 8, 2022, 1:30 PM - 2:30 PM \| In-Person, Virtual Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What Do We Know and What Should We Do S2247 \| Head and Neck Pathology \| 1.50 CME Credits	S2247	Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What Do We Know and What Should We Do	1.50 CME Credits	No need to feel intimidated when you see a pediatric hematopathology sample! Though we may have different differential diagnoses when it comes to kids since they aren’t small adults, join the faculty to learn a step-by-step approach to tackle these questions: It looks different from the adult marrows – is it normal? Is it neoplastic? Can this be inherited? Do I need additional studies? What else should I do if I made a diagnosis of acute leukemia? All these questions are important. The faculty will present selected cases to illustrate findings and workup for acquired aplastic anemia, bone marrow failure syndrome associated with germline mutations, myeloid proliferations related to Down syndrome, JMML, MDS, and acute leukemia. The faculty will cover the utilization of molecular tools and the updates on pediatric hematopathology entities. The course is appropriate for all pathologists and trainees who want to improve their understanding in evaluating pediatric hematopathology samples.	Juan C. Hernandez-Prera, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	02:30 PM		Saturday, October 8, 2022, 1:30 PM - 2:30 PM	Head and Neck Pathology	Juan C. Hernandez-Prera, MD, FCAP					jua-era
Dina 9/12		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Sweating the Small Stuff: Navigating Lymphoma Workups on Core Needle Biopsies S2013 \| Head and Neck Pathology \| 1.50 CME Credits	S2013	Sweating the Small Stuff: Navigating Lymphoma Workups on Core Needle Biopsies	1.50 CME Credits	This interactive lecture, designed for pathologists working in close contact with proceduralists and oncologists, will provide focused discussions regarding safe and efficient specimen processing, test selection, and reporting of core needle biopsies in patients with suspected or known hematologic neoplasms. The faculty will use six specific clinical case scenarios to discuss the utility and prioritization of ancillary testing with consideration of sample requirements and test limitations. The faculty will also address multiparametric flow cytometry and next-generation sequencing studies in addition to IHC, cytogenetic, and PCR-based molecular testing. The successful participant will analyze their current practices and leave with practical ideas for improvement. All levels of experience will benefit from this activity.	Juan C. Hernandez-Prera, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Head and Neck Pathology	Juan C. Hernandez-Prera, MD, FCAP					jua-era
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person Can’t-Miss Diagnoses: Using Flow Cytometry to Identify Hematolymphoid Neoplasms With Genetic Abnormalities and Prognostic Significance S2258 \| Head and Neck Pathology \| 1.50 CME Credits	S2258	Can’t-Miss Diagnoses: Using Flow Cytometry to Identify Hematolymphoid Neoplasms With Genetic Abnormalities and Prognostic Significance	1.50 CME Credits	Flow cytometry is a powerful diagnostic tool, and is a sensitive method to identify hematolymphoid neoplasms in body fluids and tissues. Some diagnoses in hematopathology are particularly time sensitive, such as acute promyelocytic leukemia. However, there are many other situations in which the oncology team may request a rapid diagnosis, including patients who are very ill, require a specific therapy, or may benefit from enrollment in a clinical trial. Careful evaluation of flow cytometric findings will facilitate interactions with the clinical team, and expedite ordering the ancillary tests in a thorough but cost-effective manner. In this course, the faculty will use case studies and audience polling to explore the strengths (and weakness) of flow cytometry in making critical and timely diagnoses. They will discuss the clinical significance of these findings as well as potential pitfalls. In this course, we will use case studies and audience polling to explore the strengths (and weakness) of flow cytometry in making critical and timely diagnoses. The clinical significance of these findings will be briefly reviewed, and potential pitfalls will also be discussed.	John Casler, MD, FACS Qihui "Jim" Zhai, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Head and Neck Pathology	John Casler, MD, FACS	Qihui "Jim" Zhai, MD, FCAP				joh-ler	qih-hai
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person Don't be Troubled by Red Cell Rubble: An Approach to Acquired Hemolytic Anemia S2261 \| Hematology/Hematopathology \| 1.50 CME Credits	S2261	Don't be Troubled by Red Cell Rubble: An Approach to Acquired Hemolytic Anemia	1.50 CME Credits	Acquired hemolytic anemias such as thrombotic microangiopathy (microangiopathic hemolytic anemia) and immune-mediated hemolysis are frequently encountered in the hospital setting. The pathologist is often consulted to help clinicians navigate these complex laboratory workups that tend to involve multiple laboratories, particularly hematology and transfusion medicine. The faculty will use a case-based approach to provide pathologists with the tools needed to provide clinical consultation in these challenging scenarios.	Julia Geyer, MD Yen-Chun Liu, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Julia Geyer, MD	Yen-Chun Liu, MD, PhD, FCAP				jul-yer	yen-liu
		Saturday, October 8, 2022, 9:30 AM - 11:00 AM \| In-Person The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist S2254 \| Hematology/Hematopathology \| 1.50 CME Credits	S2254	The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist	1.50 CME Credits	This course is designed to provide attendees with a case-based algorithmic approach to the contemporary workup of large B-cell lymphomas (LBCL). The faculty will provide a step-by-step approach to the initial diagnosis and subclassification of all major subcategories of LBCLs with emphasis on integration of cytogenetic and molecular findings. Additionally, the faculty will provide attendees with a practical algorithm designed to simplify the workup of these neoplasms.	Megan S. Lim, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	11:00 AM		Saturday, October 8, 2022, 9:30 AM - 11:00 AM	Hematology/Hematopathology	Megan S. Lim, MD, PhD, FCAP					meg-lim
Keep Abreast of Innovation	KAI1	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual How to Optimize or Implement Laboratory Testing For Xa-Inhibitory Direct Oral Anticoagulant (DOAC) Detection M2214 \| Hematology/Hematopathology \| 1.00 CME Credit	M2214	How to Optimize or Implement Laboratory Testing For Xa-Inhibitory Direct Oral Anticoagulant (DOAC) Detection	1.00 CME Credit	Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, arrived on the market with no need for monitoring. As the use of DOACs expand, it is becoming clearer that measurement of these may be necessary in specific situations. More institutions are integrating either qualitative or quantitative assays. This course will use cases and audience polling to illustrate and prepare attendees for how to bring in new testing. The faculty will address questions such as: Which type of assay is most appropriate for your institution? How do you validate these assays, many of which are not FDA cleared? When should they be used? How do you integrate the testing in the ordering menu for clinicians?	Amy S. Duffield, MD, PhD, FCAP Laura Wake, MD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Amy S. Duffield, MD, PhD, FCAP	Laura Wake, MD				amy-eld	lau-ake
Get a Strong Start	GASS2	Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person COVID-19 and Hemostasis M2181 \| Hematology/Hematopathology \| 1.00 CME Credits	M2181	COVID-19 and Hemostasis	1.00 CME Credits	Coronavirus disease 2019 (COVID-19) can progress to a severe pro-inflammatory state with unique coagulopathy and procoagulant endothelial phenotype. A constellation of laboratory findings, including prominent elevation of fibrinogen, D-dimer/fibrin(ogen) degradation products, positive lupus anticoagulant, and altered viscoelastic tests have been reported. Increased platelet consumption, a corresponding increase in production, and increased activation of circulating platelets appear to occur. As the disease progresses, patients can develop findings similar to disseminated intravascular coagulation (DIC), but the rarity of severe bleeding events in these patients is not typical. Overall, these findings are associated with systemic hypercoagulability, frequent venous, arterial, and microvascular thrombotic and thromboembolic events. The laboratory may be consulted to interpret results and/or to monitor or guide anticoagulation in this severe thrombotic disease.	Vandita P. Johari, MD, FCAP Alexis R. Peedin, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Vandita P. Johari, MD, FCAP	Alexis R. Peedin, MD, FCAP				van-ari	ale-din
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Next Generation of von Willebrand Activity Factor Testing: Are You Performing the Right One S2273 \| Hematology/Hematopathology \| 1.50 CME Credits	S2273	Next Generation of von Willebrand Activity Factor Testing: Are You Performing the Right One	1.50 CME Credits	In 2021, the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) issued a joint guidance document on the diagnosis of von Willebrand Disease (VWD). These guidelines suggest automated von Willebrand Factor (VWF) platelet-binding activity assays, VWF:GP1bM and VWF:GP1bR, over the traditional VWF:Ristocetin cofactor (RCo) activity assay. While neither of these are currently FDA approved, the VWF:Ab assay, which is FDA-cleared, was not included in the recommendation statement. During this interactive lecture, the faculty will use case studies and audience polling to answer the questions you or your hematology colleagues may ask, such as “Which VWF activity assay does your laboratory perform/send out?” and “Is it appropriate based on the new guidelines?”	Sanam Loghavi, MD, FCAP Kamran Mirza, MD, PhD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Sanam Loghavi, MD, FCAP	Kamran Mirza, MD, PhD, FCAP				san-avi	kam-rza
Grow as a Leader	GAL4	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Common Queries in Medical Liver Pathology: What the Practicing Pathologist Needs to Know S2018 \| Hemostasis Pathology \| 1.50 CME Credits	S2018	Common Queries in Medical Liver Pathology: What the Practicing Pathologist Needs to Know	1.50 CME Credits	In this course, the faculty will address common questions that arise in the daily practice of surgical pathologists who sign out medical liver. Using case-based presentations, the faculty will facilitate discussions on a range of common, but difficult, topics in medical liver biopsy. Some of these topics include how to approach a liver biopsy from a patient who presents with increased liver function tests, provide a thorough assessment of a fatty liver diseases, and rule in/out autoimmune hepatitis. They will also discuss how to avoid pitfalls in the evaluation of donor liver biopsy on frozen section, and how to compose a valuable liver pathology report that answers your clinician’s (sometimes unspoken) concerns. This course will be targeted towards practicing pathologists and pathologists in training.	Marian Rollins-Raval, MD, MPH, FCAP Geoffrey Wool, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Hemostasis Pathology	Marian Rollins-Raval, MD, MPH, FCAP	Geoffrey Wool, MD, PhD, FCAP				mar-val	geo-ool
Grow as a Leader	GAL1	Saturday, October 8, 2022, 1:30 PM - 2:30 PM \| In-Person Biopsies of Liver Mass Lesions: Let’s Master the Challenges and Pitfalls (Even on tiny Biopsy!) S2168 \| Hemostasis Pathology \| 1.50 CME Credits	S2168	Biopsies of Liver Mass Lesions: Let’s Master the Challenges and Pitfalls (Even on tiny Biopsy!)	1.50 CME Credits	Liver mass biopsy interpretation remains challenging for practicing pathologists, even for those with experience or a fellowship training in gastrointestinal/liver pathology. These lesions encompass a variety of benign and malignant hepatic neoplasms and metastases. Even within the category of primary hepatic neoplasms (hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma), new classifications/subtypes have emerged in recent years that have major implications in clinical practice. Metastatic lesions can not only closely mimic hepatocellular tumors, but they also sometimes come from an unknown primary. This requires a judicious IHC workup with a cost-effective approach, and an attempt to preserve tissues that might be needed for any subsequent molecular tests. Faculty will address practical approaches to a pathologic diagnosis of liver mass lesions, present an update on classifications/subtypes of liver tumors, and provide a guide to best practices in the application of IHC and other ancillary tests to the workup of hepatic metastases, particularly in the setting of limited biopsy material. This course is cosponsored by the Hans Popper Hepatopathology Society.	Eric Salazar, MD, PhD, FCAP Geoffrey Wool, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	02:30 PM		Saturday, October 8, 2022, 1:30 PM - 2:30 PM	Hemostasis Pathology	Eric Salazar, MD, PhD, FCAP	Geoffrey Wool, MD, PhD, FCAP				eri-zar	geo-ool
Keep Abreast of Innovation	KAI1	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Practical approaches to Liver Mass Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls V2180 \| Hemostasis Pathology \| 1.50 CME Credits	V2180	Practical approaches to Liver Mass Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls	1.50 CME Credits	Liver mass lesions encompass a variety of benign and malignant hepatic neoplasms, and metastases. Even within the category of primary hepatic neoplasms (hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma), new classifications/subtypes have emerged in recent years that have major implications in clinical practice. Metastatic lesions can not only closely mimic hepatocellular tumors, but they also sometimes come from an unknown primary. This requires a judicious IHC workup with a cost-effective approach, and an attempt to preserve tissues that might be needed for any subsequent molecular tests. This two-hour virtual microscopy tutorial will demonstrate practical approaches to a pathologic diagnosis of liver mass lesions, present an update on classifications/subtypes of liver tumors, and provide a guide to best practices in the application of IHC and other ancillary tests to the workup of hepatic metastases, particularly in the setting of limited biopsy material. This course is cosponsored by the Hans Popper Hepatopathology Society.	Neil S. Harris, MD, FCAP Marian Rollins-Raval, MD, MPH, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Hemostasis Pathology	Neil S. Harris, MD, FCAP	Marian Rollins-Raval, MD, MPH, FCAP				nei-ris	mar-val
Grow as a Leader	GAL2	Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person Practical Immunohistochemistry (IHC) Approach for Small Tissue and Challenging Diagnostic Dilemmas S2157 \| Hepatopathology \| 1.50 CME Credits	S2157	Practical Immunohistochemistry (IHC) Approach for Small Tissue and Challenging Diagnostic Dilemmas	1.50 CME Credits	The advancement of precision medicine mandates pathologists to make accurate diagnoses and provide actionable recommendations based on scant tissue from sophisticated minimal invasive procedures. To apply IHC becomes essential, yet to preserve tissue for potential molecular analysis is also imperative. A systemic and data-proven best-practice approach is required to effectively execute this balancing act. The faculty will teach practical steps involving tissue triage and showcase smart IHC which entails specific markers, small panels, and stepwise workup. The focus of this course will be on commonly encountered challenging diagnostic dilemmas of general surgical pathology such as morphologically undifferentiated neoplasms and carcinomas of unknown primary origin. This course is intended for pathology trainees and practicing pathologists.	Maryam K. Pezhouh, MD, MSc, FCAP Meredith E. Pittman, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Hepatopathology	Maryam K. Pezhouh, MD, MSc, FCAP	Meredith E. Pittman, MD, FCAP				mar-ouh	mer-man
Keep Abreast of Innovation	KAI1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual To Improve is to Change: Tips and Tools for Quality Planning, Predictive Marker Monitoring, and Process Improvement in IHC S2282 \| Hepatopathology \| 1.50 CME Credits	S2282	To Improve is to Change: Tips and Tools for Quality Planning, Predictive Marker Monitoring, and Process Improvement in IHC	1.50 CME Credits	New monitoring and regulatory requirements for IHC laboratories performing predictive marker testing provide an opportunity for IHC laboratory directors to generate a comprehensive IHC laboratory quality plan. The faculty will review new PT survey monitoring requirements and discuss a standard approach to creating an IHC laboratory quality plan. The faculty will use selected cases based on the experience of the CAP IHC Subcommittee and past proficiency testing challenges to highlight process improvement principles that can be applied to current and future monitored assays.	Dhanpat Jain, MD, FCAP Xuchen Zhang, MD, PhD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Hepatopathology	Dhanpat Jain, MD, FCAP	Xuchen Zhang, MD, PhD, FCAP				dha-ain	xuc-ang
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person Uncultured: Infectious Diseases in Surgical Pathology S2136 \| Hepatopathology \| 1.50 CME Credits	S2136	Uncultured: Infectious Diseases in Surgical Pathology	1.50 CME Credits	Surgical pathologists can have a big impact upon diagnosing infectious diseases, particularly when cultures are not obtained, the agent is slow-growing not amenable to culture, or when colonization must be distinguished from infection. Armed with informed morphology and a few adjunctive tests, pathologists can learn to identify many agents to the species level. The faculty will review the morphologic features of several common and uncommon agents and elaborate on the available adjunctive tests.	Dhanpat Jain, MD, FCAP Xuchen Zhang, MD, PhD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Hepatopathology	Dhanpat Jain, MD, FCAP	Xuchen Zhang, MD, PhD, FCAP				dha-ain	xuc-ang
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person What’s Bugging the Gut: A Gastrointestinal Pathology and Microbiology Team Approach in Diagnosing Alimentary Tract Infections M2020 \| Immunohistochemistry \| 1.00 CME Credit	M2020	What’s Bugging the Gut: A Gastrointestinal Pathology and Microbiology Team Approach in Diagnosing Alimentary Tract Infections	1.00 CME Credit	The goal of this course is to facilitate a practical, case-based discussion of gastrointestinal infections that raise differential diagnostic challenges in surgical pathology. The faculty’s review focuses on the histological features of easy-to-miss infections and highlights the role of clinical laboratory testing in pathogen diagnosis through an integrated anatomic and clinical pathology team approach. This course will enhance attendees’ ability to look for and correctly identify gut infections. The course is intended for practicing surgical pathologists as well as clinical laboratory professionals with a goal to prepare attendees for an active role in multidisciplinary care.	Zong-Ming "Eric" Chen, MD, PhD, FCAP Anja C. Roden, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Immunohistochemistry	Zong-Ming "Eric" Chen, MD, PhD, FCAP	Anja C. Roden, MD, FCAP				zon-hen	anj-den
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Glassless and Paperless: Everything You Are Wondering About a 100% Primary Diagnosis Digital Workflow S2284 \| Immunohistochemistry \| 1.50 CME Credits	S2284	Glassless and Paperless: Everything You Are Wondering About a 100% Primary Diagnosis Digital Workflow	1.50 CME Credits	Pathologists are facing a once in a lifetime disruption, which is the transition to a digital workflow. Much has been said about the countless benefits of entering the digital realm and how it will enhance pathologists’ practice. While some colleagues are experiencing this change with excitement, others are experiencing some anxiety, and some are in total denial. Human beings are creatures of habits, and pathologists are no exception. Thus a future with no microscope, no glass slides, and no paperwork can seem so stressful that it blocks the view of all the benefits that come after this transition. The presenting faculty will describe and demonstrate step by step how this transition can been done and how they not only survived, but are thriving in an uncluttered environment free of glass and paperwork. This workshop is for practicing pathologists at any stage in their careers.	Andrew Bellizzi, MD, FCAP Recording complete - St Emily Meserve, MD, MPH, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Immunohistochemistry	Andrew Bellizzi, MD, FCAP	Recording complete - St	Emily Meserve, MD, MPH, FCAP			and-zzi	rec-- s	emi-rve
Keep Abreast of Innovation	KAI1	Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Practical, Real-World Applications of Machine Learning in Pathology S2251 \| Infectious Disease Pathology \| 1.50 CME Credits	S2251	Practical, Real-World Applications of Machine Learning in Pathology	1.50 CME Credits	The potential of machine learning in pathology has stimulated substantial speculation in recent years. The deployment of machine learning applications in routine practice has now begun, yielding practical experience and best practices that can be shared. Machine learning in pathology remains a new domain in which there are challenges in matching the tool to the task, deploying machine learning tools successfully, and eliciting optimal ongoing performance. The faculty will introduce digital pathology for machine learning. They will review case-based examples of machine learning in anatomic pathology and laboratory medicine to illustrate opportunities and best practices for pathologists in the current landscape of machine learning systems.	Daniel Mais, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Infectious Disease Pathology	Daniel Mais, MD, FCAP					dan-ais
		Tuesday, October 11, 2022, 11:00:00 AM - 12:00 PM \| In-Person, Virtual Artificial Intelligence and Anatomical Pathology: What Every Practicing Pathologist Should Know S2288 \| Infectious Disease Pathology \| 1.50 CME Credits	S2288	Artificial Intelligence and Anatomical Pathology: What Every Practicing Pathologist Should Know	1.50 CME Credits	With recent advances in machine and deep learning, the integration of artificial intelligence (AI) into routine pathology practice is becoming a reality. Properly designed AI-enabled tools can potentially enhance a pathologist's job in many ways. In anatomical pathology, this could involve screening cases, automating tedious tasks, standardizing biomarker scoring, offering diagnostic assurance, novel prognostication, and much more. The faculty will provide an introduction to AI concepts and terminologies, review currently available products for anatomic pathologists, and explore deployment considerations in a practice setting. To provide a better understanding of AI principles, participants will be given an opportunity to train a machine learning algorithm using open-source (free) machine learning software (please bring a laptop running Windows/Mac OS/Linux to participate).	Alina Iuga, MD, FCAP Christina M. Wojewoda, MD, FCAP Maryam J. Zenali, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00:00 AM - 12:00 PM	Infectious Disease Pathology	Alina Iuga, MD, FCAP	Christina M. Wojewoda, MD, FCAP	Maryam J. Zenali, MD, FCAP			ali-uga	chr-oda	mar-ali
Get a Strong Start	GASS4	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Beyond Normal Limits: Uplifting Inclusivity Within Laboratory Medicine P2200 \| Informatics \| 1.25 CME Credits	P2200	Beyond Normal Limits: Uplifting Inclusivity Within Laboratory Medicine	1.25 CME Credits	The scientific plenary will focus on tangible changes laboratorians are able to make to help achieve health equity. Join our faculty for a discussion on health disparities and the connection with laboratory medicine. The discussion will cover deriving inclusive reference intervals representative of gender and race diversity, evaluate the clinical laboratory as a key stakeholder in propagating change, and elaborate on the responsibility pathologists and medical scientists have in mitigating negative implications of scientific “isms.” This session will also identify critical laboratory medicine changes to help eliminate health disparities. After this session, you will have an increased awareness of how reference ranges may contribute to inequality in health care and recognize your role in creating equity-centered change. Topics to be covered: Breaking Barriers to Gender-Inclusive Laboratory Medicine, Dina N. Greene, PhD, DABCC The NKF-ASN Task Force Recommendation on the Inclusion of Race in Diagnosing and Treating Kidney Disease, a Path Towards Health Equity, Cynthia Delgado, MD Toward Equity-Centered Science – Our Call to Action, Stephen P. Richmond, MD	Giovanni Lujan, MD, FCAP Anil V. Parwani, MD, PhD, MBA	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Informatics	Giovanni Lujan, MD, FCAP	Anil V. Parwani, MD, PhD, MBA				gio-jan	ani-ani
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Anatomic and Clinical Pathology Needs in Transgender Care S2275 \| Informatics \| 1.50 CME Credits	S2275	Anatomic and Clinical Pathology Needs in Transgender Care	1.50 CME Credits	Medical and surgical gender-affirmation therapies for transgender people have introduced a new spectrum to pathology practices. Sex hormones influence both anatomic and clinical pathology, which can complicate result interpretation for surgical specimens, chemistry, hematology, and microbiology. Our team has established transgender-specific reference intervals and performed in-depth analyses of surgical pathology aspects received from transgender men and women. Some of the nuances may not even be related to hormone administration, but rather are iatrogenically induced in the course of surgical affirmation. This session will empower pathologists with the tools necessary for serving the transgender population and prepare attendees to address the needs of their clinical colleagues in this regard.	Matthew G. Hanna, MD, FCAP James Harrison, MD, PhD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Informatics	Matthew G. Hanna, MD, FCAP	James Harrison, MD, PhD, FCAP				mat-nna	jam-son
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person Nailed It: How to Select and Track Meaningful Metrics in Your Lab M2260 \| Informatics \| 1.00 CME Credit	M2260	Nailed It: How to Select and Track Meaningful Metrics in Your Lab	1.00 CME Credit	Are you stuck in a rut measuring the same metrics in your lab year after year? Do you long for a more effective way to display and analyze your metrics? If you answered “yes,” please join us as we review the characteristics of meaningful metrics and different ways to display and report your data. This active course will allow you to practice defining, analyzing, and reporting metrics within your lab and to your organization in small peer groups. This course is geared toward new-in-practice or new-to-leadership roles, such as section director/technical supervisor, but open to all who enjoy quality assurance and subscribe to continuous improvement.	Jerome Y. Cheng, MD Liron Pantanowitz, MD, MHA, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Informatics	Jerome Y. Cheng, MD	Liron Pantanowitz, MD, MHA, FCAP				jer-eng	lir-itz
Grow as a Leader	GAL3	Sunday, October 9, 2022, 1:00 PM - 2:15 PM \| In-Person, Virtual Sweating Through PPE: Make Professional Practice Evaluation Less of a Workout R2209 \| Laboratory Medical Direction \| 1.00 CME Credit	R2209	Sweating Through PPE: Make Professional Practice Evaluation Less of a Workout	1.00 CME Credit	Join the experts for lunch! Discuss our struggles when creating and conducting meaningful professional practice evaluations (PPE) of pathologists and scientists in our lab. Realize it is okay to be anxious and be open to sharing our experiences and what-not-to-dos. If you’ve wondered, “What and how much should we evaluate?” and “Should the evaluation of a new-in-practice pathologist differ from a mid-career or senior pathologist?” to meet accreditation requirements, then this round table is for you! Attendees will walk away from this session with tips and tools for constructing a meaningful and balanced PPE program for their practice, including those for initial (focused), ongoing, and remedial evaluations.	Cynthia Delgado, MD Dina N. Greene, PhD, DABCC Stephen P. Richmond, MD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	01:00 PM	10/09/2022 01:00 PM	02:15 PM		Sunday, October 9, 2022, 1:00 PM - 2:15 PM	Laboratory Medical Direction	Cynthia Delgado, MD	Dina N. Greene, PhD, DABCC	Stephen P. Richmond, MD			cyn-ado	din-ene	ste-ond
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Lemonade out of Lemons: Adjustments to Difficult Inspection Encounters M2250 \| Laboratory Medical Direction \| 1.00 CME Credit	M2250	Lemonade out of Lemons: Adjustments to Difficult Inspection Encounters	1.00 CME Credit	Would you say your last laboratory inspection was a lemon? Are you still carrying the wounds? In this session, the faculty will present difficult inspection scenarios and offer insights, recommendations, and strategies for navigating these difficult inspections. More importantly, the faculty will facilitate the discussion of sharing techniques designed to avoid adverse situations during future inspections. The faculty will also provide practical information from the collective experience of team leaders and laboratory directors focused on optimizing the inspection experience. Attendees will find communication techniques, such as effective listening and separating the people from the problem, invaluable in their everyday dealing with laboratory professionals, clinicians, administrators, and patients. This course is designed to benefit both the experienced and novice team leaders and lab directors.	Dina N. Greene, PhD, DABCC Mahmoud A. Khalifa, MD, PhD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Laboratory Medical Direction	Dina N. Greene, PhD, DABCC	Mahmoud A. Khalifa, MD, PhD				din-ene	mah-ifa
Broaden Your Influence	BYI	Monday, October 10, 2022, 7:30 AM - 8:30 AM \| In-Person Succession Planning...Because Life Happens M2287 \| Laboratory Medical Direction \| 1.00 CME Credit	M2287	Succession Planning...Because Life Happens	1.00 CME Credit	Succession planning is a critical tool in securing leadership continuity, recruitment, staff retention, and overall job enrichment and satisfaction. In the laboratory industry, succession planning is often treated as an after-thought or not considered at all in the business and human resources strategic planning. In this course, the faculty will help define this critically important activity and provide participants at all levels of their career, especially those interested in leadership growth, with the tools needed to succeed in the establishment, implementation, and communication of a comprehensive corporate succession plan.	Jesse L. Kresak, MD, FCAP Ericka J. Olgaard, DO, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	08:30 AM		Monday, October 10, 2022, 7:30 AM - 8:30 AM	Laboratory Medical Direction	Jesse L. Kresak, MD, FCAP	Ericka J. Olgaard, DO, FCAP				jes-sak	eri-ard
		Monday, October 10, 2022, 11:30 AM - 12:30 PM \| In-Person Unmasking the Post-Pandemic Pathologist: How to Succeed More While Working LESS M2229 \| Laboratory Medical Direction \| 1.00 CME Credit	M2229	Unmasking the Post-Pandemic Pathologist: How to Succeed More While Working LESS	1.00 CME Credit	Drivers of burnout heightened in the pandemic with 30% of health care workers considering leaving medicine, more than 50% feeling burned out, and 60% feeling harmed by the stress. We do not have to wait for medicine to change to feel better. We can feel better now by learning enduring coaching skills that can lead to immediate relief no matter the crisis. A randomized clinical trial published in JAMA (2019) demonstrated that professional coaching reduced emotional exhaustion by 20%, decreased burnout by 17%, and improved quality of life and resilience. In this course, the audience will learn practical self-coaching tools that can be put in place today to feel better now. This interactive course allows learners to apply the coaching tools to real-life vignettes on the most common issues facing the post-pandemic physician: feeling overwhelmed, time scarcity, feeling devalued, and dealing with difficult people. Learners will be empowered with practical strategies to achieve more by working LESS.	Jesse L. Kresak, MD, FCAP Ericka J. Olgaard, DO, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	11:30 AM	10/10/2022 11:30 AM	12:30 PM		Monday, October 10, 2022, 11:30 AM - 12:30 PM	Laboratory Medical Direction	Jesse L. Kresak, MD, FCAP	Ericka J. Olgaard, DO, FCAP				jes-sak	eri-ard
Grow as a Leader	GAL1	Monday, October 10, 2022, 2:30 PM - 3:30 PM \| In-Person How to Create More Success by Working LESS: Small Group Coaching to Empower You R2206 \| Laboratory Medical Direction \| 1.00 CME Credit	R2206	How to Create More Success by Working LESS: Small Group Coaching to Empower You	1.00 CME Credit	Join the experts for lunch! Exchange information about enduring coaching skills and share solutions in a relaxed setting with your peers. Learn to improve your ability to identify solutions to challenging scenarios through interactive sessions.	Chad D. Galderisi, DO, FCAP Shane David Basil Smith, MD	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	03:30 PM		Monday, October 10, 2022, 2:30 PM - 3:30 PM	Laboratory Medical Direction	Chad D. Galderisi, DO, FCAP	Shane David Basil Smith, MD				cha-isi	sha-ith
Broaden Your Influence	BYI	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Coping With Labor Shortages – Key Solutions to Create Change S2202 \| Leadership \| 1.50 CME Credit	S2202	Coping With Labor Shortages – Key Solutions to Create Change	1.50 CME Credit	Labor shortages of both pathologists and a wide range of laboratory staff are becoming a commonplace occurrence in laboratories. Labor shortages create direct adverse effects upon laboratory teams and laboratory service levels. Both society-wide recent trends in labor dynamics and certain health care-specific labor dynamics, are now impacting most laboratories. In this session, there will be discussion of creative approaches for strengthening staff retention and addressing labor shortages. These approaches will include low-cost, commonsense changes that can be readily implemented in your practice. Strategies for collaboration between physicians and hospital administration will also be highlighted. Attendees will engage in small group discussions to collaborate on ideas for change and improvement.	Karim E. Sirgi MD, MBA, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Leadership	Karim E. Sirgi MD, MBA, FCAP					kar- md
Grow as a Leader	GAL4	Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person Train How You Will Practice: Strategies for Becoming a Great New-in-Practice Pathologist S2026 \| Leadership \| 1.50 CME Credits	S2026	Train How You Will Practice: Strategies for Becoming a Great New-in-Practice Pathologist	1.50 CME Credits	The transition from junior member to “new-in-practice pathologist” can be a time of stress and great change. This workshop specifically targets CAP junior members, with a goal of achieving successful independent practice, focusing on five specific areas: 1) determining the proper type of workplace for career goals (academic versus private, and group structure); 2) building skills to keep up with real-life case volume; 3) developing interpersonal skills needed for practice success; 4) establishing management and leadership skills; and 5) developing resilience in taking on new responsibilities with receptiveness to on-the-job training. The faculty will utilize small group team-based learning to aid trainees in establishing practices and habits for career success. The interactive learning will be led by new-in-practice faculty mediators from diverse practice settings, ranging from private practice to academic settings.	Christina A. Arnold, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Leadership	Christina A. Arnold, MD, FCAP					chr-old
Get a Strong Start	GASS1	Monday, October 10, 2022, 11:30 AM - 12:30 PM \| In-Person Make Change Happen: Don’t Let It Happen to You! M2224 \| Leadership \| 1.00 CME Credit	M2224	Make Change Happen: Don’t Let It Happen to You!	1.00 CME Credit	The current state of health care is mandating consolidation and integration of practices and laboratories and requiring pathologists to change organizational structures, test menus, and practice patterns to provide value and support. The scope and rapidity of these changes have been heightened in the setting of COVID, are unsettling and disruptive to physicians and staff, and can lead to workplace conflicts and unusually large numbers of resignations. The faculty do not anticipate that this will slow down in the near future. It is important for pathologists who will lead and be part of these changes to be cognizant of the impact of change and how they might manage and facilitate the process to minimize disruption and maximize outcomes. The faculty will discuss the challenges and solutions that others have implemented and will provide guidance to smooth the way to harmony.	Christina A. Arnold, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	11:30 AM	10/10/2022 11:30 AM	12:30 PM		Monday, October 10, 2022, 11:30 AM - 12:30 PM	Leadership	Christina A. Arnold, MD, FCAP					chr-old
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Setting Career Direction: Using Personal Leadership to Ignite the Flame and Keep it Going M2025 \| Leadership \| 1.00 CME Credit	M2025	Setting Career Direction: Using Personal Leadership to Ignite the Flame and Keep it Going	1.00 CME Credit	Your ship may have set sail, but is your career headed in the right direction? It is never too early or too late to set career direction and consider your professional legacy. In this course, the faculty will explore the concepts of meaning in work and values and how they relate to physician engagement and burnout. Come prepared to do some self-reflection! You will learn practical personal leadership strategies that set direction for your career. You will identify your great work—the work that makes you feel energized, define professional values, and discover your passions. This work sets the stage for a fulfilling career. Everyone can use these strategies, especially leaders and mentors, as they guide others in their journeys as pathologists.	Jennifer Fralick Christina S. Kong, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Leadership	Jennifer Fralick	Christina S. Kong, MD, FCAP				jen-lic	chr-ong
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person What is Your Why, and How Do You Do It: Identifying the Spark and Strategies To Keep the Flame Going R2223 \| Leadership \| 1.00 CME Credit	R2223	What is Your Why, and How Do You Do It: Identifying the Spark and Strategies To Keep the Flame Going	1.00 CME Credit	Join the experts for lunch! To be fulfilled as pathologists we need to understand our why, but have you ever contemplated your why? In this round table, we will explore our experience with understanding our why. Then, we will consider how we make time for our great work by sharing strategies and identifying solutions to challenges and barriers that keep us from our great work.	Juanita J. Evans, MD, FCAP Lauren King, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Leadership	Juanita J. Evans, MD, FCAP	Lauren King, MD, FCAP				jua-ans	lau-ing
		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Neighborhoods Matter: Identifying Spatial Biomarkers in the Tumor Microenvironment M2208 \| Leadership \| 1.00 CME Credit	M2208	Neighborhoods Matter: Identifying Spatial Biomarkers in the Tumor Microenvironment	1.00 CME Credit	Tumors are composed of many cell types, and for some tumors, the most dominant cell type is not the malignant cell. Immunotherapy has demonstrated that clinically relevant molecular properties of a tumor are a function of interactions among the varying cell types in the tumor microenvironment, and not exclusively intrinsic to the malignant cells. Advances in highly multiplexed imaging are enabling single cell resolution of cell type heterogeneity of the tumor microenvironment in a spatial context. The faculty will review state of the art technologies in multiplexed in situ imaging, methods for computational analysis of multiplexed in situ images, and identification of spatial biomarkers.	Moira P. Larsen, MD, MBA, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Leadership	Moira P. Larsen, MD, MBA, FCAP					moi-sen
Keep Abreast of Innovation	KAI2	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Understanding NGS and Interpreting Reports for Oncologic Pathology S2037 \| Leadership \| 1.50 CME Credits	S2037	Understanding NGS and Interpreting Reports for Oncologic Pathology	1.50 CME Credits	In this course, the faculty will provide a detailed description of informatics resources and databases used for tertiary data analysis, including interpretation and reporting of germline and somatic next-generation sequencing (NGS) assays. These resources include external data sources such as population, disease, and functional databases as well as internal variant databases maintained by the testing laboratory. The faculty will also discuss guidelines by the Association for Molecular Pathology and American College of Medical Genetics and Genomics to aid interpretation. As the size of NGS assays expand and big data analysis experiences a bottleneck at interpretation, the potential to use machine learning for improved variant filtration and ranking is being explored. Finally, the faculty will also discuss the impact of informatics in clinical decision making and the importance of training pathologists in using these resources appropriately. This course is cosponsored by the Association for Molecular Pathology.	Sarah M. Bean, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Leadership	Sarah M. Bean, MD, FCAP					sar-ean
		Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Gene Editing: A Primer for Practicing Pathologists M2114 \| Leadership \| 1.00 CME Credit	M2114	Gene Editing: A Primer for Practicing Pathologists	1.00 CME Credit	Gene-editing technology is being investigated in the clinical setting for treatment of inherited diseases, infectious diseases, and cancer. In addition to the scientific and medical issues related to gene-editing technology, there are ethical, financial, and regulatory issues that also must be considered. As gene-editing-based therapies expand into the clinical setting, pathologists must be educated on the topic. This course serves to both educate pathologists on gene-editing technologies and serve as a point of initial discussions in areas of gene-editing science, clinical therapy, and regulatory issues associated with gene-editing-based therapies, as these therapies are eventually introduced into clinical practice.	Sarah M. Bean, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Leadership	Sarah M. Bean, MD, FCAP					sar-ean
		Saturday, October 8, 2022, 7:30 AM - 8:30 AM \| In-Person, Virtual Genomic Pathology101: An Interactive Workshop S2027 \| Microbiology \| 1.50 CME Credits	S2027	Genomic Pathology101: An Interactive Workshop	1.50 CME Credits	Genomic testing is being integrated into pathology practice. From selecting the appropriate samples for testing to integrating findings into clinical reports, all pathologists need to understand genomic assays. The faculty will review introductory principles related to testing of tumor tissue including selection of samples and interpretation of results including the potential for detecting relevant germline variants. Using a case-based, interactive approach, participants will work in teams to answer clinically relevant questions integrating actual patient testing reports and utilizing online genomic pathology tools. If available, participants should bring a tablet or laptop (preferred). The faculty will provide directly applicable knowledge and skills for pathologists at all levels and practice settings. Members of the Training Residents in Genomics (TRIG) Working group committee at the Association of Pathology Chairs, experts in molecular pathology, medical education, and genetic counseling have developed this session.	Sylvia K. Plevritis, PhD	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	08:30 AM		Saturday, October 8, 2022, 7:30 AM - 8:30 AM	Microbiology	Sylvia K. Plevritis, PhD					syl-tis
Keep Abreast of Innovation	KAI2	Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person OMG! MSI, MMR IHC, NGS, or TMB for Checkpoint Inhibitor Treatment Screening: An Overview of the CAP Guideline on Mismatch Repair and Microsatellite Instability Testing S2166 \| Molecular Genetics \| 1.50 CME Credits	S2166	OMG! MSI, MMR IHC, NGS, or TMB for Checkpoint Inhibitor Treatment Screening: An Overview of the CAP Guideline on Mismatch Repair and Microsatellite Instability Testing	1.50 CME Credits	Checkpoint inhibitors are associated with durable (more than 12 months) treatment responses in patients with advanced cancers. This therapeutic approach is also associated with severe toxicities and side effects. The accurate identification of patients most likely to respond to this approach is therefore crucial in the clinical laboratory. In 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the immune checkpoint inhibitor, pembrolizumab, for patients with any advanced solid tumor malignancy that is MSI high or MMR deficient. The FDA did not specify which specific assay should be used. Faculty will summarize the benefits and limitations of different laboratory assays, including IHC, PCR-based microsatellite instability, microsatellite instability derived from next-generation sequencing, and tumor mutation burden derived from next-generation sequencing. Some of these assays have tumor-specific performance characteristics. Faculty will discuss the evidence-based recommendations from the CAP MMR/MSI guideline, including areas the committee identified as requiring further study.	Vera Paulson, MD, PhD Cecilia Yeung, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Molecular Genetics	Vera Paulson, MD, PhD	Cecilia Yeung, MD, FCAP				ver-son	cec-ung
Grow as a Leader	GAL3	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Selecting the Right Tool for the Job: Practical Considerations for Application of Molecular Diagnostics Methods in Surgical Pathology S2165 \| Molecular Genetics \| 1.50 CME Credits	S2165	Selecting the Right Tool for the Job: Practical Considerations for Application of Molecular Diagnostics Methods in Surgical Pathology	1.50 CME Credits	Multiple technologies exist to evaluate molecular alterations across tumors. They can overlap in their ability to provide information about diagnostic, therapeutic, and prognostic strategies in oncology. Selecting the most appropriate testing modality may be challenging, and understanding the indications and limitations of different molecular tests in clinical practice is critical to interpretation and appropriate patient care. This course will provide an overview of commonly used and emerging molecular techniques, capabilities and indications for interrogating different types of genetic alterations, compare advantages and limitations, and discuss when they may be complementary to one another. These concepts will be reinforced with examples of molecular analysis from a variety of solid tumors. Faculty will also discuss applications of emerging molecular testing approaches and strategies for interpretation and reporting of molecular results.	Allison M. Cushman-Vokoun, MD, PhD, FCAP Wayne W. Grody, MD,PhD	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Molecular Genetics	Allison M. Cushman-Vokoun, MD, PhD, FCAP	Wayne W. Grody, MD,PhD				all-oun	way-ody
Get a Strong Start	GASS3	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Detection of Alzheimer's Disease Pathology in the Living Patient: What Combination of Plasma Biomarkers Works Best? M2207 \| Molecular Oncology \| 1.00 CME Credit	M2207	Detection of Alzheimer's Disease Pathology in the Living Patient: What Combination of Plasma Biomarkers Works Best?	1.00 CME Credit	Alzheimer’s disease (AD) is an evolving medical nightmare with no end in sight. Learning to detect and treat this disease early is vital to the lifespan of the patient. During this session, the faculty will discuss plasma biomarker tests that are proven to be helpful in the detection of amyloid pathology and tau pathology. In addition, published studies examining the accuracy of detecting AD using plasma biomarker tests in individuals who are mildly cognitively impaired following clinical evaluation will be covered. This session is based on extensive expertise in the development, validation, and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies.	Brent T. Tan, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Molecular Oncology	Brent T. Tan, MD, PhD, FCAP					bre-tan
		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person How is my Payment Determined for Pathology Services? M2171 \| Molecular Oncology \| 1.00 CME Credit	M2171	How is my Payment Determined for Pathology Services?	1.00 CME Credit	Learn about concepts of current procedural terminology (CPT) coding and payment for services on the Medicare Physician Fee Schedule (PFS). In this highly interactive course, faculty will provide a historical introduction and overview of how current coding and billing practices were developed, and how the Centers for Medicare & Medicaid Services (CMS) values codes on the PFS. They will discuss how CPT codes are modified and the steps involved. Faculty will also cover aspects of payment policy (eg, National Correct Coding Initiative) and the role of existing process in the new value-based payment system. As a result of attending this course, participants will better comprehend the changing payment and regulatory environment, anticipate future trends, and better adapt their practice to current reimbursement trends.	Richard L. Haspel, MD, PhD, FCAP Phillip Michaels, MD, FCAP Nikoletta Sidiropoulos, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Molecular Oncology	Richard L. Haspel, MD, PhD, FCAP	Phillip Michaels, MD, FCAP	Nikoletta Sidiropoulos, MD, FCAP			ric-pel	phi-els	nik-los
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person Are You Working Harder and Going Broke: Tools to Drive Practice Profitability S2292 \| Molecular Oncology \| 1.50 CME Credits	S2292	Are You Working Harder and Going Broke: Tools to Drive Practice Profitability	1.50 CME Credits	The lifeblood of any practice revolves around its ability to collect for services provided and know the true cost of a lab test. Revenue Cycle Management guides the audience through correct data capture with accessioning to the final billing and collection from payors. Attendees will compute contractual adjustments, collection and bad debt rates, and other key metrics from a practice’s financial data. Then compare this to industry standards, which will help them to recognize and thwart trends that will negatively impact their practice. The faculty will use case studies to illustrate the calculation laboratory expenses. Additionally, they will use precise data on direct and indirect costs to tabulate the cost per specific lab test.	Russell R. Broaddus, MD, PhD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Molecular Oncology	Russell R. Broaddus, MD, PhD, FCAP					rus-dus
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person The American Board of Pathology: 85 Years of Service to the Public and the Profession P2201 \| Molecular Oncology \| 1.00 CME Credit	P2201	The American Board of Pathology: 85 Years of Service to the Public and the Profession	1.00 CME Credit	Pathology emerged as a specialty in the late 1800s as the value to patient care gained greater appreciation and respect. Pathologists were not considered “equal” in medical practice by their clinical colleagues; however, in 1926 pathologists received significant recognition when the American College of Surgeons revised its standards to require that laboratories be under the direction of MD physicians with special training in pathology and that “all tissue removed at operations shall be examined in the laboratory and reports rendered.” Recognition of pathologists as physicians and pathology as a medical specialty was reinforced in 1935 when a joint committee of the AMA Section on Pathology and the ASCP agreed that a Board of Pathology should be established. In 1936, the ABPath was incorporated in Michigan and approval was granted by the ABMS and the AMA Council on Medical Education. On July 19, 1936, the ABPath met for the first time in Chicago. The growth in specialty medicine and certification boards were the result of advancements in medical science, leading to improvements in patient care. Before the creation of board certification, there was no way to assure the public or the profession that a physician claiming to be a specialist had the requisite skills. Board certification demonstrates that a physician has: 1) completed an extended period of rigorous training and assessment of the knowledge, skills, and professionalism required to practice in a specialty; and 2) passed a secure, comprehensive examination of knowledge and skills. Consistent with rapid changes in medicine and societal expectations, ABPath began issuing time-limited certification in 2006. Diplomates maintain certification by meeting requirements for professionalism, life-long learning, and self-assessment, including longitudinal assessment with ABPath CertLink®, and health and health care improvement activities.	Larissa V. Furtado, MD, FCAP Laura J. Tafe, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Molecular Oncology	Larissa V. Furtado, MD, FCAP	Laura J. Tafe, MD, FCAP				lar-ado	lau-afe
		Tuesday, October 11, 2022, 1:00 PM - 2:00 PM \| In-Person, Virtual Demonstrating Your Value and Protecting Your Reimbursement in Evolving Quality Payment Models (On-Demand) M2177 \| Neuropathology \| 1.00 CME Credit	M2177	Demonstrating Your Value and Protecting Your Reimbursement in Evolving Quality Payment Models (On-Demand)	1.00 CME Credit	Value-based payment models continue to evolve to include considerations for quality of care, cost, and population health through a set of evidence-based metrics. While demonstrating the value of laboratory medicine to the health system, pathologists must also find quantitative ways to demonstrate their value in newer payment models. Pathologists must report on measures of quality, utilization, and cost, depending on the program or payer. For example, within the Centers of Medicare and Medicaid (CMS) Quality Payment Program, there are two participation pathways that impact an individual’s or group’s Medicare payments. The faculty will provide information to pathologists on how to demonstrate their impact on overall quality and cost to the organization through various quality measures to maximize reimbursement in these payment programs. The faculty will also present an interactive portion to facilitate discussions about the challenges and opportunities related to developing and implementing quality measures for accountability and quality payment program purposes.	Leslie M. Shaw, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM	02:00 PM		Tuesday, October 11, 2022, 1:00 PM - 2:00 PM	Neuropathology	Leslie M. Shaw, PhD					les-haw
		Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Early Detection of Lung Cancer: Radiology-Pathology Correlation M2212 \| Practice Finance \| 1.00 CME Credit	M2212	Early Detection of Lung Cancer: Radiology-Pathology Correlation	1.00 CME Credit	Recent literature shows that low-dose CT screening has significantly increased the detection of stage I lung cancer and reduced lung cancer mortality. This finding has led to the increased tissue sampling of smaller nodules detected by radiology, leading to several challenges encountered on microscopic analysis. With the World Health Organization (WHO) fifth edition of Thoracic Tumors and the Internatinoal Association for the Study of Lung Cancer Pathology Committee recommendations, accurate histologic typing and triaging of the smaller biopsy samples have become increasingly complex. In this course, the faculty will present the radiological characteristics of lung nodules <2 cm along with the pathology correlation. In addition, faculty will offer guidance using the most recent recommendations provided by the WHO classification especially in small biopsies.	Jonathan Myles, MD, FCAP Mark S. Synovec, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Practice Finance	Jonathan Myles, MD, FCAP	Mark S. Synovec, MD, FCAP				jon-les	mar-vec
Grow as a Leader	GAL1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing M2183 \| Practice Finance \| 1.00 CME Credit	M2183	Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing	1.00 CME Credit	Most lung cancer patients are diagnosed at an advanced stage by minimally invasive techniques that include small biopsies and cytology specimens. Potential challenges for diagnosis and biomarker testing can arise in these limited volume specimens. Therefore, judicious triaging in an effort to maximize the information one can obtain on these small specimens is important. With rapid advances in predictive and prognostic biomarker testing in lung cancer, pathologists are at the forefront of triaging these small specimens for diagnosis as well as performing and interpreting clinically needed biomarker testing. Hence, an understanding of the best practices to ensure adequate collection and handling of small specimens is critical. This course is designed for practicing pathologists, molecular laboratory personnel, and pathology trainees. The faculty will address various challenges in lung cancer diagnosis and the ever-expanding list of biomarker testing targets for small biopsy and cytology specimens, as well as discuss strategies to improve specimen collection and handling with a focus on therapeutic implications.	Chiraag N. Gangahar, MD, FCAP Susan B. Kern, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Practice Finance	Chiraag N. Gangahar, MD, FCAP	Susan B. Kern, MD, FCAP				chi-har	sus-ern
		Monday, October 10, 2022, 1:00 PM - 2:00 PM \| In-Person, Virtual Challenges in Diagnosis and Biomarker Testing of Lung Cancer Using Cytology and Small Biopsy Specimens V2296 \| Process and Outcome Improvement \| 1.50 CME Credits	V2296	Challenges in Diagnosis and Biomarker Testing of Lung Cancer Using Cytology and Small Biopsy Specimens	1.50 CME Credits	This video microscopy will expand upon the companion course, Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing, on updates for the use of cytology and small biopsy specimens for lung cancer diagnosis and biomarker testing. The faculty will identify potential diagnosis and biomarker testing challenges that could arise with limited samples. Pathologists need to be at the forefront of rapid advances in lung cancer diagnosis and predictive biomarker testing.	Rebecca L. Johnson, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	01:00 PM	10/10/2022 01:00 PM	02:00 PM		Monday, October 10, 2022, 1:00 PM - 2:00 PM	Process and Outcome Improvement	Rebecca L. Johnson, MD, FCAP					reb-son
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Lung Cancer and Neoadjuvant Therapy: What Pathologists Need to Know M2179 \| Process and Outcome Improvement \| 1.00 CME Credit	M2179	Lung Cancer and Neoadjuvant Therapy: What Pathologists Need to Know	1.00 CME Credit	Even though major pathologic response in patients with lung cancer treated with neoadjuvant therapy has been recognized as a predictor of survival and a potential surrogate end point in clinical trials, few studies have described gross and microscopic assessment of the lung resection specimens. Until recently, there was no established guidance on how to process and evaluate those specimens. This course is designed to provide practicing pathologists and pathologists in training with recommendations for gross and microscopic pathologic assessment of response to neoadjuvant therapy in lung cancer. Pulmonary pathologists who wish to receive updates on current guideline should also attend. Faculty will address challenges in the gross and histologic assessment of response to the specific neoadjuvant therapies including chemotherapy, targeted therapies, and immunotherapies. Practical tips for generation of surgical pathology reports easily understandable by thoracic surgeons and oncologists will be provided. This course is sponsored by the Pulmonary Pathology Society.	Diana M. Cardona, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Process and Outcome Improvement	Diana M. Cardona, MD, FCAP					dia-ona
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person Ancillary Testing In Non-Small Cell Lung Carcinoma With an Eye to Immunotherapy and Targeted Therapies: How and Why to Get It Done In 2022 S2289 \| Pulmonary Pathology \| 1.50 CME Credits	S2289	Ancillary Testing In Non-Small Cell Lung Carcinoma With an Eye to Immunotherapy and Targeted Therapies: How and Why to Get It Done In 2022	1.50 CME Credits	Ancillary testing in non-small lung carcinoma has evolved considerably in the last decade beyond IHC for TTF1 and single gene assays for EGFR and ALK. As the clinical paradigm has continued to shift, the standard of care now includes IHC for PD-L1 as well as, in most major institutions, large next-generation sequencing (NGS)-based panels to identify patients who qualify for treatment with an ever-expanding array of FDA-approved targeted therapies. In this session, a molecular pathologist and a cytopathologist with an interest in lung pathology, will discuss the current guidelines for therapy and testing as mandated by the National Cancer Care Network. In addition, the faculty will present strategies to implement, perform, and accurately report PD-L1 IHC as well as multiplex NGS-based testing in cytologic specimens and small biopsies. Faculty will also discuss the prognostic and predictive significance as well as the clinicopathologic correlates of the common driver mutations and the role of testing in cases with acquired resistance to common targeted therapies. Attendees can expect to leave this session with a thorough understanding of the current treatment paradigm for metastatic non-small cell lung carcinoma as well a firm grasp on the issues and challenges related to PD-L1 IHC and molecular testing. As this is a rapidly evolving topic and an extremely common disease state, this session will be of value to both junior and senior practicing pathologists as well as senior trainees.	Shaimaa A. Fadl, MBChB, MD Raghavendra Pillappa, MD, MBBS, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Pulmonary Pathology	Shaimaa A. Fadl, MBChB, MD	Raghavendra Pillappa, MD, MBBS, FCAP				sha-adl	rag-ppa
		Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Understanding Diversity in Pathology: Impact on Recruitment and Retention S2167 \| Pulmonary Pathology \| 1.50 CME Credits	S2167	Understanding Diversity in Pathology: Impact on Recruitment and Retention	1.50 CME Credits	This interactive course will explore our understanding of diversity, allowing attendees a glimpse into this issue within pathology. The faculty will look at its impact on different groups by collectively and honestly exploring some of the challenges, including microaggressions, that many pathologists have face in their daily lives. Moving from the personal to the institutional perspective, faculty will also discuss the impact of diversity (or lack of) on recruitment and retention. It is essential for pathologists to learn more about and appreciate the experiences of diverse populations in order to maintain them as members of our faculty and residency programs. This course will look at ways to improve diversity and what the pathologist can do about this issue going forward.	Sinchita Roy-Chowdhuri, MD, PhD, FCAP Paul VanderLaan, MD, PhD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Pulmonary Pathology	Sinchita Roy-Chowdhuri, MD, PhD, FCAP	Paul VanderLaan, MD, PhD, FCAP				sin-uri	pau-aan
		Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Soft Tissue Pathology is Fun…Really: A Crash Course for General Pathologists S2228 \| Pulmonary Pathology \| 1.50 CME Credits	S2228	Soft Tissue Pathology is Fun…Really: A Crash Course for General Pathologists	1.50 CME Credits	This course provides a whirlwind—but thorough—tour of soft tissue pathology highlighting the most common entities, pitfalls, and the appropriate ancillary testing usage. Faculty will cover topics including dermal-based, myxoid, and myoepithelial lesions, in addition to the usual adipocytic, neural, and myogenic entities. The faculty also will provide a comprehensive update on selected topics pertinent to the everyday practice of pathology using a partial case-based approach and audience participation. Presentation of content will meet the needs of the pathologist in training and the more experienced general pathologist, as well as those interested in sharpening their soft tissue pathology skills.	Sinchita Roy-Chowdhuri, MD, PhD, FCAP Paul VanderLaan, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Pulmonary Pathology	Sinchita Roy-Chowdhuri, MD, PhD, FCAP	Paul VanderLaan, MD, PhD, FCAP				sin-uri	pau-aan
		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Slide Seminar: Problem Cases in Surgical Pathology (On-Demand) S2010 \| Pulmonary Pathology \| 1.50 CME Credits	S2010	Slide Seminar: Problem Cases in Surgical Pathology (On-Demand)	1.50 CME Credits	This course highlights problem areas in surgical pathology related to change. Faculty will review recent changes in diagnostic criteria, terminology, and the development of testing platforms that shed new light on our understanding of disease processes. This course is cosponsored by the Arkadi M. Rywlin International Slide Seminar Club.	Sanja Dacic, MD PhD	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Pulmonary Pathology	Sanja Dacic, MD PhD					san-cic
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person, Virtual Can You Bank on Your Blood Supply: Using Blood Wisely and in Shortages S2286 \| Pulmonary Pathology \| 1.50 CME Credits	S2286	Can You Bank on Your Blood Supply: Using Blood Wisely and in Shortages	1.50 CME Credits	Are your transfusion guidelines up to date? Can you cope with a critical RBC or platelet shortage? The faculty will succinctly synthesize current multidisciplinary transfusion practice recommendations for all blood components into a logical framework applicable to peer education, blood management programs, and electronic guidance for blood ordering. In this interactive presentation, participants will use audience response technology to share benchmarking information on their hospital's current practices and learn how they can apply up-to-date guidelines to everyday patient problems. With this foundation, the faculty will discuss the next steps to prepare for and mitigate potential future blood shortages.	Mir B. Alikhan, MD Ajit Paintal, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM			Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Pulmonary Pathology	Mir B. Alikhan, MD	Ajit Paintal, MD, FCAP				mir-han	aji-tal
		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Debating the Mitigation of Future Blood Shortages R2230 \| Respect for Diversity \| 1.00 CME Credit	R2230	Debating the Mitigation of Future Blood Shortages	1.00 CME Credit	Join the experts for lunch! Exchange information about current multidisciplinary transfusion practices and share solutions in a relaxed setting with your peers. Learn to improve your ability in identifying resolutions to challenging scenarios through this interactive session.	Valerie A. Fitzhugh, MD FCAP Amyn Rojiani MD, PhD, CPE, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM			Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Respect for Diversity	Valerie A. Fitzhugh, MD FCAP	Amyn Rojiani MD, PhD, CPE, FCAP				val-ugh	amy- md
		\| Back to the Future: Low Titer O Whole Blood in Trauma S2034 \| \| 1.50 CME Credit	S2034	Back to the Future: Low Titer O Whole Blood in Trauma	1.50 CME Credit	In its earliest days, transfusion medicine focused almost exclusively on the transfusion of whole blood. In the latter part of the twentieth century, whole blood transfusion was largely abandoned in favor of blood component therapy. In recent years, there has been renewed interest in whole blood transfusion, especially in the context of trauma resuscitation. During this session, the faculty will explore the recent revival of whole blood transfusion, specifically low titer O whole blood (LTOWB). In addition, they will review relevant literature pertaining to whole blood, LTOWB, and resuscitation. Faculty will also present perspectives from both the hospital/trauma center and blood center, including the logistics of manufacturing and supplying LTOWB, regulatory/accreditation requirements, the challenges of optimizing the use of LTOWB, and the types of patients who can most benefit from this blood product.						12/30/1899 12:00 AM

Identify and Prepare for the Future of Pathology

Path	Category
Path	Category	List	Code	Title	CreditHours	Description	SpeakersList	Pass Type	FilterByDate	Date	Start Time	DateStartTime	End Time	Time	DateTime	Competency	Faculty 1	Faculty 2	Faculty 3	Faculty 4	Details	F1ID	F2ID	F3ID	F4ID
Keep Abreast of Innovation	KAI2	Sunday, October 9, 2022, 7:30 AM - 8:30 AM \| In-Person How Many Pathologists do We Really Have in the US? Threats, Opportunities, and Implications for Future Practice A2261 \| Advocacy \| 0.00 CME Credit	A2261	How Many Pathologists do We Really Have in the US? Threats, Opportunities, and Implications for Future Practice	0.00 CME Credit	Recent research by the CAP and the Association of American Medical Colleges (AAMC) has revealed, in its Physician Specialty Data Reports – one of the most important data sources on physician supply in the US, that the AAMC has been dramatically undercounting the number of pathologists. This undercount has been increasing each year since 2004 and reached nearly 40% in 2020. In this session, faculty will discuss the research that led to this important finding; show how the discovery of this shortfall changes what we know about the rate of growth in pathologist supply, the distribution of pathologists by whether or not they specialize, and the gender, age distribution, and racial/ethnic mix of pathologists. The faculty will also discuss what the data tells us about threats, opportunities, and implications for the future of pathology practice.	W. Stephen Black-Schaffer, MD, FCAP Kalisha A. Hill, MD, MBA, FCAP Thomas M. Wheeler, MD, FCAP Kalisha A. Hill, MD, MBA, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	08:30 AM		Sunday, October 9, 2022, 7:30 AM - 8:30 AM	Advocacy	W. Stephen Black-Schaffer, MD, FCAP	Kalisha A. Hill, MD, MBA, FCAP	Thomas M. Wheeler, MD, FCAP	Kalisha A. Hill, MD, MBA, FCAP		w. -fer	kal-ill	tho-ler	kal-ill
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 3:30 PM \| In-Person CPT Coding…You Can’t Practice Without It! Why Pathologists Need to Understand CPT Coding A2276 \| Dermatopathology \| 0.00 CME Credit	A2276	CPT Coding…You Can’t Practice Without It! Why Pathologists Need to Understand CPT Coding	0.00 CME Credit	Is understanding current procedural terminology (CPT) coding and its impact on your practice making your head spin? Get an insider expert’s insights and examples of current CPT coding practices and relevant payment policies for pathology and laboratory medicine. This workshop is designed to provide a comprehensive review of concepts as well as recent and anticipated changes in CPT coding that pathologists use to report their services. Faculty also will address your CPT coding problems and direct you to additional resources for answering your coding and related payment policy questions.	Mark S. Synovec, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	03:30 PM		Sunday, October 9, 2022, 2:30 PM - 3:30 PM	Dermatopathology	Mark S. Synovec, MD, FCAP					mar-vec
		Monday, October 10, 2022, 11:00 AM - 12:30 PM \| In-Person, Virtual Advocacy Town Hall A2260 \| Advocacy \| 0.00 CME Credit	A2260	Advocacy Town Hall	0.00 CME Credit	This session will provide members with a better understanding of the scope of our advocacy agenda. The CAP continually works to expand the public policy impact of pathology at the federal and state levels of government by engaging members in advocacy efforts. By combining grassroots advocacy with events like our annual policy meeting, town hall meetings, and other forums, engaged members help strengthen the profession's influence with policymakers.	Kalisha A. Hill, MD, MBA, FCAP Jonathan L. Myles, MD, FCAP Emily Volk, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	11:00 AM	10/10/2022 11:00 AM	12:30 PM		Monday, October 10, 2022, 11:00 AM - 12:30 PM	Advocacy	Kalisha A. Hill, MD, MBA, FCAP	Jonathan L. Myles, MD, FCAP	Emily Volk, MD, FCAP			kal-ill	jon-les	emi-olk
Get a Strong Start	GASS2	Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Current Payment Policy Challenges in Pathology Practice A2275 \| Advocacy \| 0.00 CME Credit	A2275	Current Payment Policy Challenges in Pathology Practice	0.00 CME Credit	Pathologists are often challenged by payment policy-related issues regarding the services they provide. It is important that pathologists better understand how Advocacy seeks to influence payment policies, why changes in reimbursement occur, and how to adapt within their practices. Workshop participants will gain knowledge and insight into the engagement opportunities available. The faculty will present payment policy information associated with Physician Fee Schedule valuation (that can influence payment policy development), Clinical Laboratory Fee Schedule Payment Reform (PAMA), emerging payment models, and other payment challenges and possible solutions.	Jonathan L. Myles, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Advocacy	Jonathan L. Myles, MD, FCAP					jon-les
Get a Strong Start	GASS2	Tuesday, October 11, 2022, 7:30 AM - 9:30 AM \| In-Person Negative Autopsies: When Routine Gross Dissection and Histology Come Up Empty H2144 \| Autopsy \| 2.00 CME Credits	H2144	Negative Autopsies: When Routine Gross Dissection and Histology Come Up Empty	2.00 CME Credits	Join us for discussion and hands-on dissection with esteemed faculty Dr. Fyfe-Kirschner and Dr. Sanchez to discover and practice vitreous humor extraction for electrolytes and toxicology and cardiac conduction system dissection. In most hospital autopsies, a routine dissection and histology will provide a cause of death. However, no cause of death will be apparent in some cases, a dissatisfying result for the pathologist, clinician, and family. This hands-on lab will provide a practical guide to approaching such cases. Interactive case presentations will be used to illustrate some of the most common causes of death in the absence of gross and histologic findings and when to suspect those diagnoses. The lecture will also cover the special testing needed to make those diagnoses, including special dissections, clinical laboratory testing, toxicology, genetic testing, and molecular testing. The participants will have the opportunity to practice several unique techniques, including a dissection of the conducting system and aspiration of the vitreous humor. The session will provide participants with a rational, cost-effective approach to diagnosing fewer common causes of a sudden unexpected death at all stages of their careers.	Meagan Chambers, MD Billie S. Fyfe-Kirschner, MD, FCAP Dylan V. Miller, MD, FCAP Harold Sanchez, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:30 AM		Tuesday, October 11, 2022, 7:30 AM - 9:30 AM	Autopsy	Meagan Chambers, MD	Billie S. Fyfe-Kirschner, MD, FCAP	Dylan V. Miller, MD, FCAP	Harold Sanchez, MD, FCAP		mea-ers	bil-ner	dyl-ler	har-hez
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Cutting Edge Pathology: Emerging Disease and Advancement of Molecular Research in Autopsy Investigation (On-Demand) S2041 \| Autopsy \| 1.50 CME Credits	S2041	Cutting Edge Pathology: Emerging Disease and Advancement of Molecular Research in Autopsy Investigation (On-Demand)	1.50 CME Credits	Autopsies remain the gold standard for cause of death; their use to educate clinicians can reduce discrepancies by half. Furthermore, large institutions benefit from rapid autopsies because of unlimited access to tissue and the opportunity to capture the biology of both normal and diseased states. Studies using autopsy tissue have greatly advanced our understanding of neurodevelopment, neurodegeneration, the pathophysiology of emerging infectious agents, and the molecular alterations responsible for disease recurrence and progression after treatment. Next-generation genomics brings new opportunities in pathology to utilize fresh tissue for the molecular advancement of neoplastic and infectious human disease, with unprecedented single cell resolution. This course will provide simple tips on how to educate administrators/clinicians on the value of autopsies. The faculty will highlight the advantages of rapid autopsies for the pathologist and the researcher, using specific case examples including their own experience gained during the COVID-19 pandemic. Finally, they will provide practical guidelines on techniques for fresh tissue procurement, including collection, single-cell dissociation, and culture.	Clare H. Bryce, MD, FCAP Nadejda Tsankova, MD, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Autopsy	Clare H. Bryce, MD, FCAP	Nadejda Tsankova, MD, PhD				cla-yce	nad-ova
		Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Book Club: Deceit and Denial: The Deadly Politics of Industrial Pollution N2204 \| Book Club \| 0.00 CME Credit	N2204	Book Club: Deceit and Denial: The Deadly Politics of Industrial Pollution	0.00 CME Credit	CAP22 will feature a book club, which offers discussion of literature topics related to pathology in an intimate, small group setting. Join Julie W. Lemmon, MD, FCAP as she facilitates a conversation about Deceit and Denial The Deadly Politics of Industrial Pollution by authors Gerald Markowitz and David Rosner. Through the lens of public health, historians Gerald Markowitz and David Rosner explore how the lead and plastic industries prioritized progress and profit at the expense of human health and the environment. They use primary sources to illustrate the complicity of industry executives, government agencies, scientists, and lobbyists in perpetuating harm against workers and the environment. Key Talking Points: •How did industries promote the benefits of lead to consumers •What were the catalysts that resulted in diminished use of lead in household products •How can relationships between industries and governments compound detrimental environmental effects that disproportionately affect marginalized communities •What types of advocacy efforts were successful at promoting improvements in safety and environmental reforms Attendees will read the book prior to the session and then engage in discussion.	Julie W. Lemmon, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Book Club	Julie W. Lemmon, MD, FCAP					jul-mon
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Roadmap Towards the “Perfect” Pathology Report of Post Neoadjuvant Therapy Breast Resections M2116 \| Breast Pathology \| 1.00 CME Credit	M2116	Roadmap Towards the “Perfect” Pathology Report of Post Neoadjuvant Therapy Breast Resections	1.00 CME Credit	Neoadjuvant therapy (NAT) is used increasingly in breast carcinoma (BC). The faculty will discuss the indications of NAT and important chemotherapeutic regimes. Additionally, faculty will cover the recommendations of the Breast International Group-North American Breast Cancer Group (BIG-NABCG) for assessing post-NAT resection specimens with emphasis on: the proper sampling of post-NAT specimens, the estimation of tumor size and residual cancer burden, post-therapy staging issues, and essential components to include in the pathology report.	Uma Krishnamurti, MD, PhD, FCAP Marina Mosunjac, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Breast Pathology	Uma Krishnamurti, MD, PhD, FCAP	Marina Mosunjac, MD, FCAP				uma-rti	mar-jac
Grow as a Leader	GAL2	Sunday, October 9, 2022, 9:00 AM - 5:00 PM \| In-Person Difficult Diagnoses in Breast Pathology and Management Challenges L2299 \| Breast Pathology \| 5.00 CME Credits	L2299	Difficult Diagnoses in Breast Pathology and Management Challenges	5.00 CME Credits	Join our team of renowned experts on Sunday, October 9, for an immersive review of challenging entities commonly seen in breast pathology practice. Faculty will help you navigate these diagnostic challenges using didactic, case-based, and interactive approaches to facilitate learning. This full-day course will cover an abundance of topics that will assist in your daily practice. Topics include diagnostic features and clinical significance of intraductal proliferative breast lesions, developing strategies for reporting papillary carcinomas, and recognizing the importance of radiologic correlation with nonneoplastic lesions. Fibroepithelial lesions will be highlighted by summarizing diagnostic features and clinical significance regarding the challenges for a core needle biopsy specimen. Attendees will learn to evaluate diagnostic criteria and clinical importance of classic and variant forms of LCIS, and classify morphologic and molecular features of special subtypes of invasive breast cancer. The faculty will also explore the role and limitations of prognostic and predictive markers, ER, PR, HER2, newer molecular assays, and PD-L1 testing in patients with breast cancer. This advanced course also includes interactive exercises illustrating the diagnostic and clinical features and management implications of several uncommon breast lesions. It will target general surgical pathologists with practical experience in diagnosing and signing out breast pathology.	Kimberly Allison, MD, FCAP Laura C. Collins, MD, FCAP Hannah L. Gilmore, MD Hannah Y. Wen, MD, PhD	In-Person	Sunday, October 9, 2022	10/09/2022	09:00 AM	10/09/2022 09:00 AM	05:00 PM		Sunday, October 9, 2022, 9:00 AM - 5:00 PM	Breast Pathology	Kimberly Allison, MD, FCAP	Laura C. Collins, MD, FCAP	Hannah L. Gilmore, MD	Hannah Y. Wen, MD, PhD		kim-son	lau-ins	han-ore	han-wen
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Hereditary Breast Cancers: What do We Know Beyond BRCA? S2149 \| Breast Pathology \| 1.50 CME Credits	S2149	Hereditary Breast Cancers: What do We Know Beyond BRCA?	1.50 CME Credits	Advances in the application of next-generation sequencing have led to the identification of germline mutations in cancer susceptibility genes other than BRCA1/2 that significantly increase risk for developing breast cancer. Guidelines for genetic testing in breast cancer patients are limited by the tedious process of extracting family history and are notorious at missing a significant proportion of patients otherwise suitable for testing. We, as pathologists, could ease this process by identifying distinct histomorphologic and immunophenotypic features associated with these mutations. Furthermore, recent approval of PARP-inhibitors for treatment of breast cancer patients with BRCA1/2 mutations has substantiated a need for embracing new tests for predicting response to therapy. The faculty will highlight the most up-to-date information related to hereditary breast cancers and will emphasize the important role the pathologist plays in their identification. This course is suitable for general surgical pathologists, subspecialized pathologists, and pathologists in training.	Rania Bakkar MD, FCAP Anupma Nayak, MD	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Breast Pathology	Rania Bakkar MD, FCAP	Anupma Nayak, MD				ran- md	anu-yak
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation using Morphology and IHC S2276 \| Breast Pathology \| 1.50 CME Credits	S2276	Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation using Morphology and IHC	1.50 CME Credits	Evaluation of spindle cell lesions of the breast is challenging and can be even more so on core needle biopsy specimens. Malignant mimics of benign lesions abound and vice versa. The diagnostic considerations are broad as some malignant lesions, such as metaplastic carcinomas, can be deceptively bland. A targeted IHC panel is often critical in evaluating these lesions, but there are important pitfalls to be aware of when evaluating IHC. The faculty will review common and unusual spindle cell lesions of the breast, considerations that should be included in the differential diagnosis, and when and how to utilize IHC to support a morphologic diagnosis. In some cases, a definitive diagnosis is not possible on core needle biopsy. The faculty will discuss how best to convey sufficient pathologic information to the clinical team so that the patient receives appropriate care. This course is appropriate for all pathologists who review breast specimens.	Laura C. Collins, MD, FCAP Liza Quintana, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Breast Pathology	Laura C. Collins, MD, FCAP	Liza Quintana, MD, FCAP				lau-ins	liz-ana
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person Spindle Cell Lesions of the Breast: A Spectrum of Cases and Their Differential Diagnoses V2293 \| Breast Pathology \| 1.50 CME Credits	V2293	Spindle Cell Lesions of the Breast: A Spectrum of Cases and Their Differential Diagnoses	1.50 CME Credits	This video microscopy course will expand on the companion course Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation Using Morphology and IHC. The differential diagnosis for spindle cell lesions is broad and the evaluation and categorization of these lesions is challenging. The faculty will review common and rare spindle cell lesions with an emphasis on how to work them up, order and interpret relevant IHC, and report them.	Laura C. Collins, MD, FCAP Liza Quintana, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Breast Pathology	Laura C. Collins, MD, FCAP	Liza Quintana, MD, FCAP				lau-ins	liz-ana
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Common Yet Challenging Diagnoses in Breast Core Biopsies: How to Recognize and Avoid the Pitfalls (On-Demand) S2148 \| Breast Pathology \| 1.50 CME Credits	S2148	Common Yet Challenging Diagnoses in Breast Core Biopsies: How to Recognize and Avoid the Pitfalls (On-Demand)	1.50 CME Credits	With the wide practice of breast cancer screening programs, breast core biopsies are among the most common specimens in academic and private pathology practice. It can be challenging to render an accurate diagnosis with limited sampling from core biopsies. Common but challenging cases in breast core biopsies include: 1) usual ductal hyperplasia versus atypical ductal hyperplasia versus low-grade ductal carcinoma in situ; 2) sclerosing lesions including benign and malignant entities; 3) papillary lesions including papilloma with uncommon features, atypical papilloma, and papillary carcinoma; and 4) fibroepithelial lesions including benign and malignant entities. The faculty will present information to help pathologists become familiar with the morphological features of these common but challenging entities, and how to order and interpret appropriate ancillary IHC studies. Faculty will also update pathologists on current recommendations on management and molecular features of these lesions.	Benjamin C. Calhoun, MD, PhD, FCAP Xiaoxian (Bill) Li, MD, PhD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Breast Pathology	Benjamin C. Calhoun, MD, PhD, FCAP	Xiaoxian (Bill) Li, MD, PhD, FCAP				ben-oun	xia- li
Keep Abreast of Innovation	KAI3	Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Point-of-Care and Rapid Tests for COVID-19, the Mayo Clinic Experience R1935 \| Chemistry \| 1.00 CME Credit	R1935	Point-of-Care and Rapid Tests for COVID-19, the Mayo Clinic Experience	1.00 CME Credit	Join the experts for lunch! Exchange information and share solutions in a relaxed setting with your peers. Learn to improve your ability to identify solutions to common problems through interactive sessions.	Bradley S. Karon, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Chemistry	Bradley S. Karon, MD, PhD, FCAP					bra-ron
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person Tips for Ensuring Quality in Your Point-of-Care Program M2221 \| Communication \| 1.00 CME Credit	M2221	Tips for Ensuring Quality in Your Point-of-Care Program	1.00 CME Credit	The rapid growth of point-of-care testing (POCT) adoption is reflective of the vital role POCT plays in patient management. With correct implementation, POCT can improve outcomes, decrease overall turnaround time, increase access to care, reduce costs, and enhance patient satisfaction. It is therefore imperative to ensure quality in POCT, however, managing this is a continuous challenge. During this course, the faculty will review the total testing process in POCT and the challenges associated with ensuring quality at each phase of testing. Using case examples, the faculty will describe strategies to overcome challenges at the preanalytic, analytic, and postanalytic phases of testing. They will also share tips on identifying quality indicators, monitoring performance, engaging personnel, reducing errors, and implementing processes that ensure quality will be described. This course is intended for pathologists, lab directors, lab managers, POCT coordinators, and pathology trainees practicing in hospital or outpatient settings. This course is cosponsored by the American Association for Clinical Chemistry.	Brenda Suh-Lailam, PhD, DABCC	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Communication	Brenda Suh-Lailam, PhD, DABCC					bre-lam
		Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual How to Avoid Death by PowerPoint and Zoom: A Field Guide to Creating More Impactful Presentations M2217 \| Communication \| 1.00 CME Credit	M2217	How to Avoid Death by PowerPoint and Zoom: A Field Guide to Creating More Impactful Presentations	1.00 CME Credit	Pathologists are the visual artists of medicine. We diagnose images and craft diagnostic stories that start patients on their treatment journeys. How do we leverage those visual skills to become a more compelling storyteller? This presentation will help you do that. It is a talk about talks—a how-to guide for presenters. During the first half the faculty will focus on live presentations, constructing a talk that engages and inspires. What are the hidden features of PowerPoint that will make your presentation stand out? The faculty will discuss graphic design principles for creating slides with the right mix of images and text. The second half of the talk will focus on virtual presentations, using Zoom, Teams, etc. What software will maximize impact? How do the interplay of lighting, sound, and virtual backgrounds lead to a better virtual experience? It’s time to unmute yourself and unleash your inner visual storyteller.	Eric F. Glassy, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Communication	Eric F. Glassy, MD, FCAP					eri-ssy
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Diagnostic Reporting Systems in Cytopathology: Updates, Aftermaths and Controversies S2164 \| Cytopathology \| 1.50 CME Credits	S2164	Diagnostic Reporting Systems in Cytopathology: Updates, Aftermaths and Controversies	1.50 CME Credits	The Diagnostic Reporting Systems in Cytopathology (DRSC) were created to meet general and specific needs. All systems address problematic terminologies and attempt to streamline patient management. Common standards improve communication between cytopathologists and their clinical colleagues. Specifically, The Bethesda System for Reporting Cervical Cytology (TBS) was born in response to problematic practices and the creation of CLIA 88. Bethesda-Thyroid and Serous Fluid Systems were created due to a need for clarification of diagnostic tiers and risks of malignancy. Paris was needed because of poor performance of low-grade urinary cytology and clarification of what urinary cytology does well. The Milan System for Salivary Gland came about because of diagnostic inconsistencies in dealing with a very difficult area. All DRSCs have been modeled after TBS. In this session, faculty will describe four DRSCs, discuss real-world implications of the proposed nomenclature, and provide updates of each reporting scheme. This course is cosponsored by the American Society of Cytopathology.	Zubair W. Baloch, MD, PhD, FCAP Guliz A. Barkan, MD, FCAP Daniel F.I. Kurtycz, MD, FCAP Ritu Nayar, MD, MBBS, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Cytopathology	Zubair W. Baloch, MD, PhD, FCAP	Guliz A. Barkan, MD, FCAP	Daniel F.I. Kurtycz, MD, FCAP	Ritu Nayar, MD, MBBS, FCAP		zub-och	gul-kan	dan-ycz	rit-yar
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Common Pitfalls and Mimickers in Dermatopathology S2259 \| Dermatopathology \| 1.50 CME Credits	S2259	Common Pitfalls and Mimickers in Dermatopathology	1.50 CME Credits	This course is tailored for general surgical pathologists with a focus on key aspects of IHC and molecular studies, and traditional clinical and histophenotypic features of difficult benign and malignant skin lesions. The faculty will use their extensive experience in a large tertiary referral cancer center to discuss and illustrate differential diagnoses. Early and correct recognition of these lesions is of utmost importance to reduce incorrect or nondefinitive diagnoses and costs for unnecessary studies, as well as streamline time to results for patients and management. The faculty will summarize the key features and algorithmic approach, and review cases with interactive discussion of this practical approach. Highlighted situations include: digital papillary adenocarcinoma versus acral hidradenoma; primary adnexal neoplasm versus metastatic adenocarcinoma to skin; cutaneous lymphoproliferative disorders such as gamma-delta T-cell lymphoma versus mycosis fungoides with CD8 expression; capsular nevus versus metastatic melanoma in sentinel lymph node of patients with melanoma; spindle melanocytic lesion (benign/malignant) versus neural tumor such as MPNST; Merkel cell carcinoma versus basal cell carcinoma; squamous cell carcinoma versus psedoepitheliomatous hyperplasia due to syphilis.	Phyu P. Aung, MD, PhD, FCAP Victor G. Prieto, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Dermatopathology	Phyu P. Aung, MD, PhD, FCAP	Victor G. Prieto, MD, PhD, FCAP				phy-ung	vic-eto
Keep Abreast of Innovation	KAI3	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Expert Testimony: What Happens After You Receive the Subpoena? M2219 \| Forensic Pathology \| 1.00 CME Credit	M2219	Expert Testimony: What Happens After You Receive the Subpoena?	1.00 CME Credit	You just get handed a subpoena, now what? This course will prepare hospital-based and forensic pathologists (residents to 10 years in practice) for a variety of interactions in the medicolegal arena. The faculty will provide an overview of the judicial system including common terminology, procedures, decorum in the witness box, and various legal orders. Further, the faculty will explain deposition and trial testimony, including how they differ and what can go wrong. Finally, they will describe common pitfalls and “trick” questions (and some answers). The goal of the course is to remove some of the mystery and trepidation around testimony and provide a solid understanding of what to expect and how to react in these proceedings.	Beth E. Frost, DO, FCAP James R. Gill, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Forensic Pathology	Beth E. Frost, DO, FCAP	James R. Gill, MD, FCAP				bet-ost	jam-ill
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person, Virtual Before the Cancer Diagnosis: Navigating Inflammatory and Pre-malignant Pathology of the Esophagus S2262 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2262	Before the Cancer Diagnosis: Navigating Inflammatory and Pre-malignant Pathology of the Esophagus	1.50 CME Credits	Premalignant and non-infectious inflammatory diseases of the esophagus are entities that present diagnostic challenges, especially when there is limited clinical information and overlapping histologic features. Proper identification is imperative in ensuring appropriate patient management. The faculty will address two compelling issues faced by pathologists in academic, private, and community practice as well as pathologists in training. First, faculty will focus on identifying and grading squamous and glandular esophageal dysplasia (Barrett mucosa). Secondly, developing a methodical approach for evaluating non-infectious inflammatory conditions (eosinophilic esophagitis, lichenoid esophagitis). Participants will gain proficiency in how to formulate diagnoses for dysplastic and inflammatory esophageal pathologies. The audience will be engaged through a series of case studies and polling questions to enhance key learning objectives.	Safia N. Salaria, MD, FCAP Annika L. Windon, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Gastrointestinal Pathology	Safia N. Salaria, MD, FCAP	Annika L. Windon, MD, FCAP				saf-ria	ann-don
		Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Inflammatory Bowel Disease: Challenges and Controversies S2263 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2263	Inflammatory Bowel Disease: Challenges and Controversies	1.50 CME Credits	During this course, the faculty will focus on the challenges and controversies in the histologic examination of specimens from patients with inflammatory bowel disease (IBD). They will discuss topics such as unusual forms of dysplasia, reporting of dysplasia are SCENIC, serrated epithelial change, Crohn's colitis, indeterminate colitis, backwash ileitis, and reporting pouch specimens, among other topics. The faculty will address emerging topics in IBD, and their relevance to the practice of GI pathology. The course is intended for practicing pathologists with at least some experience or interest in GI pathology who want to deepen their knowledge in IBD, including pathology residents and fellows in GI pathology. This course is cosponsored by the Rodger C. Haggitt Gastrointestinal Pathology Society.	Won-tak Choi MD, PhD Joseph Misdraji, MD, FCAP Bita V. Naini, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Gastrointestinal Pathology	Won-tak Choi MD, PhD	Joseph Misdraji, MD, FCAP	Bita V. Naini, MD, FCAP			won- md	jos-aji	bit-ini
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Keeping Up With the Advances in Gastric Neoplasms S2153 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2153	Keeping Up With the Advances in Gastric Neoplasms	1.50 CME Credits	In the current era of evolving integration between traditional pathology and molecular advances, this course offers a practical review of neoplastic gastric pathology combining updated morphologic classification and advanced techniques. Faculty will use case-based illustrations to cover updated information on the classification of gastric polyps, dysplasia, and cancer based on morphologic assessment, IHC studies, and molecular techniques. Additionally, faculty will present a combination of succinct up-to-date summaries and real practice examples to explain the updates relevant to routine practice such as novel World Health Organiazation classification, the value of gastric intestinal metaplasia subtyping, and evaluation of HER2/neu and PD-L1 expression in gastric cancer. Examples of molecularly defined subtypes of gastric neoplasms that may direct therapy will also be discussed. The course is designed for academic and community pathologists.	Gregory Lauwers, MD, FCAP Namrata Setia, MD, MBBS	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Gastrointestinal Pathology	Gregory Lauwers, MD, FCAP	Namrata Setia, MD, MBBS				gre-ers	nam-tia
Keep Abreast of Innovation	KAI3	Monday, October 10, 2022, 9:30 AM - 11:00 AM \| In-Person, Virtual Appendix Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis S2172 \| Gastrointestinal Pathology \| 1.50 CME Credit	S2172	Appendix Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis	1.50 CME Credit	This course will provide an update on the classification, nomenclature, and staging of commonly encountered and newly described lesions of the appendix. This course features a case-based discussion from two gastrointestinal pathology experts who will emphasize practical diagnostic pearls and pitfalls and reporting strategies. The faculty will present the latest guidelines and recent changes to nomenclature and staging. An interactive quiz component will emphasize key learning points and allow the audience to practice applying the course content with real-time feedback. There will be ample time for questions and discussion between the faculty and participants. The course is intended for practicing surgical pathologists, gastrointestinal subspecialized pathologists, as well as residents and fellows.	Jacqueline E. Birkness-Gartman, MD Maryam K. Pezhouh, MD, MSc, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	11:00 AM		Monday, October 10, 2022, 9:30 AM - 11:00 AM	Gastrointestinal Pathology	Jacqueline E. Birkness-Gartman, MD	Maryam K. Pezhouh, MD, MSc, FCAP				jac-man	mar-ouh
Keep Abreast of Innovation	KAI3	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual EUS-guided and 'SpyBite' Biopsies of Pancreatic and Biliary Tract Lesions (FNA vs Biopsy) S2178 \| Gastrointestinal Pathology \| 1.50 CME Credit	S2178	EUS-guided and 'SpyBite' Biopsies of Pancreatic and Biliary Tract Lesions (FNA vs Biopsy)	1.50 CME Credit	This course is presented by the Pancreatobiliary Pathology Society and will provide an overview and step-wise, algorithmic approach to the evaluation of “SpyBite” biopsies and cytologic samples (including endoscopic ultrasound (EUS)-guided fine-needle aspirations and bile duct brushings) from cystic/solid lesions/strictures of pancreas and biliary tract. The faculty include a cytopathologist and gastrointestinal pathologist who subspecialize in pancreatobiliary pathology. These faculty will outline practical diagnostic pearls and reporting strategies as well as judicious utility of ancillary IHC/molecular studies. Additionally, the faculty will emphasize changes in terminology, classification, and diagnosis/grading of classical and newly described site-specific entities (intraductal papillary mucinous (IPMN), oncocytic (IOPN) and tubulopapillary (ITPN) neoplasm, flat (Bil-IN) and tumoral intraepithelial biliary tract neoplasms (IPN-B), and neuroendocrine neoplasms). This course is intended for surgical, gastrointestinal, and cytopathologists in community/academic practice as well as pathologists in training. An interactive quiz will emphasize key learning points and allow the audience to practice/apply course content with real-time feedback. This course is sponsored by the Pancreatobiliary Pathology Society.	Olca Basturk, MD Michelle Reid, MD, MS, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Gastrointestinal Pathology	Olca Basturk, MD	Michelle Reid, MD, MS, FCAP				olc-urk	mic-eid
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual When is Enough Enough? Making Sense of the Small Changes in GI Biopsies S2011 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2011	When is Enough Enough? Making Sense of the Small Changes in GI Biopsies	1.50 CME Credits	This course will examine fundamental concepts of histology in upper and lower gastrointestinal biopsies with a focus on intraepithelial lymphocytosis and dysplastic epithelial changes in an ever-increasing, complex patient environment. The faculty will use a case-based approach to provide practical examples of how to sign out cases from different sites, and highlight subtle histologic details to aid recognition of key features. In addition, faculty will review recent literature and the American Joint Committee on Cancer and World Health Organization updates to clarify diagnostic criteria, ensure consistency in reporting, and optimize patient care. These discussions will help both practicing pathologists as well as trainees. This course is cosponsored by the Rodger C. Haggitt Gastrointestinal Pathology Society.	Stephen M. Lagana, MD, FCAP David F. Schaeffer, MD, FRCPC	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Gastrointestinal Pathology	Stephen M. Lagana, MD, FCAP	David F. Schaeffer, MD, FRCPC				ste-ana	dav-fer
Get a Strong Start	GASS2	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21) S2274 \| Genitourinary Pathology \| 1.50 CME Credits	S2274	Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21)	1.50 CME Credits	The classification of genitourinary cancers has significantly advanced due to the rapidly evolving understanding of the molecular underpinnings of cancer with excellent clinical and pathologic correlation. The faculty have designed this course to concisely summarize new diagnostic entities in genitourinary pathology. They have incorporated critical changes in diagnostic nomenclature from the upcoming World Health Organization 2021 (WHO-21) book and will cover all areas of the genitourinary system, including the kidney, prostate, penis, testis, and urinary tract. The faculty will: 1) describe the overarching, evolving paradigm of urologic tumor classification based on morphologic, clinical, and molecular correlations; 2) present new and emerging entities in genitourinary pathology in the context of existing classification schema; 3) highlight molecular testing as relevant to genitourinary diagnostic categories; and 4) discuss the impact of these new modalities and diagnoses on clinical management.	Mahul B. Amin, MD, FCAP Donna E. Hansel, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Genitourinary Pathology	Mahul B. Amin, MD, FCAP	Donna E. Hansel, MD, PhD, FCAP				mah-min	don-sel
Get a Strong Start	GASS3	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Identifying New and Emerging Entities in Genitourinary Pathology V2245 \| Genitourinary Pathology \| 1.50 CME Credits	V2245	Identifying New and Emerging Entities in Genitourinary Pathology	1.50 CME Credits	This video microscopy course will expand upon the companion course on updates in the morphological and molecular classification of urologic malignancies Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21). The faculty will identify critical changes in diagnostic nomenclature from the upcoming World Health Organization 2021 book and cover all areas of the genitourinary system. The faculty will also cover new and emerging entities in genitourinary pathology and discuss the impact of these new modalities and diagnoses on clinical management.	Mahul B. Amin, MD, FCAP Donna E. Hansel, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Genitourinary Pathology	Mahul B. Amin, MD, FCAP	Donna E. Hansel, MD, PhD, FCAP				mah-min	don-sel
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Difficult Differential Diagnoses in Genitourinary Pathology: Mimickers and Beyond S2291 \| Genitourinary Pathology \| 1.50 CME Credits	S2291	Difficult Differential Diagnoses in Genitourinary Pathology: Mimickers and Beyond	1.50 CME Credits	This course focuses on addressing challenging scenarios and contemporary differential diagnosis for a broad array of genitourinary specimens relevant to pathologists in practice and in training. Using a case presentation with an organ-based approach, the faculty will address evolving concepts in old and emerging entities, diagnostic pitfalls, and controversies in numerous genitourinary cancer subtypes. A large number of images in a tumor board format will expose the audience to a wide spectrum of lesions. Faculty will place significant emphasis on contemporary updates, interpretation of diagnostic pitfalls, exclusion of benign mimickers, and application of ancillary studies. Additionally, the faculty will emphasize key pathologic reporting parameters that are of greatest value to clinicians in the context of clinical application and management.	Giovanna A. Giannico, MD, FCAP Sean R. Williamson, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Genitourinary Pathology	Giovanna A. Giannico, MD, FCAP	Sean R. Williamson, MD, FCAP				gio-ico	sea-son
		Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Embracing Diversity in Bladder Cancer: Variants, Divergence, and Molecular Findings in Urothelial Carcinoma M2270 \| Genitourinary Pathology \| 1.00 CME Credit	M2270	Embracing Diversity in Bladder Cancer: Variants, Divergence, and Molecular Findings in Urothelial Carcinoma	1.00 CME Credit	Urothelial carcinomas with variant/divergent differentiation convey a worse prognosis than pure high-grade urothelial carcinoma. They remain unrecognized and underreported, despite their clinical and prognostic importance. They usually present with high pT stage and nodal metastasis. Treatment guidelines may also differ with aggressive multimodal therapy recommended in this setting. The faculty will present the morphologic features of clinically significant divergent histology in the urothelial tract and the need to consistently report them due to their prognostic and therapeutic impact. They will also discuss the differential diagnosis including the preneoplastic lesions and mimickers to ensure accurate recognition. Finally, the faculty will focus on the role of molecular advances in the diagnosis, classification, and management of urothelial carcinoma, including when and how to fully integrate such advances in routine diagnostic practice. This course is suitable for pathologists in training and in practice, irrespective of years of practice, in both academic and community settings.	Hikmat A. Al-Ahmadie, MD Lara R. Harik, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Genitourinary Pathology	Hikmat A. Al-Ahmadie, MD	Lara R. Harik, MD, FCAP				hik-die	lar-rik
Keep Abreast of Innovation	KAI1	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Big Results From Small Specimens: Maximizing the Impact of Renal Mass Biopsy for Best Clinical Outcomes S2246 \| Genitourinary Pathology \| 1.50 CME Credits	S2246	Big Results From Small Specimens: Maximizing the Impact of Renal Mass Biopsy for Best Clinical Outcomes	1.50 CME Credits	Renal mass biopsies are increasingly utilized in the workup of renal masses, especially those that are found incidentally. Simultaneously, the classification of renal neoplasms is expanding with numerous new entities being introduced into the literature. The faculty will focus on the utility and limitations of renal mass biopsies, providing numerous case-based examples of how to effectively approach these small specimens. Video microscopy will be used to review cases in real time with genitourinary pathologists from academic and private settings. The course will be interactive with questions from the audience as well as polling questions. As renal mass biopsies may be seen in any practice setting, this course is geared to pathologists at any stage of their career who are interested in gaining practical insight into the diagnosis of renal mass biopsies.	Ankur R. Sangoi, MD, FCAP Sara E. Wobker, MD, MPH, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Genitourinary Pathology	Ankur R. Sangoi, MD, FCAP	Sara E. Wobker, MD, MPH, FCAP				ank-goi	sar-ker
Get a Strong Start	GASS4	Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Money is in the LAST Detail: Diagnosis and Management of Human Papillomavirus Infection-Associated Lesions S2155 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2155	Money is in the LAST Detail: Diagnosis and Management of Human Papillomavirus Infection-Associated Lesions	1.50 CME Credits	The human papillomavirus (HPV) is mainly responsible for malignancies of the lower anogenital tract and oropharynx. The faculty will review the epidemiology and life cycle of HPV, and the steps in HPV-related carcinogenesis. They will emphasize criteria to accurately identify and classify HPV-driven preneoplastic and neoplastic lesions in both cytology and histologic specimens following the recommendations of the Lower Anogenital Squamous Terminology (LAST) project. There are challenges in the proper implementation of p16 IHC, recommended by the LAST project as a biomarker to identify high-grade squamous intraepithelial lesion. The faculty will discuss sources of error and present solutions to correctly apply and interpret p16 IHC, and will also review the American Society for Colposcopy and Cervical Pathology guidelines for management of women with abnormal Pap test, screening guidelines for various HPV-related cancers, and will conclude by reviewing the HPV vaccine. A case-based approach with live audience response will be used to cover these topics.	Krisztina Z. Hanley, MD Uma Krishnamurti, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Gynecologic/Obstetric Pathology	Krisztina Z. Hanley, MD	Uma Krishnamurti, MD, PhD, FCAP				kri-ley	uma-rti
Grow as a Leader	GAL3	Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Clinically Relevant, Pattern-Based Approach to Diagnosing Uterine Mesenchymal Tumors (On-Demand) S2156 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2156	Clinically Relevant, Pattern-Based Approach to Diagnosing Uterine Mesenchymal Tumors (On-Demand)	1.50 CME Credits	This course will use a pattern-based approach (spindled, epithelioid, rhabdoid, myxoid patterns; low-grade versus high-grade atypia) to build differential diagnoses and emphasize selection and interpretion of the most useful, current IHC and molecular tests for each diagnostic scenario of uterine mesenchymal tumors. The faculty will highlight common pitfalls, new diagnostic tools, and features that predict response to targeted therapy; and the novel role of the pathologist in recognizing morphologic features associated with risk of a hereditary syndrome. Special issues in the diagnosis and reporting of mesenchymal tumors in endometrial biopsy, curettage, and polypectomy and their unique challenges will be addressed. Updates from the new World Health Organization (WHO) Classification System of Tumors (“blue book”), of which both faculty are authors, will also be discussed.	Amy S. Joehlin-Price, MD, MS, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Gynecologic/Obstetric Pathology	Amy S. Joehlin-Price, MD, MS, FCAP					amy-ice
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual What’s in a Name? Serous Neoplasms of the Ovary and Fallopian Tube: Classification Updates, Common Conundrums, and Outcomes (On-Demand) S2169 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2169	What’s in a Name? Serous Neoplasms of the Ovary and Fallopian Tube: Classification Updates, Common Conundrums, and Outcomes (On-Demand)	1.50 CME Credits	The practicing pathologist, whether in a community or academic setting, commonly encounters serous neoplasms of the ovary and fallopian tube. However, correct application of updated nomenclature which can alter patient management can be challenging. The faculty will cover diagnostic dilemmas using a case study method with audience interaction, starting at frozen section/case presentation and ending with the final diagnosis. The course will cover areas such as serous cystadenomas with proliferation versus borderline tumors, sampling and diagnosis of tumors with micropapillary architecture, and features of low-grade carcinoma including implant classification. The faculty will review problematic cases of high-grade serous carcinoma, including diagnosis and reporting of post-neoadjuvant high-grade serous carcinoma, overlap with low-grade carcinoma, and diagnostic features of serous tubal intraepithelial carcinoma. The faculty will use each case to instruct attendees about recent updates to the World Health Organization classification, molecular characteristics which can be exploited in routine practice for diagnosis and clinical management, and implications of diagnosis for patient outcomes and treatment.	Jennifer Bennett, MD Joseph Rabban, MD, MPH, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Jennifer Bennett, MD	Joseph Rabban, MD, MPH, FCAP				jen-ett	jos-ban
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Beyond the Correct Diagnosis: Ancillary Testing in Gynecologic Pathology – Things Your Gynecologic Oncologist Do Not Want You to Miss S2252 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2252	Beyond the Correct Diagnosis: Ancillary Testing in Gynecologic Pathology – Things Your Gynecologic Oncologist Do Not Want You to Miss	1.50 CME Credits	With the inclusion of molecular classification of endometrioid carcinoma in the 2020 World Health Organization Female Genital Tumors, the necessity of ancillary techniques such as next-generation sequencing and/or IHC staining will likely become routine for subclassification of these and other tumor types. Additionally, criteria for clinical trials and emerging therapies for gynecolgic tract malignancies often require results of mismatch repair testing, p53, or HER2 IHC. In this context, the signing pathologist, must understand not only the significance of these ancillary tests, but also when they are required. The faculty will use a case-based presentation to review various entities of the gynecolgic tract with a focus on the clinical and therapeutic implications from the viewpoint of a gynecologic oncologist.	Natalie Banet, MD, FCAP Deyin Xing, MS, BM, MBBS, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Natalie Banet, MD, FCAP	Deyin Xing, MS, BM, MBBS, PhD				nat-net	dey-ing
Keep Abreast of Innovation	KAI2	Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual We Can Do Better Than Hyperkeratosis: Approaches for the Differential Diagnosis of Oral Pathology Lesions M2190 \| Gynecologic/Obstetric Pathology \| 1.00 CME Credits	M2190	We Can Do Better Than Hyperkeratosis: Approaches for the Differential Diagnosis of Oral Pathology Lesions	1.00 CME Credits	Do you have an interest in oral pathology and the diagnosis of oral keratotic lesions? If so, this course will provide specific diagnostic criteria in this area for attendees, including residents, general and even specialist pathologists. These diagnoses range from keratoses caused by friction such as from parafunctional habits, oral lichen simplex chronicus, and inflammatory conditions. The faculty will focus on the architectural, organizational, and cytologic features of oral epithelial dysplasia. Current data suggest that most, if not all leukoplakia’s, are precancerous whether they show cytologic evidence of dysplasia or not. At this time, too much emphasis has been placed on cytologic atypia so that many dysplastic lesions that show organization and architectural atypia have not been correctly diagnosed as such with serious consequences for patients. The faculty will show the clinical lesions and the corresponding histopathology which may look innocuous, and will also provide specific sign-out phrases that may be helpful.	Natalie Banet, MD, FCAP Deyin Xing, MS, BM, MBBS, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Natalie Banet, MD, FCAP	Deyin Xing, MS, BM, MBBS, PhD				nat-net	dey-ing
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Lessons Learned From the New WHO Classification of Head and Neck Tumors M2222 \| Gynecologic/Obstetric Pathology \| 1.00 CME Credit	M2222	Lessons Learned From the New WHO Classification of Head and Neck Tumors	1.00 CME Credit	The fifth edition of the World Health Organization Classification of Head and Neck Tumors presents several advancements and developments in our understanding of tumors and tumor-like lesions that affect the upper aerodigestive tract and salivary glands. The faculty will emphasize emerging diagnostic concepts and key nomenclature changes that were incorporated in the new 2022 “blue book.” The faculty will use a case-based approach to discuss how histopathology, IHC, and molecular testing can be integrated in the daily practice of head and neck pathology.	Leslie Randall, MD Sadia Sayeed, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Gynecologic/Obstetric Pathology	Leslie Randall, MD	Sadia Sayeed, MD, FCAP				les-all	sad-eed
Get a Strong Start	GASS3	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Emerging Diagnostic Concepts of the New WHO Classification of Head and Neck Tumours V2294 \| Head and Neck Pathology \| 1.50 CME Credits	V2294	Emerging Diagnostic Concepts of the New WHO Classification of Head and Neck Tumours	1.50 CME Credits	This video microscopy course will expand upon the complimentary course on the new WHO Classification of Head and Neck Tumours. This 5th edition presents several advancements and developments in our understanding tumors and tumor-like lesions that affect the upper aerodigestive tract and salivary glands. The faculty will emphasize emerging diagnostic concepts and key nomenclature changes that were incorporated in the new 2022 “blue book.”	Sook-Bin Woo, MD, DMD	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Head and Neck Pathology	Sook-Bin Woo, MD, DMD					soo-woo
		Saturday, October 8, 2022, 1:30 PM - 2:30 PM \| In-Person, Virtual Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What Do We Know and What Should We Do S2247 \| Head and Neck Pathology \| 1.50 CME Credits	S2247	Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What Do We Know and What Should We Do	1.50 CME Credits	No need to feel intimidated when you see a pediatric hematopathology sample! Though we may have different differential diagnoses when it comes to kids since they aren’t small adults, join the faculty to learn a step-by-step approach to tackle these questions: It looks different from the adult marrows – is it normal? Is it neoplastic? Can this be inherited? Do I need additional studies? What else should I do if I made a diagnosis of acute leukemia? All these questions are important. The faculty will present selected cases to illustrate findings and workup for acquired aplastic anemia, bone marrow failure syndrome associated with germline mutations, myeloid proliferations related to Down syndrome, JMML, MDS, and acute leukemia. The faculty will cover the utilization of molecular tools and the updates on pediatric hematopathology entities. The course is appropriate for all pathologists and trainees who want to improve their understanding in evaluating pediatric hematopathology samples.	Juan C. Hernandez-Prera, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	02:30 PM		Saturday, October 8, 2022, 1:30 PM - 2:30 PM	Head and Neck Pathology	Juan C. Hernandez-Prera, MD, FCAP					jua-era
Dina 9/12		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Sweating the Small Stuff: Navigating Lymphoma Workups on Core Needle Biopsies S2013 \| Head and Neck Pathology \| 1.50 CME Credits	S2013	Sweating the Small Stuff: Navigating Lymphoma Workups on Core Needle Biopsies	1.50 CME Credits	This interactive lecture, designed for pathologists working in close contact with proceduralists and oncologists, will provide focused discussions regarding safe and efficient specimen processing, test selection, and reporting of core needle biopsies in patients with suspected or known hematologic neoplasms. The faculty will use six specific clinical case scenarios to discuss the utility and prioritization of ancillary testing with consideration of sample requirements and test limitations. The faculty will also address multiparametric flow cytometry and next-generation sequencing studies in addition to IHC, cytogenetic, and PCR-based molecular testing. The successful participant will analyze their current practices and leave with practical ideas for improvement. All levels of experience will benefit from this activity.	Juan C. Hernandez-Prera, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Head and Neck Pathology	Juan C. Hernandez-Prera, MD, FCAP					jua-era
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person Can’t-Miss Diagnoses: Using Flow Cytometry to Identify Hematolymphoid Neoplasms With Genetic Abnormalities and Prognostic Significance S2258 \| Head and Neck Pathology \| 1.50 CME Credits	S2258	Can’t-Miss Diagnoses: Using Flow Cytometry to Identify Hematolymphoid Neoplasms With Genetic Abnormalities and Prognostic Significance	1.50 CME Credits	Flow cytometry is a powerful diagnostic tool, and is a sensitive method to identify hematolymphoid neoplasms in body fluids and tissues. Some diagnoses in hematopathology are particularly time sensitive, such as acute promyelocytic leukemia. However, there are many other situations in which the oncology team may request a rapid diagnosis, including patients who are very ill, require a specific therapy, or may benefit from enrollment in a clinical trial. Careful evaluation of flow cytometric findings will facilitate interactions with the clinical team, and expedite ordering the ancillary tests in a thorough but cost-effective manner. In this course, the faculty will use case studies and audience polling to explore the strengths (and weakness) of flow cytometry in making critical and timely diagnoses. They will discuss the clinical significance of these findings as well as potential pitfalls. In this course, we will use case studies and audience polling to explore the strengths (and weakness) of flow cytometry in making critical and timely diagnoses. The clinical significance of these findings will be briefly reviewed, and potential pitfalls will also be discussed.	John Casler, MD, FACS Qihui "Jim" Zhai, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Head and Neck Pathology	John Casler, MD, FACS	Qihui "Jim" Zhai, MD, FCAP				joh-ler	qih-hai
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person Don't be Troubled by Red Cell Rubble: An Approach to Acquired Hemolytic Anemia S2261 \| Hematology/Hematopathology \| 1.50 CME Credits	S2261	Don't be Troubled by Red Cell Rubble: An Approach to Acquired Hemolytic Anemia	1.50 CME Credits	Acquired hemolytic anemias such as thrombotic microangiopathy (microangiopathic hemolytic anemia) and immune-mediated hemolysis are frequently encountered in the hospital setting. The pathologist is often consulted to help clinicians navigate these complex laboratory workups that tend to involve multiple laboratories, particularly hematology and transfusion medicine. The faculty will use a case-based approach to provide pathologists with the tools needed to provide clinical consultation in these challenging scenarios.	Julia Geyer, MD Yen-Chun Liu, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Julia Geyer, MD	Yen-Chun Liu, MD, PhD, FCAP				jul-yer	yen-liu
		Saturday, October 8, 2022, 9:30 AM - 11:00 AM \| In-Person The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist S2254 \| Hematology/Hematopathology \| 1.50 CME Credits	S2254	The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist	1.50 CME Credits	This course is designed to provide attendees with a case-based algorithmic approach to the contemporary workup of large B-cell lymphomas (LBCL). The faculty will provide a step-by-step approach to the initial diagnosis and subclassification of all major subcategories of LBCLs with emphasis on integration of cytogenetic and molecular findings. Additionally, the faculty will provide attendees with a practical algorithm designed to simplify the workup of these neoplasms.	Megan S. Lim, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	11:00 AM		Saturday, October 8, 2022, 9:30 AM - 11:00 AM	Hematology/Hematopathology	Megan S. Lim, MD, PhD, FCAP					meg-lim
Keep Abreast of Innovation	KAI1	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual How to Optimize or Implement Laboratory Testing For Xa-Inhibitory Direct Oral Anticoagulant (DOAC) Detection M2214 \| Hematology/Hematopathology \| 1.00 CME Credit	M2214	How to Optimize or Implement Laboratory Testing For Xa-Inhibitory Direct Oral Anticoagulant (DOAC) Detection	1.00 CME Credit	Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, arrived on the market with no need for monitoring. As the use of DOACs expand, it is becoming clearer that measurement of these may be necessary in specific situations. More institutions are integrating either qualitative or quantitative assays. This course will use cases and audience polling to illustrate and prepare attendees for how to bring in new testing. The faculty will address questions such as: Which type of assay is most appropriate for your institution? How do you validate these assays, many of which are not FDA cleared? When should they be used? How do you integrate the testing in the ordering menu for clinicians?	Amy S. Duffield, MD, PhD, FCAP Laura Wake, MD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Amy S. Duffield, MD, PhD, FCAP	Laura Wake, MD				amy-eld	lau-ake
Get a Strong Start	GASS2	Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person COVID-19 and Hemostasis M2181 \| Hematology/Hematopathology \| 1.00 CME Credits	M2181	COVID-19 and Hemostasis	1.00 CME Credits	Coronavirus disease 2019 (COVID-19) can progress to a severe pro-inflammatory state with unique coagulopathy and procoagulant endothelial phenotype. A constellation of laboratory findings, including prominent elevation of fibrinogen, D-dimer/fibrin(ogen) degradation products, positive lupus anticoagulant, and altered viscoelastic tests have been reported. Increased platelet consumption, a corresponding increase in production, and increased activation of circulating platelets appear to occur. As the disease progresses, patients can develop findings similar to disseminated intravascular coagulation (DIC), but the rarity of severe bleeding events in these patients is not typical. Overall, these findings are associated with systemic hypercoagulability, frequent venous, arterial, and microvascular thrombotic and thromboembolic events. The laboratory may be consulted to interpret results and/or to monitor or guide anticoagulation in this severe thrombotic disease.	Vandita P. Johari, MD, FCAP Alexis R. Peedin, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Vandita P. Johari, MD, FCAP	Alexis R. Peedin, MD, FCAP				van-ari	ale-din
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Next Generation of von Willebrand Activity Factor Testing: Are You Performing the Right One S2273 \| Hematology/Hematopathology \| 1.50 CME Credits	S2273	Next Generation of von Willebrand Activity Factor Testing: Are You Performing the Right One	1.50 CME Credits	In 2021, the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) issued a joint guidance document on the diagnosis of von Willebrand Disease (VWD). These guidelines suggest automated von Willebrand Factor (VWF) platelet-binding activity assays, VWF:GP1bM and VWF:GP1bR, over the traditional VWF:Ristocetin cofactor (RCo) activity assay. While neither of these are currently FDA approved, the VWF:Ab assay, which is FDA-cleared, was not included in the recommendation statement. During this interactive lecture, the faculty will use case studies and audience polling to answer the questions you or your hematology colleagues may ask, such as “Which VWF activity assay does your laboratory perform/send out?” and “Is it appropriate based on the new guidelines?”	Sanam Loghavi, MD, FCAP Kamran Mirza, MD, PhD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Sanam Loghavi, MD, FCAP	Kamran Mirza, MD, PhD, FCAP				san-avi	kam-rza
Grow as a Leader	GAL4	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Common Queries in Medical Liver Pathology: What the Practicing Pathologist Needs to Know S2018 \| Hemostasis Pathology \| 1.50 CME Credits	S2018	Common Queries in Medical Liver Pathology: What the Practicing Pathologist Needs to Know	1.50 CME Credits	In this course, the faculty will address common questions that arise in the daily practice of surgical pathologists who sign out medical liver. Using case-based presentations, the faculty will facilitate discussions on a range of common, but difficult, topics in medical liver biopsy. Some of these topics include how to approach a liver biopsy from a patient who presents with increased liver function tests, provide a thorough assessment of a fatty liver diseases, and rule in/out autoimmune hepatitis. They will also discuss how to avoid pitfalls in the evaluation of donor liver biopsy on frozen section, and how to compose a valuable liver pathology report that answers your clinician’s (sometimes unspoken) concerns. This course will be targeted towards practicing pathologists and pathologists in training.	Marian Rollins-Raval, MD, MPH, FCAP Geoffrey Wool, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Hemostasis Pathology	Marian Rollins-Raval, MD, MPH, FCAP	Geoffrey Wool, MD, PhD, FCAP				mar-val	geo-ool
Grow as a Leader	GAL1	Saturday, October 8, 2022, 1:30 PM - 2:30 PM \| In-Person Biopsies of Liver Mass Lesions: Let’s Master the Challenges and Pitfalls (Even on tiny Biopsy!) S2168 \| Hemostasis Pathology \| 1.50 CME Credits	S2168	Biopsies of Liver Mass Lesions: Let’s Master the Challenges and Pitfalls (Even on tiny Biopsy!)	1.50 CME Credits	Liver mass biopsy interpretation remains challenging for practicing pathologists, even for those with experience or a fellowship training in gastrointestinal/liver pathology. These lesions encompass a variety of benign and malignant hepatic neoplasms and metastases. Even within the category of primary hepatic neoplasms (hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma), new classifications/subtypes have emerged in recent years that have major implications in clinical practice. Metastatic lesions can not only closely mimic hepatocellular tumors, but they also sometimes come from an unknown primary. This requires a judicious IHC workup with a cost-effective approach, and an attempt to preserve tissues that might be needed for any subsequent molecular tests. Faculty will address practical approaches to a pathologic diagnosis of liver mass lesions, present an update on classifications/subtypes of liver tumors, and provide a guide to best practices in the application of IHC and other ancillary tests to the workup of hepatic metastases, particularly in the setting of limited biopsy material. This course is cosponsored by the Hans Popper Hepatopathology Society.	Eric Salazar, MD, PhD, FCAP Geoffrey Wool, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	02:30 PM		Saturday, October 8, 2022, 1:30 PM - 2:30 PM	Hemostasis Pathology	Eric Salazar, MD, PhD, FCAP	Geoffrey Wool, MD, PhD, FCAP				eri-zar	geo-ool
Keep Abreast of Innovation	KAI1	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Practical approaches to Liver Mass Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls V2180 \| Hemostasis Pathology \| 1.50 CME Credits	V2180	Practical approaches to Liver Mass Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls	1.50 CME Credits	Liver mass lesions encompass a variety of benign and malignant hepatic neoplasms, and metastases. Even within the category of primary hepatic neoplasms (hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma), new classifications/subtypes have emerged in recent years that have major implications in clinical practice. Metastatic lesions can not only closely mimic hepatocellular tumors, but they also sometimes come from an unknown primary. This requires a judicious IHC workup with a cost-effective approach, and an attempt to preserve tissues that might be needed for any subsequent molecular tests. This two-hour virtual microscopy tutorial will demonstrate practical approaches to a pathologic diagnosis of liver mass lesions, present an update on classifications/subtypes of liver tumors, and provide a guide to best practices in the application of IHC and other ancillary tests to the workup of hepatic metastases, particularly in the setting of limited biopsy material. This course is cosponsored by the Hans Popper Hepatopathology Society.	Neil S. Harris, MD, FCAP Marian Rollins-Raval, MD, MPH, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Hemostasis Pathology	Neil S. Harris, MD, FCAP	Marian Rollins-Raval, MD, MPH, FCAP				nei-ris	mar-val
Grow as a Leader	GAL2	Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person Practical Immunohistochemistry (IHC) Approach for Small Tissue and Challenging Diagnostic Dilemmas S2157 \| Hepatopathology \| 1.50 CME Credits	S2157	Practical Immunohistochemistry (IHC) Approach for Small Tissue and Challenging Diagnostic Dilemmas	1.50 CME Credits	The advancement of precision medicine mandates pathologists to make accurate diagnoses and provide actionable recommendations based on scant tissue from sophisticated minimal invasive procedures. To apply IHC becomes essential, yet to preserve tissue for potential molecular analysis is also imperative. A systemic and data-proven best-practice approach is required to effectively execute this balancing act. The faculty will teach practical steps involving tissue triage and showcase smart IHC which entails specific markers, small panels, and stepwise workup. The focus of this course will be on commonly encountered challenging diagnostic dilemmas of general surgical pathology such as morphologically undifferentiated neoplasms and carcinomas of unknown primary origin. This course is intended for pathology trainees and practicing pathologists.	Maryam K. Pezhouh, MD, MSc, FCAP Meredith E. Pittman, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Hepatopathology	Maryam K. Pezhouh, MD, MSc, FCAP	Meredith E. Pittman, MD, FCAP				mar-ouh	mer-man
Keep Abreast of Innovation	KAI1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual To Improve is to Change: Tips and Tools for Quality Planning, Predictive Marker Monitoring, and Process Improvement in IHC S2282 \| Hepatopathology \| 1.50 CME Credits	S2282	To Improve is to Change: Tips and Tools for Quality Planning, Predictive Marker Monitoring, and Process Improvement in IHC	1.50 CME Credits	New monitoring and regulatory requirements for IHC laboratories performing predictive marker testing provide an opportunity for IHC laboratory directors to generate a comprehensive IHC laboratory quality plan. The faculty will review new PT survey monitoring requirements and discuss a standard approach to creating an IHC laboratory quality plan. The faculty will use selected cases based on the experience of the CAP IHC Subcommittee and past proficiency testing challenges to highlight process improvement principles that can be applied to current and future monitored assays.	Dhanpat Jain, MD, FCAP Xuchen Zhang, MD, PhD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Hepatopathology	Dhanpat Jain, MD, FCAP	Xuchen Zhang, MD, PhD, FCAP				dha-ain	xuc-ang
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person Uncultured: Infectious Diseases in Surgical Pathology S2136 \| Hepatopathology \| 1.50 CME Credits	S2136	Uncultured: Infectious Diseases in Surgical Pathology	1.50 CME Credits	Surgical pathologists can have a big impact upon diagnosing infectious diseases, particularly when cultures are not obtained, the agent is slow-growing not amenable to culture, or when colonization must be distinguished from infection. Armed with informed morphology and a few adjunctive tests, pathologists can learn to identify many agents to the species level. The faculty will review the morphologic features of several common and uncommon agents and elaborate on the available adjunctive tests.	Dhanpat Jain, MD, FCAP Xuchen Zhang, MD, PhD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Hepatopathology	Dhanpat Jain, MD, FCAP	Xuchen Zhang, MD, PhD, FCAP				dha-ain	xuc-ang
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person What’s Bugging the Gut: A Gastrointestinal Pathology and Microbiology Team Approach in Diagnosing Alimentary Tract Infections M2020 \| Immunohistochemistry \| 1.00 CME Credit	M2020	What’s Bugging the Gut: A Gastrointestinal Pathology and Microbiology Team Approach in Diagnosing Alimentary Tract Infections	1.00 CME Credit	The goal of this course is to facilitate a practical, case-based discussion of gastrointestinal infections that raise differential diagnostic challenges in surgical pathology. The faculty’s review focuses on the histological features of easy-to-miss infections and highlights the role of clinical laboratory testing in pathogen diagnosis through an integrated anatomic and clinical pathology team approach. This course will enhance attendees’ ability to look for and correctly identify gut infections. The course is intended for practicing surgical pathologists as well as clinical laboratory professionals with a goal to prepare attendees for an active role in multidisciplinary care.	Zong-Ming "Eric" Chen, MD, PhD, FCAP Anja C. Roden, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Immunohistochemistry	Zong-Ming "Eric" Chen, MD, PhD, FCAP	Anja C. Roden, MD, FCAP				zon-hen	anj-den
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Glassless and Paperless: Everything You Are Wondering About a 100% Primary Diagnosis Digital Workflow S2284 \| Immunohistochemistry \| 1.50 CME Credits	S2284	Glassless and Paperless: Everything You Are Wondering About a 100% Primary Diagnosis Digital Workflow	1.50 CME Credits	Pathologists are facing a once in a lifetime disruption, which is the transition to a digital workflow. Much has been said about the countless benefits of entering the digital realm and how it will enhance pathologists’ practice. While some colleagues are experiencing this change with excitement, others are experiencing some anxiety, and some are in total denial. Human beings are creatures of habits, and pathologists are no exception. Thus a future with no microscope, no glass slides, and no paperwork can seem so stressful that it blocks the view of all the benefits that come after this transition. The presenting faculty will describe and demonstrate step by step how this transition can been done and how they not only survived, but are thriving in an uncluttered environment free of glass and paperwork. This workshop is for practicing pathologists at any stage in their careers.	Andrew Bellizzi, MD, FCAP Recording complete - St Emily Meserve, MD, MPH, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Immunohistochemistry	Andrew Bellizzi, MD, FCAP	Recording complete - St	Emily Meserve, MD, MPH, FCAP			and-zzi	rec-- s	emi-rve
Keep Abreast of Innovation	KAI1	Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Practical, Real-World Applications of Machine Learning in Pathology S2251 \| Infectious Disease Pathology \| 1.50 CME Credits	S2251	Practical, Real-World Applications of Machine Learning in Pathology	1.50 CME Credits	The potential of machine learning in pathology has stimulated substantial speculation in recent years. The deployment of machine learning applications in routine practice has now begun, yielding practical experience and best practices that can be shared. Machine learning in pathology remains a new domain in which there are challenges in matching the tool to the task, deploying machine learning tools successfully, and eliciting optimal ongoing performance. The faculty will introduce digital pathology for machine learning. They will review case-based examples of machine learning in anatomic pathology and laboratory medicine to illustrate opportunities and best practices for pathologists in the current landscape of machine learning systems.	Daniel Mais, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Infectious Disease Pathology	Daniel Mais, MD, FCAP					dan-ais
		Tuesday, October 11, 2022, 11:00:00 AM - 12:00 PM \| In-Person, Virtual Artificial Intelligence and Anatomical Pathology: What Every Practicing Pathologist Should Know S2288 \| Infectious Disease Pathology \| 1.50 CME Credits	S2288	Artificial Intelligence and Anatomical Pathology: What Every Practicing Pathologist Should Know	1.50 CME Credits	With recent advances in machine and deep learning, the integration of artificial intelligence (AI) into routine pathology practice is becoming a reality. Properly designed AI-enabled tools can potentially enhance a pathologist's job in many ways. In anatomical pathology, this could involve screening cases, automating tedious tasks, standardizing biomarker scoring, offering diagnostic assurance, novel prognostication, and much more. The faculty will provide an introduction to AI concepts and terminologies, review currently available products for anatomic pathologists, and explore deployment considerations in a practice setting. To provide a better understanding of AI principles, participants will be given an opportunity to train a machine learning algorithm using open-source (free) machine learning software (please bring a laptop running Windows/Mac OS/Linux to participate).	Alina Iuga, MD, FCAP Christina M. Wojewoda, MD, FCAP Maryam J. Zenali, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00:00 AM - 12:00 PM	Infectious Disease Pathology	Alina Iuga, MD, FCAP	Christina M. Wojewoda, MD, FCAP	Maryam J. Zenali, MD, FCAP			ali-uga	chr-oda	mar-ali
Get a Strong Start	GASS4	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Beyond Normal Limits: Uplifting Inclusivity Within Laboratory Medicine P2200 \| Informatics \| 1.25 CME Credits	P2200	Beyond Normal Limits: Uplifting Inclusivity Within Laboratory Medicine	1.25 CME Credits	The scientific plenary will focus on tangible changes laboratorians are able to make to help achieve health equity. Join our faculty for a discussion on health disparities and the connection with laboratory medicine. The discussion will cover deriving inclusive reference intervals representative of gender and race diversity, evaluate the clinical laboratory as a key stakeholder in propagating change, and elaborate on the responsibility pathologists and medical scientists have in mitigating negative implications of scientific “isms.” This session will also identify critical laboratory medicine changes to help eliminate health disparities. After this session, you will have an increased awareness of how reference ranges may contribute to inequality in health care and recognize your role in creating equity-centered change. Topics to be covered: Breaking Barriers to Gender-Inclusive Laboratory Medicine, Dina N. Greene, PhD, DABCC The NKF-ASN Task Force Recommendation on the Inclusion of Race in Diagnosing and Treating Kidney Disease, a Path Towards Health Equity, Cynthia Delgado, MD Toward Equity-Centered Science – Our Call to Action, Stephen P. Richmond, MD	Giovanni Lujan, MD, FCAP Anil V. Parwani, MD, PhD, MBA	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Informatics	Giovanni Lujan, MD, FCAP	Anil V. Parwani, MD, PhD, MBA				gio-jan	ani-ani
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Anatomic and Clinical Pathology Needs in Transgender Care S2275 \| Informatics \| 1.50 CME Credits	S2275	Anatomic and Clinical Pathology Needs in Transgender Care	1.50 CME Credits	Medical and surgical gender-affirmation therapies for transgender people have introduced a new spectrum to pathology practices. Sex hormones influence both anatomic and clinical pathology, which can complicate result interpretation for surgical specimens, chemistry, hematology, and microbiology. Our team has established transgender-specific reference intervals and performed in-depth analyses of surgical pathology aspects received from transgender men and women. Some of the nuances may not even be related to hormone administration, but rather are iatrogenically induced in the course of surgical affirmation. This session will empower pathologists with the tools necessary for serving the transgender population and prepare attendees to address the needs of their clinical colleagues in this regard.	Matthew G. Hanna, MD, FCAP James Harrison, MD, PhD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Informatics	Matthew G. Hanna, MD, FCAP	James Harrison, MD, PhD, FCAP				mat-nna	jam-son
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person Nailed It: How to Select and Track Meaningful Metrics in Your Lab M2260 \| Informatics \| 1.00 CME Credit	M2260	Nailed It: How to Select and Track Meaningful Metrics in Your Lab	1.00 CME Credit	Are you stuck in a rut measuring the same metrics in your lab year after year? Do you long for a more effective way to display and analyze your metrics? If you answered “yes,” please join us as we review the characteristics of meaningful metrics and different ways to display and report your data. This active course will allow you to practice defining, analyzing, and reporting metrics within your lab and to your organization in small peer groups. This course is geared toward new-in-practice or new-to-leadership roles, such as section director/technical supervisor, but open to all who enjoy quality assurance and subscribe to continuous improvement.	Jerome Y. Cheng, MD Liron Pantanowitz, MD, MHA, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Informatics	Jerome Y. Cheng, MD	Liron Pantanowitz, MD, MHA, FCAP				jer-eng	lir-itz
Grow as a Leader	GAL3	Sunday, October 9, 2022, 1:00 PM - 2:15 PM \| In-Person, Virtual Sweating Through PPE: Make Professional Practice Evaluation Less of a Workout R2209 \| Laboratory Medical Direction \| 1.00 CME Credit	R2209	Sweating Through PPE: Make Professional Practice Evaluation Less of a Workout	1.00 CME Credit	Join the experts for lunch! Discuss our struggles when creating and conducting meaningful professional practice evaluations (PPE) of pathologists and scientists in our lab. Realize it is okay to be anxious and be open to sharing our experiences and what-not-to-dos. If you’ve wondered, “What and how much should we evaluate?” and “Should the evaluation of a new-in-practice pathologist differ from a mid-career or senior pathologist?” to meet accreditation requirements, then this round table is for you! Attendees will walk away from this session with tips and tools for constructing a meaningful and balanced PPE program for their practice, including those for initial (focused), ongoing, and remedial evaluations.	Cynthia Delgado, MD Dina N. Greene, PhD, DABCC Stephen P. Richmond, MD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	01:00 PM	10/09/2022 01:00 PM	02:15 PM		Sunday, October 9, 2022, 1:00 PM - 2:15 PM	Laboratory Medical Direction	Cynthia Delgado, MD	Dina N. Greene, PhD, DABCC	Stephen P. Richmond, MD			cyn-ado	din-ene	ste-ond
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Lemonade out of Lemons: Adjustments to Difficult Inspection Encounters M2250 \| Laboratory Medical Direction \| 1.00 CME Credit	M2250	Lemonade out of Lemons: Adjustments to Difficult Inspection Encounters	1.00 CME Credit	Would you say your last laboratory inspection was a lemon? Are you still carrying the wounds? In this session, the faculty will present difficult inspection scenarios and offer insights, recommendations, and strategies for navigating these difficult inspections. More importantly, the faculty will facilitate the discussion of sharing techniques designed to avoid adverse situations during future inspections. The faculty will also provide practical information from the collective experience of team leaders and laboratory directors focused on optimizing the inspection experience. Attendees will find communication techniques, such as effective listening and separating the people from the problem, invaluable in their everyday dealing with laboratory professionals, clinicians, administrators, and patients. This course is designed to benefit both the experienced and novice team leaders and lab directors.	Dina N. Greene, PhD, DABCC Mahmoud A. Khalifa, MD, PhD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Laboratory Medical Direction	Dina N. Greene, PhD, DABCC	Mahmoud A. Khalifa, MD, PhD				din-ene	mah-ifa
Broaden Your Influence	BYI	Monday, October 10, 2022, 7:30 AM - 8:30 AM \| In-Person Succession Planning...Because Life Happens M2287 \| Laboratory Medical Direction \| 1.00 CME Credit	M2287	Succession Planning...Because Life Happens	1.00 CME Credit	Succession planning is a critical tool in securing leadership continuity, recruitment, staff retention, and overall job enrichment and satisfaction. In the laboratory industry, succession planning is often treated as an after-thought or not considered at all in the business and human resources strategic planning. In this course, the faculty will help define this critically important activity and provide participants at all levels of their career, especially those interested in leadership growth, with the tools needed to succeed in the establishment, implementation, and communication of a comprehensive corporate succession plan.	Jesse L. Kresak, MD, FCAP Ericka J. Olgaard, DO, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	08:30 AM		Monday, October 10, 2022, 7:30 AM - 8:30 AM	Laboratory Medical Direction	Jesse L. Kresak, MD, FCAP	Ericka J. Olgaard, DO, FCAP				jes-sak	eri-ard
		Monday, October 10, 2022, 11:30 AM - 12:30 PM \| In-Person Unmasking the Post-Pandemic Pathologist: How to Succeed More While Working LESS M2229 \| Laboratory Medical Direction \| 1.00 CME Credit	M2229	Unmasking the Post-Pandemic Pathologist: How to Succeed More While Working LESS	1.00 CME Credit	Drivers of burnout heightened in the pandemic with 30% of health care workers considering leaving medicine, more than 50% feeling burned out, and 60% feeling harmed by the stress. We do not have to wait for medicine to change to feel better. We can feel better now by learning enduring coaching skills that can lead to immediate relief no matter the crisis. A randomized clinical trial published in JAMA (2019) demonstrated that professional coaching reduced emotional exhaustion by 20%, decreased burnout by 17%, and improved quality of life and resilience. In this course, the audience will learn practical self-coaching tools that can be put in place today to feel better now. This interactive course allows learners to apply the coaching tools to real-life vignettes on the most common issues facing the post-pandemic physician: feeling overwhelmed, time scarcity, feeling devalued, and dealing with difficult people. Learners will be empowered with practical strategies to achieve more by working LESS.	Jesse L. Kresak, MD, FCAP Ericka J. Olgaard, DO, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	11:30 AM	10/10/2022 11:30 AM	12:30 PM		Monday, October 10, 2022, 11:30 AM - 12:30 PM	Laboratory Medical Direction	Jesse L. Kresak, MD, FCAP	Ericka J. Olgaard, DO, FCAP				jes-sak	eri-ard
Grow as a Leader	GAL1	Monday, October 10, 2022, 2:30 PM - 3:30 PM \| In-Person How to Create More Success by Working LESS: Small Group Coaching to Empower You R2206 \| Laboratory Medical Direction \| 1.00 CME Credit	R2206	How to Create More Success by Working LESS: Small Group Coaching to Empower You	1.00 CME Credit	Join the experts for lunch! Exchange information about enduring coaching skills and share solutions in a relaxed setting with your peers. Learn to improve your ability to identify solutions to challenging scenarios through interactive sessions.	Chad D. Galderisi, DO, FCAP Shane David Basil Smith, MD	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	03:30 PM		Monday, October 10, 2022, 2:30 PM - 3:30 PM	Laboratory Medical Direction	Chad D. Galderisi, DO, FCAP	Shane David Basil Smith, MD				cha-isi	sha-ith
Broaden Your Influence	BYI	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Coping With Labor Shortages – Key Solutions to Create Change S2202 \| Leadership \| 1.50 CME Credit	S2202	Coping With Labor Shortages – Key Solutions to Create Change	1.50 CME Credit	Labor shortages of both pathologists and a wide range of laboratory staff are becoming a commonplace occurrence in laboratories. Labor shortages create direct adverse effects upon laboratory teams and laboratory service levels. Both society-wide recent trends in labor dynamics and certain health care-specific labor dynamics, are now impacting most laboratories. In this session, there will be discussion of creative approaches for strengthening staff retention and addressing labor shortages. These approaches will include low-cost, commonsense changes that can be readily implemented in your practice. Strategies for collaboration between physicians and hospital administration will also be highlighted. Attendees will engage in small group discussions to collaborate on ideas for change and improvement.	Karim E. Sirgi MD, MBA, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Leadership	Karim E. Sirgi MD, MBA, FCAP					kar- md
Grow as a Leader	GAL4	Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person Train How You Will Practice: Strategies for Becoming a Great New-in-Practice Pathologist S2026 \| Leadership \| 1.50 CME Credits	S2026	Train How You Will Practice: Strategies for Becoming a Great New-in-Practice Pathologist	1.50 CME Credits	The transition from junior member to “new-in-practice pathologist” can be a time of stress and great change. This workshop specifically targets CAP junior members, with a goal of achieving successful independent practice, focusing on five specific areas: 1) determining the proper type of workplace for career goals (academic versus private, and group structure); 2) building skills to keep up with real-life case volume; 3) developing interpersonal skills needed for practice success; 4) establishing management and leadership skills; and 5) developing resilience in taking on new responsibilities with receptiveness to on-the-job training. The faculty will utilize small group team-based learning to aid trainees in establishing practices and habits for career success. The interactive learning will be led by new-in-practice faculty mediators from diverse practice settings, ranging from private practice to academic settings.	Christina A. Arnold, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Leadership	Christina A. Arnold, MD, FCAP					chr-old
Get a Strong Start	GASS1	Monday, October 10, 2022, 11:30 AM - 12:30 PM \| In-Person Make Change Happen: Don’t Let It Happen to You! M2224 \| Leadership \| 1.00 CME Credit	M2224	Make Change Happen: Don’t Let It Happen to You!	1.00 CME Credit	The current state of health care is mandating consolidation and integration of practices and laboratories and requiring pathologists to change organizational structures, test menus, and practice patterns to provide value and support. The scope and rapidity of these changes have been heightened in the setting of COVID, are unsettling and disruptive to physicians and staff, and can lead to workplace conflicts and unusually large numbers of resignations. The faculty do not anticipate that this will slow down in the near future. It is important for pathologists who will lead and be part of these changes to be cognizant of the impact of change and how they might manage and facilitate the process to minimize disruption and maximize outcomes. The faculty will discuss the challenges and solutions that others have implemented and will provide guidance to smooth the way to harmony.	Christina A. Arnold, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	11:30 AM	10/10/2022 11:30 AM	12:30 PM		Monday, October 10, 2022, 11:30 AM - 12:30 PM	Leadership	Christina A. Arnold, MD, FCAP					chr-old
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Setting Career Direction: Using Personal Leadership to Ignite the Flame and Keep it Going M2025 \| Leadership \| 1.00 CME Credit	M2025	Setting Career Direction: Using Personal Leadership to Ignite the Flame and Keep it Going	1.00 CME Credit	Your ship may have set sail, but is your career headed in the right direction? It is never too early or too late to set career direction and consider your professional legacy. In this course, the faculty will explore the concepts of meaning in work and values and how they relate to physician engagement and burnout. Come prepared to do some self-reflection! You will learn practical personal leadership strategies that set direction for your career. You will identify your great work—the work that makes you feel energized, define professional values, and discover your passions. This work sets the stage for a fulfilling career. Everyone can use these strategies, especially leaders and mentors, as they guide others in their journeys as pathologists.	Jennifer Fralick Christina S. Kong, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Leadership	Jennifer Fralick	Christina S. Kong, MD, FCAP				jen-lic	chr-ong
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person What is Your Why, and How Do You Do It: Identifying the Spark and Strategies To Keep the Flame Going R2223 \| Leadership \| 1.00 CME Credit	R2223	What is Your Why, and How Do You Do It: Identifying the Spark and Strategies To Keep the Flame Going	1.00 CME Credit	Join the experts for lunch! To be fulfilled as pathologists we need to understand our why, but have you ever contemplated your why? In this round table, we will explore our experience with understanding our why. Then, we will consider how we make time for our great work by sharing strategies and identifying solutions to challenges and barriers that keep us from our great work.	Juanita J. Evans, MD, FCAP Lauren King, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Leadership	Juanita J. Evans, MD, FCAP	Lauren King, MD, FCAP				jua-ans	lau-ing
		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Neighborhoods Matter: Identifying Spatial Biomarkers in the Tumor Microenvironment M2208 \| Leadership \| 1.00 CME Credit	M2208	Neighborhoods Matter: Identifying Spatial Biomarkers in the Tumor Microenvironment	1.00 CME Credit	Tumors are composed of many cell types, and for some tumors, the most dominant cell type is not the malignant cell. Immunotherapy has demonstrated that clinically relevant molecular properties of a tumor are a function of interactions among the varying cell types in the tumor microenvironment, and not exclusively intrinsic to the malignant cells. Advances in highly multiplexed imaging are enabling single cell resolution of cell type heterogeneity of the tumor microenvironment in a spatial context. The faculty will review state of the art technologies in multiplexed in situ imaging, methods for computational analysis of multiplexed in situ images, and identification of spatial biomarkers.	Moira P. Larsen, MD, MBA, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Leadership	Moira P. Larsen, MD, MBA, FCAP					moi-sen
Keep Abreast of Innovation	KAI2	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Understanding NGS and Interpreting Reports for Oncologic Pathology S2037 \| Leadership \| 1.50 CME Credits	S2037	Understanding NGS and Interpreting Reports for Oncologic Pathology	1.50 CME Credits	In this course, the faculty will provide a detailed description of informatics resources and databases used for tertiary data analysis, including interpretation and reporting of germline and somatic next-generation sequencing (NGS) assays. These resources include external data sources such as population, disease, and functional databases as well as internal variant databases maintained by the testing laboratory. The faculty will also discuss guidelines by the Association for Molecular Pathology and American College of Medical Genetics and Genomics to aid interpretation. As the size of NGS assays expand and big data analysis experiences a bottleneck at interpretation, the potential to use machine learning for improved variant filtration and ranking is being explored. Finally, the faculty will also discuss the impact of informatics in clinical decision making and the importance of training pathologists in using these resources appropriately. This course is cosponsored by the Association for Molecular Pathology.	Sarah M. Bean, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Leadership	Sarah M. Bean, MD, FCAP					sar-ean
		Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Gene Editing: A Primer for Practicing Pathologists M2114 \| Leadership \| 1.00 CME Credit	M2114	Gene Editing: A Primer for Practicing Pathologists	1.00 CME Credit	Gene-editing technology is being investigated in the clinical setting for treatment of inherited diseases, infectious diseases, and cancer. In addition to the scientific and medical issues related to gene-editing technology, there are ethical, financial, and regulatory issues that also must be considered. As gene-editing-based therapies expand into the clinical setting, pathologists must be educated on the topic. This course serves to both educate pathologists on gene-editing technologies and serve as a point of initial discussions in areas of gene-editing science, clinical therapy, and regulatory issues associated with gene-editing-based therapies, as these therapies are eventually introduced into clinical practice.	Sarah M. Bean, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Leadership	Sarah M. Bean, MD, FCAP					sar-ean
		Saturday, October 8, 2022, 7:30 AM - 8:30 AM \| In-Person, Virtual Genomic Pathology101: An Interactive Workshop S2027 \| Microbiology \| 1.50 CME Credits	S2027	Genomic Pathology101: An Interactive Workshop	1.50 CME Credits	Genomic testing is being integrated into pathology practice. From selecting the appropriate samples for testing to integrating findings into clinical reports, all pathologists need to understand genomic assays. The faculty will review introductory principles related to testing of tumor tissue including selection of samples and interpretation of results including the potential for detecting relevant germline variants. Using a case-based, interactive approach, participants will work in teams to answer clinically relevant questions integrating actual patient testing reports and utilizing online genomic pathology tools. If available, participants should bring a tablet or laptop (preferred). The faculty will provide directly applicable knowledge and skills for pathologists at all levels and practice settings. Members of the Training Residents in Genomics (TRIG) Working group committee at the Association of Pathology Chairs, experts in molecular pathology, medical education, and genetic counseling have developed this session.	Sylvia K. Plevritis, PhD	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	08:30 AM		Saturday, October 8, 2022, 7:30 AM - 8:30 AM	Microbiology	Sylvia K. Plevritis, PhD					syl-tis
Keep Abreast of Innovation	KAI2	Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person OMG! MSI, MMR IHC, NGS, or TMB for Checkpoint Inhibitor Treatment Screening: An Overview of the CAP Guideline on Mismatch Repair and Microsatellite Instability Testing S2166 \| Molecular Genetics \| 1.50 CME Credits	S2166	OMG! MSI, MMR IHC, NGS, or TMB for Checkpoint Inhibitor Treatment Screening: An Overview of the CAP Guideline on Mismatch Repair and Microsatellite Instability Testing	1.50 CME Credits	Checkpoint inhibitors are associated with durable (more than 12 months) treatment responses in patients with advanced cancers. This therapeutic approach is also associated with severe toxicities and side effects. The accurate identification of patients most likely to respond to this approach is therefore crucial in the clinical laboratory. In 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the immune checkpoint inhibitor, pembrolizumab, for patients with any advanced solid tumor malignancy that is MSI high or MMR deficient. The FDA did not specify which specific assay should be used. Faculty will summarize the benefits and limitations of different laboratory assays, including IHC, PCR-based microsatellite instability, microsatellite instability derived from next-generation sequencing, and tumor mutation burden derived from next-generation sequencing. Some of these assays have tumor-specific performance characteristics. Faculty will discuss the evidence-based recommendations from the CAP MMR/MSI guideline, including areas the committee identified as requiring further study.	Vera Paulson, MD, PhD Cecilia Yeung, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Molecular Genetics	Vera Paulson, MD, PhD	Cecilia Yeung, MD, FCAP				ver-son	cec-ung
Grow as a Leader	GAL3	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Selecting the Right Tool for the Job: Practical Considerations for Application of Molecular Diagnostics Methods in Surgical Pathology S2165 \| Molecular Genetics \| 1.50 CME Credits	S2165	Selecting the Right Tool for the Job: Practical Considerations for Application of Molecular Diagnostics Methods in Surgical Pathology	1.50 CME Credits	Multiple technologies exist to evaluate molecular alterations across tumors. They can overlap in their ability to provide information about diagnostic, therapeutic, and prognostic strategies in oncology. Selecting the most appropriate testing modality may be challenging, and understanding the indications and limitations of different molecular tests in clinical practice is critical to interpretation and appropriate patient care. This course will provide an overview of commonly used and emerging molecular techniques, capabilities and indications for interrogating different types of genetic alterations, compare advantages and limitations, and discuss when they may be complementary to one another. These concepts will be reinforced with examples of molecular analysis from a variety of solid tumors. Faculty will also discuss applications of emerging molecular testing approaches and strategies for interpretation and reporting of molecular results.	Allison M. Cushman-Vokoun, MD, PhD, FCAP Wayne W. Grody, MD,PhD	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Molecular Genetics	Allison M. Cushman-Vokoun, MD, PhD, FCAP	Wayne W. Grody, MD,PhD				all-oun	way-ody
Get a Strong Start	GASS3	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Detection of Alzheimer's Disease Pathology in the Living Patient: What Combination of Plasma Biomarkers Works Best? M2207 \| Molecular Oncology \| 1.00 CME Credit	M2207	Detection of Alzheimer's Disease Pathology in the Living Patient: What Combination of Plasma Biomarkers Works Best?	1.00 CME Credit	Alzheimer’s disease (AD) is an evolving medical nightmare with no end in sight. Learning to detect and treat this disease early is vital to the lifespan of the patient. During this session, the faculty will discuss plasma biomarker tests that are proven to be helpful in the detection of amyloid pathology and tau pathology. In addition, published studies examining the accuracy of detecting AD using plasma biomarker tests in individuals who are mildly cognitively impaired following clinical evaluation will be covered. This session is based on extensive expertise in the development, validation, and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies.	Brent T. Tan, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Molecular Oncology	Brent T. Tan, MD, PhD, FCAP					bre-tan
		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person How is my Payment Determined for Pathology Services? M2171 \| Molecular Oncology \| 1.00 CME Credit	M2171	How is my Payment Determined for Pathology Services?	1.00 CME Credit	Learn about concepts of current procedural terminology (CPT) coding and payment for services on the Medicare Physician Fee Schedule (PFS). In this highly interactive course, faculty will provide a historical introduction and overview of how current coding and billing practices were developed, and how the Centers for Medicare & Medicaid Services (CMS) values codes on the PFS. They will discuss how CPT codes are modified and the steps involved. Faculty will also cover aspects of payment policy (eg, National Correct Coding Initiative) and the role of existing process in the new value-based payment system. As a result of attending this course, participants will better comprehend the changing payment and regulatory environment, anticipate future trends, and better adapt their practice to current reimbursement trends.	Richard L. Haspel, MD, PhD, FCAP Phillip Michaels, MD, FCAP Nikoletta Sidiropoulos, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Molecular Oncology	Richard L. Haspel, MD, PhD, FCAP	Phillip Michaels, MD, FCAP	Nikoletta Sidiropoulos, MD, FCAP			ric-pel	phi-els	nik-los
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person Are You Working Harder and Going Broke: Tools to Drive Practice Profitability S2292 \| Molecular Oncology \| 1.50 CME Credits	S2292	Are You Working Harder and Going Broke: Tools to Drive Practice Profitability	1.50 CME Credits	The lifeblood of any practice revolves around its ability to collect for services provided and know the true cost of a lab test. Revenue Cycle Management guides the audience through correct data capture with accessioning to the final billing and collection from payors. Attendees will compute contractual adjustments, collection and bad debt rates, and other key metrics from a practice’s financial data. Then compare this to industry standards, which will help them to recognize and thwart trends that will negatively impact their practice. The faculty will use case studies to illustrate the calculation laboratory expenses. Additionally, they will use precise data on direct and indirect costs to tabulate the cost per specific lab test.	Russell R. Broaddus, MD, PhD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Molecular Oncology	Russell R. Broaddus, MD, PhD, FCAP					rus-dus
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person The American Board of Pathology: 85 Years of Service to the Public and the Profession P2201 \| Molecular Oncology \| 1.00 CME Credit	P2201	The American Board of Pathology: 85 Years of Service to the Public and the Profession	1.00 CME Credit	Pathology emerged as a specialty in the late 1800s as the value to patient care gained greater appreciation and respect. Pathologists were not considered “equal” in medical practice by their clinical colleagues; however, in 1926 pathologists received significant recognition when the American College of Surgeons revised its standards to require that laboratories be under the direction of MD physicians with special training in pathology and that “all tissue removed at operations shall be examined in the laboratory and reports rendered.” Recognition of pathologists as physicians and pathology as a medical specialty was reinforced in 1935 when a joint committee of the AMA Section on Pathology and the ASCP agreed that a Board of Pathology should be established. In 1936, the ABPath was incorporated in Michigan and approval was granted by the ABMS and the AMA Council on Medical Education. On July 19, 1936, the ABPath met for the first time in Chicago. The growth in specialty medicine and certification boards were the result of advancements in medical science, leading to improvements in patient care. Before the creation of board certification, there was no way to assure the public or the profession that a physician claiming to be a specialist had the requisite skills. Board certification demonstrates that a physician has: 1) completed an extended period of rigorous training and assessment of the knowledge, skills, and professionalism required to practice in a specialty; and 2) passed a secure, comprehensive examination of knowledge and skills. Consistent with rapid changes in medicine and societal expectations, ABPath began issuing time-limited certification in 2006. Diplomates maintain certification by meeting requirements for professionalism, life-long learning, and self-assessment, including longitudinal assessment with ABPath CertLink®, and health and health care improvement activities.	Larissa V. Furtado, MD, FCAP Laura J. Tafe, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Molecular Oncology	Larissa V. Furtado, MD, FCAP	Laura J. Tafe, MD, FCAP				lar-ado	lau-afe
		Tuesday, October 11, 2022, 1:00 PM - 2:00 PM \| In-Person, Virtual Demonstrating Your Value and Protecting Your Reimbursement in Evolving Quality Payment Models (On-Demand) M2177 \| Neuropathology \| 1.00 CME Credit	M2177	Demonstrating Your Value and Protecting Your Reimbursement in Evolving Quality Payment Models (On-Demand)	1.00 CME Credit	Value-based payment models continue to evolve to include considerations for quality of care, cost, and population health through a set of evidence-based metrics. While demonstrating the value of laboratory medicine to the health system, pathologists must also find quantitative ways to demonstrate their value in newer payment models. Pathologists must report on measures of quality, utilization, and cost, depending on the program or payer. For example, within the Centers of Medicare and Medicaid (CMS) Quality Payment Program, there are two participation pathways that impact an individual’s or group’s Medicare payments. The faculty will provide information to pathologists on how to demonstrate their impact on overall quality and cost to the organization through various quality measures to maximize reimbursement in these payment programs. The faculty will also present an interactive portion to facilitate discussions about the challenges and opportunities related to developing and implementing quality measures for accountability and quality payment program purposes.	Leslie M. Shaw, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM	02:00 PM		Tuesday, October 11, 2022, 1:00 PM - 2:00 PM	Neuropathology	Leslie M. Shaw, PhD					les-haw
		Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Early Detection of Lung Cancer: Radiology-Pathology Correlation M2212 \| Practice Finance \| 1.00 CME Credit	M2212	Early Detection of Lung Cancer: Radiology-Pathology Correlation	1.00 CME Credit	Recent literature shows that low-dose CT screening has significantly increased the detection of stage I lung cancer and reduced lung cancer mortality. This finding has led to the increased tissue sampling of smaller nodules detected by radiology, leading to several challenges encountered on microscopic analysis. With the World Health Organization (WHO) fifth edition of Thoracic Tumors and the Internatinoal Association for the Study of Lung Cancer Pathology Committee recommendations, accurate histologic typing and triaging of the smaller biopsy samples have become increasingly complex. In this course, the faculty will present the radiological characteristics of lung nodules <2 cm along with the pathology correlation. In addition, faculty will offer guidance using the most recent recommendations provided by the WHO classification especially in small biopsies.	Jonathan Myles, MD, FCAP Mark S. Synovec, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Practice Finance	Jonathan Myles, MD, FCAP	Mark S. Synovec, MD, FCAP				jon-les	mar-vec
Grow as a Leader	GAL1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing M2183 \| Practice Finance \| 1.00 CME Credit	M2183	Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing	1.00 CME Credit	Most lung cancer patients are diagnosed at an advanced stage by minimally invasive techniques that include small biopsies and cytology specimens. Potential challenges for diagnosis and biomarker testing can arise in these limited volume specimens. Therefore, judicious triaging in an effort to maximize the information one can obtain on these small specimens is important. With rapid advances in predictive and prognostic biomarker testing in lung cancer, pathologists are at the forefront of triaging these small specimens for diagnosis as well as performing and interpreting clinically needed biomarker testing. Hence, an understanding of the best practices to ensure adequate collection and handling of small specimens is critical. This course is designed for practicing pathologists, molecular laboratory personnel, and pathology trainees. The faculty will address various challenges in lung cancer diagnosis and the ever-expanding list of biomarker testing targets for small biopsy and cytology specimens, as well as discuss strategies to improve specimen collection and handling with a focus on therapeutic implications.	Chiraag N. Gangahar, MD, FCAP Susan B. Kern, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Practice Finance	Chiraag N. Gangahar, MD, FCAP	Susan B. Kern, MD, FCAP				chi-har	sus-ern
		Monday, October 10, 2022, 1:00 PM - 2:00 PM \| In-Person, Virtual Challenges in Diagnosis and Biomarker Testing of Lung Cancer Using Cytology and Small Biopsy Specimens V2296 \| Process and Outcome Improvement \| 1.50 CME Credits	V2296	Challenges in Diagnosis and Biomarker Testing of Lung Cancer Using Cytology and Small Biopsy Specimens	1.50 CME Credits	This video microscopy will expand upon the companion course, Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing, on updates for the use of cytology and small biopsy specimens for lung cancer diagnosis and biomarker testing. The faculty will identify potential diagnosis and biomarker testing challenges that could arise with limited samples. Pathologists need to be at the forefront of rapid advances in lung cancer diagnosis and predictive biomarker testing.	Rebecca L. Johnson, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	01:00 PM	10/10/2022 01:00 PM	02:00 PM		Monday, October 10, 2022, 1:00 PM - 2:00 PM	Process and Outcome Improvement	Rebecca L. Johnson, MD, FCAP					reb-son
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Lung Cancer and Neoadjuvant Therapy: What Pathologists Need to Know M2179 \| Process and Outcome Improvement \| 1.00 CME Credit	M2179	Lung Cancer and Neoadjuvant Therapy: What Pathologists Need to Know	1.00 CME Credit	Even though major pathologic response in patients with lung cancer treated with neoadjuvant therapy has been recognized as a predictor of survival and a potential surrogate end point in clinical trials, few studies have described gross and microscopic assessment of the lung resection specimens. Until recently, there was no established guidance on how to process and evaluate those specimens. This course is designed to provide practicing pathologists and pathologists in training with recommendations for gross and microscopic pathologic assessment of response to neoadjuvant therapy in lung cancer. Pulmonary pathologists who wish to receive updates on current guideline should also attend. Faculty will address challenges in the gross and histologic assessment of response to the specific neoadjuvant therapies including chemotherapy, targeted therapies, and immunotherapies. Practical tips for generation of surgical pathology reports easily understandable by thoracic surgeons and oncologists will be provided. This course is sponsored by the Pulmonary Pathology Society.	Diana M. Cardona, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Process and Outcome Improvement	Diana M. Cardona, MD, FCAP					dia-ona
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person Ancillary Testing In Non-Small Cell Lung Carcinoma With an Eye to Immunotherapy and Targeted Therapies: How and Why to Get It Done In 2022 S2289 \| Pulmonary Pathology \| 1.50 CME Credits	S2289	Ancillary Testing In Non-Small Cell Lung Carcinoma With an Eye to Immunotherapy and Targeted Therapies: How and Why to Get It Done In 2022	1.50 CME Credits	Ancillary testing in non-small lung carcinoma has evolved considerably in the last decade beyond IHC for TTF1 and single gene assays for EGFR and ALK. As the clinical paradigm has continued to shift, the standard of care now includes IHC for PD-L1 as well as, in most major institutions, large next-generation sequencing (NGS)-based panels to identify patients who qualify for treatment with an ever-expanding array of FDA-approved targeted therapies. In this session, a molecular pathologist and a cytopathologist with an interest in lung pathology, will discuss the current guidelines for therapy and testing as mandated by the National Cancer Care Network. In addition, the faculty will present strategies to implement, perform, and accurately report PD-L1 IHC as well as multiplex NGS-based testing in cytologic specimens and small biopsies. Faculty will also discuss the prognostic and predictive significance as well as the clinicopathologic correlates of the common driver mutations and the role of testing in cases with acquired resistance to common targeted therapies. Attendees can expect to leave this session with a thorough understanding of the current treatment paradigm for metastatic non-small cell lung carcinoma as well a firm grasp on the issues and challenges related to PD-L1 IHC and molecular testing. As this is a rapidly evolving topic and an extremely common disease state, this session will be of value to both junior and senior practicing pathologists as well as senior trainees.	Shaimaa A. Fadl, MBChB, MD Raghavendra Pillappa, MD, MBBS, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Pulmonary Pathology	Shaimaa A. Fadl, MBChB, MD	Raghavendra Pillappa, MD, MBBS, FCAP				sha-adl	rag-ppa
		Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Understanding Diversity in Pathology: Impact on Recruitment and Retention S2167 \| Pulmonary Pathology \| 1.50 CME Credits	S2167	Understanding Diversity in Pathology: Impact on Recruitment and Retention	1.50 CME Credits	This interactive course will explore our understanding of diversity, allowing attendees a glimpse into this issue within pathology. The faculty will look at its impact on different groups by collectively and honestly exploring some of the challenges, including microaggressions, that many pathologists have face in their daily lives. Moving from the personal to the institutional perspective, faculty will also discuss the impact of diversity (or lack of) on recruitment and retention. It is essential for pathologists to learn more about and appreciate the experiences of diverse populations in order to maintain them as members of our faculty and residency programs. This course will look at ways to improve diversity and what the pathologist can do about this issue going forward.	Sinchita Roy-Chowdhuri, MD, PhD, FCAP Paul VanderLaan, MD, PhD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Pulmonary Pathology	Sinchita Roy-Chowdhuri, MD, PhD, FCAP	Paul VanderLaan, MD, PhD, FCAP				sin-uri	pau-aan
		Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Soft Tissue Pathology is Fun…Really: A Crash Course for General Pathologists S2228 \| Pulmonary Pathology \| 1.50 CME Credits	S2228	Soft Tissue Pathology is Fun…Really: A Crash Course for General Pathologists	1.50 CME Credits	This course provides a whirlwind—but thorough—tour of soft tissue pathology highlighting the most common entities, pitfalls, and the appropriate ancillary testing usage. Faculty will cover topics including dermal-based, myxoid, and myoepithelial lesions, in addition to the usual adipocytic, neural, and myogenic entities. The faculty also will provide a comprehensive update on selected topics pertinent to the everyday practice of pathology using a partial case-based approach and audience participation. Presentation of content will meet the needs of the pathologist in training and the more experienced general pathologist, as well as those interested in sharpening their soft tissue pathology skills.	Sinchita Roy-Chowdhuri, MD, PhD, FCAP Paul VanderLaan, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Pulmonary Pathology	Sinchita Roy-Chowdhuri, MD, PhD, FCAP	Paul VanderLaan, MD, PhD, FCAP				sin-uri	pau-aan
		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Slide Seminar: Problem Cases in Surgical Pathology (On-Demand) S2010 \| Pulmonary Pathology \| 1.50 CME Credits	S2010	Slide Seminar: Problem Cases in Surgical Pathology (On-Demand)	1.50 CME Credits	This course highlights problem areas in surgical pathology related to change. Faculty will review recent changes in diagnostic criteria, terminology, and the development of testing platforms that shed new light on our understanding of disease processes. This course is cosponsored by the Arkadi M. Rywlin International Slide Seminar Club.	Sanja Dacic, MD PhD	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Pulmonary Pathology	Sanja Dacic, MD PhD					san-cic
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person, Virtual Can You Bank on Your Blood Supply: Using Blood Wisely and in Shortages S2286 \| Pulmonary Pathology \| 1.50 CME Credits	S2286	Can You Bank on Your Blood Supply: Using Blood Wisely and in Shortages	1.50 CME Credits	Are your transfusion guidelines up to date? Can you cope with a critical RBC or platelet shortage? The faculty will succinctly synthesize current multidisciplinary transfusion practice recommendations for all blood components into a logical framework applicable to peer education, blood management programs, and electronic guidance for blood ordering. In this interactive presentation, participants will use audience response technology to share benchmarking information on their hospital's current practices and learn how they can apply up-to-date guidelines to everyday patient problems. With this foundation, the faculty will discuss the next steps to prepare for and mitigate potential future blood shortages.	Mir B. Alikhan, MD Ajit Paintal, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM			Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Pulmonary Pathology	Mir B. Alikhan, MD	Ajit Paintal, MD, FCAP				mir-han	aji-tal
		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Debating the Mitigation of Future Blood Shortages R2230 \| Respect for Diversity \| 1.00 CME Credit	R2230	Debating the Mitigation of Future Blood Shortages	1.00 CME Credit	Join the experts for lunch! Exchange information about current multidisciplinary transfusion practices and share solutions in a relaxed setting with your peers. Learn to improve your ability in identifying resolutions to challenging scenarios through this interactive session.	Valerie A. Fitzhugh, MD FCAP Amyn Rojiani MD, PhD, CPE, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM			Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Respect for Diversity	Valerie A. Fitzhugh, MD FCAP	Amyn Rojiani MD, PhD, CPE, FCAP				val-ugh	amy- md
		\| Back to the Future: Low Titer O Whole Blood in Trauma S2034 \| \| 1.50 CME Credit	S2034	Back to the Future: Low Titer O Whole Blood in Trauma	1.50 CME Credit	In its earliest days, transfusion medicine focused almost exclusively on the transfusion of whole blood. In the latter part of the twentieth century, whole blood transfusion was largely abandoned in favor of blood component therapy. In recent years, there has been renewed interest in whole blood transfusion, especially in the context of trauma resuscitation. During this session, the faculty will explore the recent revival of whole blood transfusion, specifically low titer O whole blood (LTOWB). In addition, they will review relevant literature pertaining to whole blood, LTOWB, and resuscitation. Faculty will also present perspectives from both the hospital/trauma center and blood center, including the logistics of manufacturing and supplying LTOWB, regulatory/accreditation requirements, the challenges of optimizing the use of LTOWB, and the types of patients who can most benefit from this blood product.						12/30/1899 12:00 AM

Update Skills and Knowledge Relative to Changing Guidelines and Protocols

Path	Category
Path	Category	List	Code	Title	CreditHours	Description	SpeakersList	Pass Type	FilterByDate	Date	Start Time	DateStartTime	End Time	Time	DateTime	Competency	Faculty 1	Faculty 2	Faculty 3	Faculty 4	Details	F1ID	F2ID	F3ID	F4ID
Keep Abreast of Innovation	KAI2	Sunday, October 9, 2022, 7:30 AM - 8:30 AM \| In-Person How Many Pathologists do We Really Have in the US? Threats, Opportunities, and Implications for Future Practice A2261 \| Advocacy \| 0.00 CME Credit	A2261	How Many Pathologists do We Really Have in the US? Threats, Opportunities, and Implications for Future Practice	0.00 CME Credit	Recent research by the CAP and the Association of American Medical Colleges (AAMC) has revealed, in its Physician Specialty Data Reports – one of the most important data sources on physician supply in the US, that the AAMC has been dramatically undercounting the number of pathologists. This undercount has been increasing each year since 2004 and reached nearly 40% in 2020. In this session, faculty will discuss the research that led to this important finding; show how the discovery of this shortfall changes what we know about the rate of growth in pathologist supply, the distribution of pathologists by whether or not they specialize, and the gender, age distribution, and racial/ethnic mix of pathologists. The faculty will also discuss what the data tells us about threats, opportunities, and implications for the future of pathology practice.	W. Stephen Black-Schaffer, MD, FCAP Kalisha A. Hill, MD, MBA, FCAP Thomas M. Wheeler, MD, FCAP Kalisha A. Hill, MD, MBA, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	08:30 AM		Sunday, October 9, 2022, 7:30 AM - 8:30 AM	Advocacy	W. Stephen Black-Schaffer, MD, FCAP	Kalisha A. Hill, MD, MBA, FCAP	Thomas M. Wheeler, MD, FCAP	Kalisha A. Hill, MD, MBA, FCAP		w. -fer	kal-ill	tho-ler	kal-ill
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 3:30 PM \| In-Person CPT Coding…You Can’t Practice Without It! Why Pathologists Need to Understand CPT Coding A2276 \| Dermatopathology \| 0.00 CME Credit	A2276	CPT Coding…You Can’t Practice Without It! Why Pathologists Need to Understand CPT Coding	0.00 CME Credit	Is understanding current procedural terminology (CPT) coding and its impact on your practice making your head spin? Get an insider expert’s insights and examples of current CPT coding practices and relevant payment policies for pathology and laboratory medicine. This workshop is designed to provide a comprehensive review of concepts as well as recent and anticipated changes in CPT coding that pathologists use to report their services. Faculty also will address your CPT coding problems and direct you to additional resources for answering your coding and related payment policy questions.	Mark S. Synovec, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	03:30 PM		Sunday, October 9, 2022, 2:30 PM - 3:30 PM	Dermatopathology	Mark S. Synovec, MD, FCAP					mar-vec
		Monday, October 10, 2022, 11:00 AM - 12:30 PM \| In-Person, Virtual Advocacy Town Hall A2260 \| Advocacy \| 0.00 CME Credit	A2260	Advocacy Town Hall	0.00 CME Credit	This session will provide members with a better understanding of the scope of our advocacy agenda. The CAP continually works to expand the public policy impact of pathology at the federal and state levels of government by engaging members in advocacy efforts. By combining grassroots advocacy with events like our annual policy meeting, town hall meetings, and other forums, engaged members help strengthen the profession's influence with policymakers.	Kalisha A. Hill, MD, MBA, FCAP Jonathan L. Myles, MD, FCAP Emily Volk, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	11:00 AM	10/10/2022 11:00 AM	12:30 PM		Monday, October 10, 2022, 11:00 AM - 12:30 PM	Advocacy	Kalisha A. Hill, MD, MBA, FCAP	Jonathan L. Myles, MD, FCAP	Emily Volk, MD, FCAP			kal-ill	jon-les	emi-olk
Get a Strong Start	GASS2	Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Current Payment Policy Challenges in Pathology Practice A2275 \| Advocacy \| 0.00 CME Credit	A2275	Current Payment Policy Challenges in Pathology Practice	0.00 CME Credit	Pathologists are often challenged by payment policy-related issues regarding the services they provide. It is important that pathologists better understand how Advocacy seeks to influence payment policies, why changes in reimbursement occur, and how to adapt within their practices. Workshop participants will gain knowledge and insight into the engagement opportunities available. The faculty will present payment policy information associated with Physician Fee Schedule valuation (that can influence payment policy development), Clinical Laboratory Fee Schedule Payment Reform (PAMA), emerging payment models, and other payment challenges and possible solutions.	Jonathan L. Myles, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Advocacy	Jonathan L. Myles, MD, FCAP					jon-les
Get a Strong Start	GASS2	Tuesday, October 11, 2022, 7:30 AM - 9:30 AM \| In-Person Negative Autopsies: When Routine Gross Dissection and Histology Come Up Empty H2144 \| Autopsy \| 2.00 CME Credits	H2144	Negative Autopsies: When Routine Gross Dissection and Histology Come Up Empty	2.00 CME Credits	Join us for discussion and hands-on dissection with esteemed faculty Dr. Fyfe-Kirschner and Dr. Sanchez to discover and practice vitreous humor extraction for electrolytes and toxicology and cardiac conduction system dissection. In most hospital autopsies, a routine dissection and histology will provide a cause of death. However, no cause of death will be apparent in some cases, a dissatisfying result for the pathologist, clinician, and family. This hands-on lab will provide a practical guide to approaching such cases. Interactive case presentations will be used to illustrate some of the most common causes of death in the absence of gross and histologic findings and when to suspect those diagnoses. The lecture will also cover the special testing needed to make those diagnoses, including special dissections, clinical laboratory testing, toxicology, genetic testing, and molecular testing. The participants will have the opportunity to practice several unique techniques, including a dissection of the conducting system and aspiration of the vitreous humor. The session will provide participants with a rational, cost-effective approach to diagnosing fewer common causes of a sudden unexpected death at all stages of their careers.	Meagan Chambers, MD Billie S. Fyfe-Kirschner, MD, FCAP Dylan V. Miller, MD, FCAP Harold Sanchez, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:30 AM		Tuesday, October 11, 2022, 7:30 AM - 9:30 AM	Autopsy	Meagan Chambers, MD	Billie S. Fyfe-Kirschner, MD, FCAP	Dylan V. Miller, MD, FCAP	Harold Sanchez, MD, FCAP		mea-ers	bil-ner	dyl-ler	har-hez
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Cutting Edge Pathology: Emerging Disease and Advancement of Molecular Research in Autopsy Investigation (On-Demand) S2041 \| Autopsy \| 1.50 CME Credits	S2041	Cutting Edge Pathology: Emerging Disease and Advancement of Molecular Research in Autopsy Investigation (On-Demand)	1.50 CME Credits	Autopsies remain the gold standard for cause of death; their use to educate clinicians can reduce discrepancies by half. Furthermore, large institutions benefit from rapid autopsies because of unlimited access to tissue and the opportunity to capture the biology of both normal and diseased states. Studies using autopsy tissue have greatly advanced our understanding of neurodevelopment, neurodegeneration, the pathophysiology of emerging infectious agents, and the molecular alterations responsible for disease recurrence and progression after treatment. Next-generation genomics brings new opportunities in pathology to utilize fresh tissue for the molecular advancement of neoplastic and infectious human disease, with unprecedented single cell resolution. This course will provide simple tips on how to educate administrators/clinicians on the value of autopsies. The faculty will highlight the advantages of rapid autopsies for the pathologist and the researcher, using specific case examples including their own experience gained during the COVID-19 pandemic. Finally, they will provide practical guidelines on techniques for fresh tissue procurement, including collection, single-cell dissociation, and culture.	Clare H. Bryce, MD, FCAP Nadejda Tsankova, MD, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Autopsy	Clare H. Bryce, MD, FCAP	Nadejda Tsankova, MD, PhD				cla-yce	nad-ova
		Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Book Club: Deceit and Denial: The Deadly Politics of Industrial Pollution N2204 \| Book Club \| 0.00 CME Credit	N2204	Book Club: Deceit and Denial: The Deadly Politics of Industrial Pollution	0.00 CME Credit	CAP22 will feature a book club, which offers discussion of literature topics related to pathology in an intimate, small group setting. Join Julie W. Lemmon, MD, FCAP as she facilitates a conversation about Deceit and Denial The Deadly Politics of Industrial Pollution by authors Gerald Markowitz and David Rosner. Through the lens of public health, historians Gerald Markowitz and David Rosner explore how the lead and plastic industries prioritized progress and profit at the expense of human health and the environment. They use primary sources to illustrate the complicity of industry executives, government agencies, scientists, and lobbyists in perpetuating harm against workers and the environment. Key Talking Points: •How did industries promote the benefits of lead to consumers •What were the catalysts that resulted in diminished use of lead in household products •How can relationships between industries and governments compound detrimental environmental effects that disproportionately affect marginalized communities •What types of advocacy efforts were successful at promoting improvements in safety and environmental reforms Attendees will read the book prior to the session and then engage in discussion.	Julie W. Lemmon, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Book Club	Julie W. Lemmon, MD, FCAP					jul-mon
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Roadmap Towards the “Perfect” Pathology Report of Post Neoadjuvant Therapy Breast Resections M2116 \| Breast Pathology \| 1.00 CME Credit	M2116	Roadmap Towards the “Perfect” Pathology Report of Post Neoadjuvant Therapy Breast Resections	1.00 CME Credit	Neoadjuvant therapy (NAT) is used increasingly in breast carcinoma (BC). The faculty will discuss the indications of NAT and important chemotherapeutic regimes. Additionally, faculty will cover the recommendations of the Breast International Group-North American Breast Cancer Group (BIG-NABCG) for assessing post-NAT resection specimens with emphasis on: the proper sampling of post-NAT specimens, the estimation of tumor size and residual cancer burden, post-therapy staging issues, and essential components to include in the pathology report.	Uma Krishnamurti, MD, PhD, FCAP Marina Mosunjac, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Breast Pathology	Uma Krishnamurti, MD, PhD, FCAP	Marina Mosunjac, MD, FCAP				uma-rti	mar-jac
Grow as a Leader	GAL2	Sunday, October 9, 2022, 9:00 AM - 5:00 PM \| In-Person Difficult Diagnoses in Breast Pathology and Management Challenges L2299 \| Breast Pathology \| 5.00 CME Credits	L2299	Difficult Diagnoses in Breast Pathology and Management Challenges	5.00 CME Credits	Join our team of renowned experts on Sunday, October 9, for an immersive review of challenging entities commonly seen in breast pathology practice. Faculty will help you navigate these diagnostic challenges using didactic, case-based, and interactive approaches to facilitate learning. This full-day course will cover an abundance of topics that will assist in your daily practice. Topics include diagnostic features and clinical significance of intraductal proliferative breast lesions, developing strategies for reporting papillary carcinomas, and recognizing the importance of radiologic correlation with nonneoplastic lesions. Fibroepithelial lesions will be highlighted by summarizing diagnostic features and clinical significance regarding the challenges for a core needle biopsy specimen. Attendees will learn to evaluate diagnostic criteria and clinical importance of classic and variant forms of LCIS, and classify morphologic and molecular features of special subtypes of invasive breast cancer. The faculty will also explore the role and limitations of prognostic and predictive markers, ER, PR, HER2, newer molecular assays, and PD-L1 testing in patients with breast cancer. This advanced course also includes interactive exercises illustrating the diagnostic and clinical features and management implications of several uncommon breast lesions. It will target general surgical pathologists with practical experience in diagnosing and signing out breast pathology.	Kimberly Allison, MD, FCAP Laura C. Collins, MD, FCAP Hannah L. Gilmore, MD Hannah Y. Wen, MD, PhD	In-Person	Sunday, October 9, 2022	10/09/2022	09:00 AM	10/09/2022 09:00 AM	05:00 PM		Sunday, October 9, 2022, 9:00 AM - 5:00 PM	Breast Pathology	Kimberly Allison, MD, FCAP	Laura C. Collins, MD, FCAP	Hannah L. Gilmore, MD	Hannah Y. Wen, MD, PhD		kim-son	lau-ins	han-ore	han-wen
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Hereditary Breast Cancers: What do We Know Beyond BRCA? S2149 \| Breast Pathology \| 1.50 CME Credits	S2149	Hereditary Breast Cancers: What do We Know Beyond BRCA?	1.50 CME Credits	Advances in the application of next-generation sequencing have led to the identification of germline mutations in cancer susceptibility genes other than BRCA1/2 that significantly increase risk for developing breast cancer. Guidelines for genetic testing in breast cancer patients are limited by the tedious process of extracting family history and are notorious at missing a significant proportion of patients otherwise suitable for testing. We, as pathologists, could ease this process by identifying distinct histomorphologic and immunophenotypic features associated with these mutations. Furthermore, recent approval of PARP-inhibitors for treatment of breast cancer patients with BRCA1/2 mutations has substantiated a need for embracing new tests for predicting response to therapy. The faculty will highlight the most up-to-date information related to hereditary breast cancers and will emphasize the important role the pathologist plays in their identification. This course is suitable for general surgical pathologists, subspecialized pathologists, and pathologists in training.	Rania Bakkar MD, FCAP Anupma Nayak, MD	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Breast Pathology	Rania Bakkar MD, FCAP	Anupma Nayak, MD				ran- md	anu-yak
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation using Morphology and IHC S2276 \| Breast Pathology \| 1.50 CME Credits	S2276	Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation using Morphology and IHC	1.50 CME Credits	Evaluation of spindle cell lesions of the breast is challenging and can be even more so on core needle biopsy specimens. Malignant mimics of benign lesions abound and vice versa. The diagnostic considerations are broad as some malignant lesions, such as metaplastic carcinomas, can be deceptively bland. A targeted IHC panel is often critical in evaluating these lesions, but there are important pitfalls to be aware of when evaluating IHC. The faculty will review common and unusual spindle cell lesions of the breast, considerations that should be included in the differential diagnosis, and when and how to utilize IHC to support a morphologic diagnosis. In some cases, a definitive diagnosis is not possible on core needle biopsy. The faculty will discuss how best to convey sufficient pathologic information to the clinical team so that the patient receives appropriate care. This course is appropriate for all pathologists who review breast specimens.	Laura C. Collins, MD, FCAP Liza Quintana, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Breast Pathology	Laura C. Collins, MD, FCAP	Liza Quintana, MD, FCAP				lau-ins	liz-ana
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person Spindle Cell Lesions of the Breast: A Spectrum of Cases and Their Differential Diagnoses V2293 \| Breast Pathology \| 1.50 CME Credits	V2293	Spindle Cell Lesions of the Breast: A Spectrum of Cases and Their Differential Diagnoses	1.50 CME Credits	This video microscopy course will expand on the companion course Breast Core Needle Biopsy of Spindle Cell Lesions: Keys to Evaluation Using Morphology and IHC. The differential diagnosis for spindle cell lesions is broad and the evaluation and categorization of these lesions is challenging. The faculty will review common and rare spindle cell lesions with an emphasis on how to work them up, order and interpret relevant IHC, and report them.	Laura C. Collins, MD, FCAP Liza Quintana, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Breast Pathology	Laura C. Collins, MD, FCAP	Liza Quintana, MD, FCAP				lau-ins	liz-ana
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Common Yet Challenging Diagnoses in Breast Core Biopsies: How to Recognize and Avoid the Pitfalls (On-Demand) S2148 \| Breast Pathology \| 1.50 CME Credits	S2148	Common Yet Challenging Diagnoses in Breast Core Biopsies: How to Recognize and Avoid the Pitfalls (On-Demand)	1.50 CME Credits	With the wide practice of breast cancer screening programs, breast core biopsies are among the most common specimens in academic and private pathology practice. It can be challenging to render an accurate diagnosis with limited sampling from core biopsies. Common but challenging cases in breast core biopsies include: 1) usual ductal hyperplasia versus atypical ductal hyperplasia versus low-grade ductal carcinoma in situ; 2) sclerosing lesions including benign and malignant entities; 3) papillary lesions including papilloma with uncommon features, atypical papilloma, and papillary carcinoma; and 4) fibroepithelial lesions including benign and malignant entities. The faculty will present information to help pathologists become familiar with the morphological features of these common but challenging entities, and how to order and interpret appropriate ancillary IHC studies. Faculty will also update pathologists on current recommendations on management and molecular features of these lesions.	Benjamin C. Calhoun, MD, PhD, FCAP Xiaoxian (Bill) Li, MD, PhD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Breast Pathology	Benjamin C. Calhoun, MD, PhD, FCAP	Xiaoxian (Bill) Li, MD, PhD, FCAP				ben-oun	xia- li
Keep Abreast of Innovation	KAI3	Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Point-of-Care and Rapid Tests for COVID-19, the Mayo Clinic Experience R1935 \| Chemistry \| 1.00 CME Credit	R1935	Point-of-Care and Rapid Tests for COVID-19, the Mayo Clinic Experience	1.00 CME Credit	Join the experts for lunch! Exchange information and share solutions in a relaxed setting with your peers. Learn to improve your ability to identify solutions to common problems through interactive sessions.	Bradley S. Karon, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Chemistry	Bradley S. Karon, MD, PhD, FCAP					bra-ron
		Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person Tips for Ensuring Quality in Your Point-of-Care Program M2221 \| Communication \| 1.00 CME Credit	M2221	Tips for Ensuring Quality in Your Point-of-Care Program	1.00 CME Credit	The rapid growth of point-of-care testing (POCT) adoption is reflective of the vital role POCT plays in patient management. With correct implementation, POCT can improve outcomes, decrease overall turnaround time, increase access to care, reduce costs, and enhance patient satisfaction. It is therefore imperative to ensure quality in POCT, however, managing this is a continuous challenge. During this course, the faculty will review the total testing process in POCT and the challenges associated with ensuring quality at each phase of testing. Using case examples, the faculty will describe strategies to overcome challenges at the preanalytic, analytic, and postanalytic phases of testing. They will also share tips on identifying quality indicators, monitoring performance, engaging personnel, reducing errors, and implementing processes that ensure quality will be described. This course is intended for pathologists, lab directors, lab managers, POCT coordinators, and pathology trainees practicing in hospital or outpatient settings. This course is cosponsored by the American Association for Clinical Chemistry.	Brenda Suh-Lailam, PhD, DABCC	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Communication	Brenda Suh-Lailam, PhD, DABCC					bre-lam
		Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual How to Avoid Death by PowerPoint and Zoom: A Field Guide to Creating More Impactful Presentations M2217 \| Communication \| 1.00 CME Credit	M2217	How to Avoid Death by PowerPoint and Zoom: A Field Guide to Creating More Impactful Presentations	1.00 CME Credit	Pathologists are the visual artists of medicine. We diagnose images and craft diagnostic stories that start patients on their treatment journeys. How do we leverage those visual skills to become a more compelling storyteller? This presentation will help you do that. It is a talk about talks—a how-to guide for presenters. During the first half the faculty will focus on live presentations, constructing a talk that engages and inspires. What are the hidden features of PowerPoint that will make your presentation stand out? The faculty will discuss graphic design principles for creating slides with the right mix of images and text. The second half of the talk will focus on virtual presentations, using Zoom, Teams, etc. What software will maximize impact? How do the interplay of lighting, sound, and virtual backgrounds lead to a better virtual experience? It’s time to unmute yourself and unleash your inner visual storyteller.	Eric F. Glassy, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Communication	Eric F. Glassy, MD, FCAP					eri-ssy
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Diagnostic Reporting Systems in Cytopathology: Updates, Aftermaths and Controversies S2164 \| Cytopathology \| 1.50 CME Credits	S2164	Diagnostic Reporting Systems in Cytopathology: Updates, Aftermaths and Controversies	1.50 CME Credits	The Diagnostic Reporting Systems in Cytopathology (DRSC) were created to meet general and specific needs. All systems address problematic terminologies and attempt to streamline patient management. Common standards improve communication between cytopathologists and their clinical colleagues. Specifically, The Bethesda System for Reporting Cervical Cytology (TBS) was born in response to problematic practices and the creation of CLIA 88. Bethesda-Thyroid and Serous Fluid Systems were created due to a need for clarification of diagnostic tiers and risks of malignancy. Paris was needed because of poor performance of low-grade urinary cytology and clarification of what urinary cytology does well. The Milan System for Salivary Gland came about because of diagnostic inconsistencies in dealing with a very difficult area. All DRSCs have been modeled after TBS. In this session, faculty will describe four DRSCs, discuss real-world implications of the proposed nomenclature, and provide updates of each reporting scheme. This course is cosponsored by the American Society of Cytopathology.	Zubair W. Baloch, MD, PhD, FCAP Guliz A. Barkan, MD, FCAP Daniel F.I. Kurtycz, MD, FCAP Ritu Nayar, MD, MBBS, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Cytopathology	Zubair W. Baloch, MD, PhD, FCAP	Guliz A. Barkan, MD, FCAP	Daniel F.I. Kurtycz, MD, FCAP	Ritu Nayar, MD, MBBS, FCAP		zub-och	gul-kan	dan-ycz	rit-yar
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Common Pitfalls and Mimickers in Dermatopathology S2259 \| Dermatopathology \| 1.50 CME Credits	S2259	Common Pitfalls and Mimickers in Dermatopathology	1.50 CME Credits	This course is tailored for general surgical pathologists with a focus on key aspects of IHC and molecular studies, and traditional clinical and histophenotypic features of difficult benign and malignant skin lesions. The faculty will use their extensive experience in a large tertiary referral cancer center to discuss and illustrate differential diagnoses. Early and correct recognition of these lesions is of utmost importance to reduce incorrect or nondefinitive diagnoses and costs for unnecessary studies, as well as streamline time to results for patients and management. The faculty will summarize the key features and algorithmic approach, and review cases with interactive discussion of this practical approach. Highlighted situations include: digital papillary adenocarcinoma versus acral hidradenoma; primary adnexal neoplasm versus metastatic adenocarcinoma to skin; cutaneous lymphoproliferative disorders such as gamma-delta T-cell lymphoma versus mycosis fungoides with CD8 expression; capsular nevus versus metastatic melanoma in sentinel lymph node of patients with melanoma; spindle melanocytic lesion (benign/malignant) versus neural tumor such as MPNST; Merkel cell carcinoma versus basal cell carcinoma; squamous cell carcinoma versus psedoepitheliomatous hyperplasia due to syphilis.	Phyu P. Aung, MD, PhD, FCAP Victor G. Prieto, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Dermatopathology	Phyu P. Aung, MD, PhD, FCAP	Victor G. Prieto, MD, PhD, FCAP				phy-ung	vic-eto
Keep Abreast of Innovation	KAI3	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Expert Testimony: What Happens After You Receive the Subpoena? M2219 \| Forensic Pathology \| 1.00 CME Credit	M2219	Expert Testimony: What Happens After You Receive the Subpoena?	1.00 CME Credit	You just get handed a subpoena, now what? This course will prepare hospital-based and forensic pathologists (residents to 10 years in practice) for a variety of interactions in the medicolegal arena. The faculty will provide an overview of the judicial system including common terminology, procedures, decorum in the witness box, and various legal orders. Further, the faculty will explain deposition and trial testimony, including how they differ and what can go wrong. Finally, they will describe common pitfalls and “trick” questions (and some answers). The goal of the course is to remove some of the mystery and trepidation around testimony and provide a solid understanding of what to expect and how to react in these proceedings.	Beth E. Frost, DO, FCAP James R. Gill, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Forensic Pathology	Beth E. Frost, DO, FCAP	James R. Gill, MD, FCAP				bet-ost	jam-ill
		Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person, Virtual Before the Cancer Diagnosis: Navigating Inflammatory and Pre-malignant Pathology of the Esophagus S2262 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2262	Before the Cancer Diagnosis: Navigating Inflammatory and Pre-malignant Pathology of the Esophagus	1.50 CME Credits	Premalignant and non-infectious inflammatory diseases of the esophagus are entities that present diagnostic challenges, especially when there is limited clinical information and overlapping histologic features. Proper identification is imperative in ensuring appropriate patient management. The faculty will address two compelling issues faced by pathologists in academic, private, and community practice as well as pathologists in training. First, faculty will focus on identifying and grading squamous and glandular esophageal dysplasia (Barrett mucosa). Secondly, developing a methodical approach for evaluating non-infectious inflammatory conditions (eosinophilic esophagitis, lichenoid esophagitis). Participants will gain proficiency in how to formulate diagnoses for dysplastic and inflammatory esophageal pathologies. The audience will be engaged through a series of case studies and polling questions to enhance key learning objectives.	Safia N. Salaria, MD, FCAP Annika L. Windon, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Gastrointestinal Pathology	Safia N. Salaria, MD, FCAP	Annika L. Windon, MD, FCAP				saf-ria	ann-don
		Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Inflammatory Bowel Disease: Challenges and Controversies S2263 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2263	Inflammatory Bowel Disease: Challenges and Controversies	1.50 CME Credits	During this course, the faculty will focus on the challenges and controversies in the histologic examination of specimens from patients with inflammatory bowel disease (IBD). They will discuss topics such as unusual forms of dysplasia, reporting of dysplasia are SCENIC, serrated epithelial change, Crohn's colitis, indeterminate colitis, backwash ileitis, and reporting pouch specimens, among other topics. The faculty will address emerging topics in IBD, and their relevance to the practice of GI pathology. The course is intended for practicing pathologists with at least some experience or interest in GI pathology who want to deepen their knowledge in IBD, including pathology residents and fellows in GI pathology. This course is cosponsored by the Rodger C. Haggitt Gastrointestinal Pathology Society.	Won-tak Choi MD, PhD Joseph Misdraji, MD, FCAP Bita V. Naini, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Gastrointestinal Pathology	Won-tak Choi MD, PhD	Joseph Misdraji, MD, FCAP	Bita V. Naini, MD, FCAP			won- md	jos-aji	bit-ini
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Keeping Up With the Advances in Gastric Neoplasms S2153 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2153	Keeping Up With the Advances in Gastric Neoplasms	1.50 CME Credits	In the current era of evolving integration between traditional pathology and molecular advances, this course offers a practical review of neoplastic gastric pathology combining updated morphologic classification and advanced techniques. Faculty will use case-based illustrations to cover updated information on the classification of gastric polyps, dysplasia, and cancer based on morphologic assessment, IHC studies, and molecular techniques. Additionally, faculty will present a combination of succinct up-to-date summaries and real practice examples to explain the updates relevant to routine practice such as novel World Health Organiazation classification, the value of gastric intestinal metaplasia subtyping, and evaluation of HER2/neu and PD-L1 expression in gastric cancer. Examples of molecularly defined subtypes of gastric neoplasms that may direct therapy will also be discussed. The course is designed for academic and community pathologists.	Gregory Lauwers, MD, FCAP Namrata Setia, MD, MBBS	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Gastrointestinal Pathology	Gregory Lauwers, MD, FCAP	Namrata Setia, MD, MBBS				gre-ers	nam-tia
Keep Abreast of Innovation	KAI3	Monday, October 10, 2022, 9:30 AM - 11:00 AM \| In-Person, Virtual Appendix Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis S2172 \| Gastrointestinal Pathology \| 1.50 CME Credit	S2172	Appendix Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis	1.50 CME Credit	This course will provide an update on the classification, nomenclature, and staging of commonly encountered and newly described lesions of the appendix. This course features a case-based discussion from two gastrointestinal pathology experts who will emphasize practical diagnostic pearls and pitfalls and reporting strategies. The faculty will present the latest guidelines and recent changes to nomenclature and staging. An interactive quiz component will emphasize key learning points and allow the audience to practice applying the course content with real-time feedback. There will be ample time for questions and discussion between the faculty and participants. The course is intended for practicing surgical pathologists, gastrointestinal subspecialized pathologists, as well as residents and fellows.	Jacqueline E. Birkness-Gartman, MD Maryam K. Pezhouh, MD, MSc, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	11:00 AM		Monday, October 10, 2022, 9:30 AM - 11:00 AM	Gastrointestinal Pathology	Jacqueline E. Birkness-Gartman, MD	Maryam K. Pezhouh, MD, MSc, FCAP				jac-man	mar-ouh
Keep Abreast of Innovation	KAI3	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual EUS-guided and 'SpyBite' Biopsies of Pancreatic and Biliary Tract Lesions (FNA vs Biopsy) S2178 \| Gastrointestinal Pathology \| 1.50 CME Credit	S2178	EUS-guided and 'SpyBite' Biopsies of Pancreatic and Biliary Tract Lesions (FNA vs Biopsy)	1.50 CME Credit	This course is presented by the Pancreatobiliary Pathology Society and will provide an overview and step-wise, algorithmic approach to the evaluation of “SpyBite” biopsies and cytologic samples (including endoscopic ultrasound (EUS)-guided fine-needle aspirations and bile duct brushings) from cystic/solid lesions/strictures of pancreas and biliary tract. The faculty include a cytopathologist and gastrointestinal pathologist who subspecialize in pancreatobiliary pathology. These faculty will outline practical diagnostic pearls and reporting strategies as well as judicious utility of ancillary IHC/molecular studies. Additionally, the faculty will emphasize changes in terminology, classification, and diagnosis/grading of classical and newly described site-specific entities (intraductal papillary mucinous (IPMN), oncocytic (IOPN) and tubulopapillary (ITPN) neoplasm, flat (Bil-IN) and tumoral intraepithelial biliary tract neoplasms (IPN-B), and neuroendocrine neoplasms). This course is intended for surgical, gastrointestinal, and cytopathologists in community/academic practice as well as pathologists in training. An interactive quiz will emphasize key learning points and allow the audience to practice/apply course content with real-time feedback. This course is sponsored by the Pancreatobiliary Pathology Society.	Olca Basturk, MD Michelle Reid, MD, MS, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Gastrointestinal Pathology	Olca Basturk, MD	Michelle Reid, MD, MS, FCAP				olc-urk	mic-eid
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual When is Enough Enough? Making Sense of the Small Changes in GI Biopsies S2011 \| Gastrointestinal Pathology \| 1.50 CME Credits	S2011	When is Enough Enough? Making Sense of the Small Changes in GI Biopsies	1.50 CME Credits	This course will examine fundamental concepts of histology in upper and lower gastrointestinal biopsies with a focus on intraepithelial lymphocytosis and dysplastic epithelial changes in an ever-increasing, complex patient environment. The faculty will use a case-based approach to provide practical examples of how to sign out cases from different sites, and highlight subtle histologic details to aid recognition of key features. In addition, faculty will review recent literature and the American Joint Committee on Cancer and World Health Organization updates to clarify diagnostic criteria, ensure consistency in reporting, and optimize patient care. These discussions will help both practicing pathologists as well as trainees. This course is cosponsored by the Rodger C. Haggitt Gastrointestinal Pathology Society.	Stephen M. Lagana, MD, FCAP David F. Schaeffer, MD, FRCPC	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Gastrointestinal Pathology	Stephen M. Lagana, MD, FCAP	David F. Schaeffer, MD, FRCPC				ste-ana	dav-fer
Get a Strong Start	GASS2	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21) S2274 \| Genitourinary Pathology \| 1.50 CME Credits	S2274	Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21)	1.50 CME Credits	The classification of genitourinary cancers has significantly advanced due to the rapidly evolving understanding of the molecular underpinnings of cancer with excellent clinical and pathologic correlation. The faculty have designed this course to concisely summarize new diagnostic entities in genitourinary pathology. They have incorporated critical changes in diagnostic nomenclature from the upcoming World Health Organization 2021 (WHO-21) book and will cover all areas of the genitourinary system, including the kidney, prostate, penis, testis, and urinary tract. The faculty will: 1) describe the overarching, evolving paradigm of urologic tumor classification based on morphologic, clinical, and molecular correlations; 2) present new and emerging entities in genitourinary pathology in the context of existing classification schema; 3) highlight molecular testing as relevant to genitourinary diagnostic categories; and 4) discuss the impact of these new modalities and diagnoses on clinical management.	Mahul B. Amin, MD, FCAP Donna E. Hansel, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Genitourinary Pathology	Mahul B. Amin, MD, FCAP	Donna E. Hansel, MD, PhD, FCAP				mah-min	don-sel
Get a Strong Start	GASS3	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Identifying New and Emerging Entities in Genitourinary Pathology V2245 \| Genitourinary Pathology \| 1.50 CME Credits	V2245	Identifying New and Emerging Entities in Genitourinary Pathology	1.50 CME Credits	This video microscopy course will expand upon the companion course on updates in the morphological and molecular classification of urologic malignancies Updates in the Morphological and Molecular Classification of Urologic Malignancies (Including WHO-21). The faculty will identify critical changes in diagnostic nomenclature from the upcoming World Health Organization 2021 book and cover all areas of the genitourinary system. The faculty will also cover new and emerging entities in genitourinary pathology and discuss the impact of these new modalities and diagnoses on clinical management.	Mahul B. Amin, MD, FCAP Donna E. Hansel, MD, PhD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Genitourinary Pathology	Mahul B. Amin, MD, FCAP	Donna E. Hansel, MD, PhD, FCAP				mah-min	don-sel
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Difficult Differential Diagnoses in Genitourinary Pathology: Mimickers and Beyond S2291 \| Genitourinary Pathology \| 1.50 CME Credits	S2291	Difficult Differential Diagnoses in Genitourinary Pathology: Mimickers and Beyond	1.50 CME Credits	This course focuses on addressing challenging scenarios and contemporary differential diagnosis for a broad array of genitourinary specimens relevant to pathologists in practice and in training. Using a case presentation with an organ-based approach, the faculty will address evolving concepts in old and emerging entities, diagnostic pitfalls, and controversies in numerous genitourinary cancer subtypes. A large number of images in a tumor board format will expose the audience to a wide spectrum of lesions. Faculty will place significant emphasis on contemporary updates, interpretation of diagnostic pitfalls, exclusion of benign mimickers, and application of ancillary studies. Additionally, the faculty will emphasize key pathologic reporting parameters that are of greatest value to clinicians in the context of clinical application and management.	Giovanna A. Giannico, MD, FCAP Sean R. Williamson, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Genitourinary Pathology	Giovanna A. Giannico, MD, FCAP	Sean R. Williamson, MD, FCAP				gio-ico	sea-son
		Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Embracing Diversity in Bladder Cancer: Variants, Divergence, and Molecular Findings in Urothelial Carcinoma M2270 \| Genitourinary Pathology \| 1.00 CME Credit	M2270	Embracing Diversity in Bladder Cancer: Variants, Divergence, and Molecular Findings in Urothelial Carcinoma	1.00 CME Credit	Urothelial carcinomas with variant/divergent differentiation convey a worse prognosis than pure high-grade urothelial carcinoma. They remain unrecognized and underreported, despite their clinical and prognostic importance. They usually present with high pT stage and nodal metastasis. Treatment guidelines may also differ with aggressive multimodal therapy recommended in this setting. The faculty will present the morphologic features of clinically significant divergent histology in the urothelial tract and the need to consistently report them due to their prognostic and therapeutic impact. They will also discuss the differential diagnosis including the preneoplastic lesions and mimickers to ensure accurate recognition. Finally, the faculty will focus on the role of molecular advances in the diagnosis, classification, and management of urothelial carcinoma, including when and how to fully integrate such advances in routine diagnostic practice. This course is suitable for pathologists in training and in practice, irrespective of years of practice, in both academic and community settings.	Hikmat A. Al-Ahmadie, MD Lara R. Harik, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Genitourinary Pathology	Hikmat A. Al-Ahmadie, MD	Lara R. Harik, MD, FCAP				hik-die	lar-rik
Keep Abreast of Innovation	KAI1	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Big Results From Small Specimens: Maximizing the Impact of Renal Mass Biopsy for Best Clinical Outcomes S2246 \| Genitourinary Pathology \| 1.50 CME Credits	S2246	Big Results From Small Specimens: Maximizing the Impact of Renal Mass Biopsy for Best Clinical Outcomes	1.50 CME Credits	Renal mass biopsies are increasingly utilized in the workup of renal masses, especially those that are found incidentally. Simultaneously, the classification of renal neoplasms is expanding with numerous new entities being introduced into the literature. The faculty will focus on the utility and limitations of renal mass biopsies, providing numerous case-based examples of how to effectively approach these small specimens. Video microscopy will be used to review cases in real time with genitourinary pathologists from academic and private settings. The course will be interactive with questions from the audience as well as polling questions. As renal mass biopsies may be seen in any practice setting, this course is geared to pathologists at any stage of their career who are interested in gaining practical insight into the diagnosis of renal mass biopsies.	Ankur R. Sangoi, MD, FCAP Sara E. Wobker, MD, MPH, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Genitourinary Pathology	Ankur R. Sangoi, MD, FCAP	Sara E. Wobker, MD, MPH, FCAP				ank-goi	sar-ker
Get a Strong Start	GASS4	Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Money is in the LAST Detail: Diagnosis and Management of Human Papillomavirus Infection-Associated Lesions S2155 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2155	Money is in the LAST Detail: Diagnosis and Management of Human Papillomavirus Infection-Associated Lesions	1.50 CME Credits	The human papillomavirus (HPV) is mainly responsible for malignancies of the lower anogenital tract and oropharynx. The faculty will review the epidemiology and life cycle of HPV, and the steps in HPV-related carcinogenesis. They will emphasize criteria to accurately identify and classify HPV-driven preneoplastic and neoplastic lesions in both cytology and histologic specimens following the recommendations of the Lower Anogenital Squamous Terminology (LAST) project. There are challenges in the proper implementation of p16 IHC, recommended by the LAST project as a biomarker to identify high-grade squamous intraepithelial lesion. The faculty will discuss sources of error and present solutions to correctly apply and interpret p16 IHC, and will also review the American Society for Colposcopy and Cervical Pathology guidelines for management of women with abnormal Pap test, screening guidelines for various HPV-related cancers, and will conclude by reviewing the HPV vaccine. A case-based approach with live audience response will be used to cover these topics.	Krisztina Z. Hanley, MD Uma Krishnamurti, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Gynecologic/Obstetric Pathology	Krisztina Z. Hanley, MD	Uma Krishnamurti, MD, PhD, FCAP				kri-ley	uma-rti
Grow as a Leader	GAL3	Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Clinically Relevant, Pattern-Based Approach to Diagnosing Uterine Mesenchymal Tumors (On-Demand) S2156 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2156	Clinically Relevant, Pattern-Based Approach to Diagnosing Uterine Mesenchymal Tumors (On-Demand)	1.50 CME Credits	This course will use a pattern-based approach (spindled, epithelioid, rhabdoid, myxoid patterns; low-grade versus high-grade atypia) to build differential diagnoses and emphasize selection and interpretion of the most useful, current IHC and molecular tests for each diagnostic scenario of uterine mesenchymal tumors. The faculty will highlight common pitfalls, new diagnostic tools, and features that predict response to targeted therapy; and the novel role of the pathologist in recognizing morphologic features associated with risk of a hereditary syndrome. Special issues in the diagnosis and reporting of mesenchymal tumors in endometrial biopsy, curettage, and polypectomy and their unique challenges will be addressed. Updates from the new World Health Organization (WHO) Classification System of Tumors (“blue book”), of which both faculty are authors, will also be discussed.	Amy S. Joehlin-Price, MD, MS, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Gynecologic/Obstetric Pathology	Amy S. Joehlin-Price, MD, MS, FCAP					amy-ice
		Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual What’s in a Name? Serous Neoplasms of the Ovary and Fallopian Tube: Classification Updates, Common Conundrums, and Outcomes (On-Demand) S2169 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2169	What’s in a Name? Serous Neoplasms of the Ovary and Fallopian Tube: Classification Updates, Common Conundrums, and Outcomes (On-Demand)	1.50 CME Credits	The practicing pathologist, whether in a community or academic setting, commonly encounters serous neoplasms of the ovary and fallopian tube. However, correct application of updated nomenclature which can alter patient management can be challenging. The faculty will cover diagnostic dilemmas using a case study method with audience interaction, starting at frozen section/case presentation and ending with the final diagnosis. The course will cover areas such as serous cystadenomas with proliferation versus borderline tumors, sampling and diagnosis of tumors with micropapillary architecture, and features of low-grade carcinoma including implant classification. The faculty will review problematic cases of high-grade serous carcinoma, including diagnosis and reporting of post-neoadjuvant high-grade serous carcinoma, overlap with low-grade carcinoma, and diagnostic features of serous tubal intraepithelial carcinoma. The faculty will use each case to instruct attendees about recent updates to the World Health Organization classification, molecular characteristics which can be exploited in routine practice for diagnosis and clinical management, and implications of diagnosis for patient outcomes and treatment.	Jennifer Bennett, MD Joseph Rabban, MD, MPH, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Jennifer Bennett, MD	Joseph Rabban, MD, MPH, FCAP				jen-ett	jos-ban
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual Beyond the Correct Diagnosis: Ancillary Testing in Gynecologic Pathology – Things Your Gynecologic Oncologist Do Not Want You to Miss S2252 \| Gynecologic/Obstetric Pathology \| 1.50 CME Credits	S2252	Beyond the Correct Diagnosis: Ancillary Testing in Gynecologic Pathology – Things Your Gynecologic Oncologist Do Not Want You to Miss	1.50 CME Credits	With the inclusion of molecular classification of endometrioid carcinoma in the 2020 World Health Organization Female Genital Tumors, the necessity of ancillary techniques such as next-generation sequencing and/or IHC staining will likely become routine for subclassification of these and other tumor types. Additionally, criteria for clinical trials and emerging therapies for gynecolgic tract malignancies often require results of mismatch repair testing, p53, or HER2 IHC. In this context, the signing pathologist, must understand not only the significance of these ancillary tests, but also when they are required. The faculty will use a case-based presentation to review various entities of the gynecolgic tract with a focus on the clinical and therapeutic implications from the viewpoint of a gynecologic oncologist.	Natalie Banet, MD, FCAP Deyin Xing, MS, BM, MBBS, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Natalie Banet, MD, FCAP	Deyin Xing, MS, BM, MBBS, PhD				nat-net	dey-ing
Keep Abreast of Innovation	KAI2	Tuesday, October 11, 2022, 1:00 PM \| In-Person, Virtual We Can Do Better Than Hyperkeratosis: Approaches for the Differential Diagnosis of Oral Pathology Lesions M2190 \| Gynecologic/Obstetric Pathology \| 1.00 CME Credits	M2190	We Can Do Better Than Hyperkeratosis: Approaches for the Differential Diagnosis of Oral Pathology Lesions	1.00 CME Credits	Do you have an interest in oral pathology and the diagnosis of oral keratotic lesions? If so, this course will provide specific diagnostic criteria in this area for attendees, including residents, general and even specialist pathologists. These diagnoses range from keratoses caused by friction such as from parafunctional habits, oral lichen simplex chronicus, and inflammatory conditions. The faculty will focus on the architectural, organizational, and cytologic features of oral epithelial dysplasia. Current data suggest that most, if not all leukoplakia’s, are precancerous whether they show cytologic evidence of dysplasia or not. At this time, too much emphasis has been placed on cytologic atypia so that many dysplastic lesions that show organization and architectural atypia have not been correctly diagnosed as such with serious consequences for patients. The faculty will show the clinical lesions and the corresponding histopathology which may look innocuous, and will also provide specific sign-out phrases that may be helpful.	Natalie Banet, MD, FCAP Deyin Xing, MS, BM, MBBS, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM		01:00 PM	Tuesday, October 11, 2022, 1:00 PM	Gynecologic/Obstetric Pathology	Natalie Banet, MD, FCAP	Deyin Xing, MS, BM, MBBS, PhD				nat-net	dey-ing
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Lessons Learned From the New WHO Classification of Head and Neck Tumors M2222 \| Gynecologic/Obstetric Pathology \| 1.00 CME Credit	M2222	Lessons Learned From the New WHO Classification of Head and Neck Tumors	1.00 CME Credit	The fifth edition of the World Health Organization Classification of Head and Neck Tumors presents several advancements and developments in our understanding of tumors and tumor-like lesions that affect the upper aerodigestive tract and salivary glands. The faculty will emphasize emerging diagnostic concepts and key nomenclature changes that were incorporated in the new 2022 “blue book.” The faculty will use a case-based approach to discuss how histopathology, IHC, and molecular testing can be integrated in the daily practice of head and neck pathology.	Leslie Randall, MD Sadia Sayeed, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Gynecologic/Obstetric Pathology	Leslie Randall, MD	Sadia Sayeed, MD, FCAP				les-all	sad-eed
Get a Strong Start	GASS3	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Emerging Diagnostic Concepts of the New WHO Classification of Head and Neck Tumours V2294 \| Head and Neck Pathology \| 1.50 CME Credits	V2294	Emerging Diagnostic Concepts of the New WHO Classification of Head and Neck Tumours	1.50 CME Credits	This video microscopy course will expand upon the complimentary course on the new WHO Classification of Head and Neck Tumours. This 5th edition presents several advancements and developments in our understanding tumors and tumor-like lesions that affect the upper aerodigestive tract and salivary glands. The faculty will emphasize emerging diagnostic concepts and key nomenclature changes that were incorporated in the new 2022 “blue book.”	Sook-Bin Woo, MD, DMD	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Head and Neck Pathology	Sook-Bin Woo, MD, DMD					soo-woo
		Saturday, October 8, 2022, 1:30 PM - 2:30 PM \| In-Person, Virtual Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What Do We Know and What Should We Do S2247 \| Head and Neck Pathology \| 1.50 CME Credits	S2247	Pediatric Hematopathology in the Era of Advanced Molecular Diagnostics: What Do We Know and What Should We Do	1.50 CME Credits	No need to feel intimidated when you see a pediatric hematopathology sample! Though we may have different differential diagnoses when it comes to kids since they aren’t small adults, join the faculty to learn a step-by-step approach to tackle these questions: It looks different from the adult marrows – is it normal? Is it neoplastic? Can this be inherited? Do I need additional studies? What else should I do if I made a diagnosis of acute leukemia? All these questions are important. The faculty will present selected cases to illustrate findings and workup for acquired aplastic anemia, bone marrow failure syndrome associated with germline mutations, myeloid proliferations related to Down syndrome, JMML, MDS, and acute leukemia. The faculty will cover the utilization of molecular tools and the updates on pediatric hematopathology entities. The course is appropriate for all pathologists and trainees who want to improve their understanding in evaluating pediatric hematopathology samples.	Juan C. Hernandez-Prera, MD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	02:30 PM		Saturday, October 8, 2022, 1:30 PM - 2:30 PM	Head and Neck Pathology	Juan C. Hernandez-Prera, MD, FCAP					jua-era
Dina 9/12		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Sweating the Small Stuff: Navigating Lymphoma Workups on Core Needle Biopsies S2013 \| Head and Neck Pathology \| 1.50 CME Credits	S2013	Sweating the Small Stuff: Navigating Lymphoma Workups on Core Needle Biopsies	1.50 CME Credits	This interactive lecture, designed for pathologists working in close contact with proceduralists and oncologists, will provide focused discussions regarding safe and efficient specimen processing, test selection, and reporting of core needle biopsies in patients with suspected or known hematologic neoplasms. The faculty will use six specific clinical case scenarios to discuss the utility and prioritization of ancillary testing with consideration of sample requirements and test limitations. The faculty will also address multiparametric flow cytometry and next-generation sequencing studies in addition to IHC, cytogenetic, and PCR-based molecular testing. The successful participant will analyze their current practices and leave with practical ideas for improvement. All levels of experience will benefit from this activity.	Juan C. Hernandez-Prera, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Head and Neck Pathology	Juan C. Hernandez-Prera, MD, FCAP					jua-era
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person Can’t-Miss Diagnoses: Using Flow Cytometry to Identify Hematolymphoid Neoplasms With Genetic Abnormalities and Prognostic Significance S2258 \| Head and Neck Pathology \| 1.50 CME Credits	S2258	Can’t-Miss Diagnoses: Using Flow Cytometry to Identify Hematolymphoid Neoplasms With Genetic Abnormalities and Prognostic Significance	1.50 CME Credits	Flow cytometry is a powerful diagnostic tool, and is a sensitive method to identify hematolymphoid neoplasms in body fluids and tissues. Some diagnoses in hematopathology are particularly time sensitive, such as acute promyelocytic leukemia. However, there are many other situations in which the oncology team may request a rapid diagnosis, including patients who are very ill, require a specific therapy, or may benefit from enrollment in a clinical trial. Careful evaluation of flow cytometric findings will facilitate interactions with the clinical team, and expedite ordering the ancillary tests in a thorough but cost-effective manner. In this course, the faculty will use case studies and audience polling to explore the strengths (and weakness) of flow cytometry in making critical and timely diagnoses. They will discuss the clinical significance of these findings as well as potential pitfalls. In this course, we will use case studies and audience polling to explore the strengths (and weakness) of flow cytometry in making critical and timely diagnoses. The clinical significance of these findings will be briefly reviewed, and potential pitfalls will also be discussed.	John Casler, MD, FACS Qihui "Jim" Zhai, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Head and Neck Pathology	John Casler, MD, FACS	Qihui "Jim" Zhai, MD, FCAP				joh-ler	qih-hai
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person Don't be Troubled by Red Cell Rubble: An Approach to Acquired Hemolytic Anemia S2261 \| Hematology/Hematopathology \| 1.50 CME Credits	S2261	Don't be Troubled by Red Cell Rubble: An Approach to Acquired Hemolytic Anemia	1.50 CME Credits	Acquired hemolytic anemias such as thrombotic microangiopathy (microangiopathic hemolytic anemia) and immune-mediated hemolysis are frequently encountered in the hospital setting. The pathologist is often consulted to help clinicians navigate these complex laboratory workups that tend to involve multiple laboratories, particularly hematology and transfusion medicine. The faculty will use a case-based approach to provide pathologists with the tools needed to provide clinical consultation in these challenging scenarios.	Julia Geyer, MD Yen-Chun Liu, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Julia Geyer, MD	Yen-Chun Liu, MD, PhD, FCAP				jul-yer	yen-liu
		Saturday, October 8, 2022, 9:30 AM - 11:00 AM \| In-Person The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist S2254 \| Hematology/Hematopathology \| 1.50 CME Credits	S2254	The ABC (and GCB) of Large B-Cell Lymphomas: An Algorithmic Approach to the Workup of Large B-Cell Lymphomas for the Surgical Pathologist	1.50 CME Credits	This course is designed to provide attendees with a case-based algorithmic approach to the contemporary workup of large B-cell lymphomas (LBCL). The faculty will provide a step-by-step approach to the initial diagnosis and subclassification of all major subcategories of LBCLs with emphasis on integration of cytogenetic and molecular findings. Additionally, the faculty will provide attendees with a practical algorithm designed to simplify the workup of these neoplasms.	Megan S. Lim, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	11:00 AM		Saturday, October 8, 2022, 9:30 AM - 11:00 AM	Hematology/Hematopathology	Megan S. Lim, MD, PhD, FCAP					meg-lim
Keep Abreast of Innovation	KAI1	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual How to Optimize or Implement Laboratory Testing For Xa-Inhibitory Direct Oral Anticoagulant (DOAC) Detection M2214 \| Hematology/Hematopathology \| 1.00 CME Credit	M2214	How to Optimize or Implement Laboratory Testing For Xa-Inhibitory Direct Oral Anticoagulant (DOAC) Detection	1.00 CME Credit	Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban, arrived on the market with no need for monitoring. As the use of DOACs expand, it is becoming clearer that measurement of these may be necessary in specific situations. More institutions are integrating either qualitative or quantitative assays. This course will use cases and audience polling to illustrate and prepare attendees for how to bring in new testing. The faculty will address questions such as: Which type of assay is most appropriate for your institution? How do you validate these assays, many of which are not FDA cleared? When should they be used? How do you integrate the testing in the ordering menu for clinicians?	Amy S. Duffield, MD, PhD, FCAP Laura Wake, MD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Amy S. Duffield, MD, PhD, FCAP	Laura Wake, MD				amy-eld	lau-ake
Get a Strong Start	GASS2	Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person COVID-19 and Hemostasis M2181 \| Hematology/Hematopathology \| 1.00 CME Credits	M2181	COVID-19 and Hemostasis	1.00 CME Credits	Coronavirus disease 2019 (COVID-19) can progress to a severe pro-inflammatory state with unique coagulopathy and procoagulant endothelial phenotype. A constellation of laboratory findings, including prominent elevation of fibrinogen, D-dimer/fibrin(ogen) degradation products, positive lupus anticoagulant, and altered viscoelastic tests have been reported. Increased platelet consumption, a corresponding increase in production, and increased activation of circulating platelets appear to occur. As the disease progresses, patients can develop findings similar to disseminated intravascular coagulation (DIC), but the rarity of severe bleeding events in these patients is not typical. Overall, these findings are associated with systemic hypercoagulability, frequent venous, arterial, and microvascular thrombotic and thromboembolic events. The laboratory may be consulted to interpret results and/or to monitor or guide anticoagulation in this severe thrombotic disease.	Vandita P. Johari, MD, FCAP Alexis R. Peedin, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Vandita P. Johari, MD, FCAP	Alexis R. Peedin, MD, FCAP				van-ari	ale-din
Keep Abreast of Innovation	KAI3	Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Next Generation of von Willebrand Activity Factor Testing: Are You Performing the Right One S2273 \| Hematology/Hematopathology \| 1.50 CME Credits	S2273	Next Generation of von Willebrand Activity Factor Testing: Are You Performing the Right One	1.50 CME Credits	In 2021, the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) issued a joint guidance document on the diagnosis of von Willebrand Disease (VWD). These guidelines suggest automated von Willebrand Factor (VWF) platelet-binding activity assays, VWF:GP1bM and VWF:GP1bR, over the traditional VWF:Ristocetin cofactor (RCo) activity assay. While neither of these are currently FDA approved, the VWF:Ab assay, which is FDA-cleared, was not included in the recommendation statement. During this interactive lecture, the faculty will use case studies and audience polling to answer the questions you or your hematology colleagues may ask, such as “Which VWF activity assay does your laboratory perform/send out?” and “Is it appropriate based on the new guidelines?”	Sanam Loghavi, MD, FCAP Kamran Mirza, MD, PhD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Hematology/Hematopathology	Sanam Loghavi, MD, FCAP	Kamran Mirza, MD, PhD, FCAP				san-avi	kam-rza
Grow as a Leader	GAL4	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Common Queries in Medical Liver Pathology: What the Practicing Pathologist Needs to Know S2018 \| Hemostasis Pathology \| 1.50 CME Credits	S2018	Common Queries in Medical Liver Pathology: What the Practicing Pathologist Needs to Know	1.50 CME Credits	In this course, the faculty will address common questions that arise in the daily practice of surgical pathologists who sign out medical liver. Using case-based presentations, the faculty will facilitate discussions on a range of common, but difficult, topics in medical liver biopsy. Some of these topics include how to approach a liver biopsy from a patient who presents with increased liver function tests, provide a thorough assessment of a fatty liver diseases, and rule in/out autoimmune hepatitis. They will also discuss how to avoid pitfalls in the evaluation of donor liver biopsy on frozen section, and how to compose a valuable liver pathology report that answers your clinician’s (sometimes unspoken) concerns. This course will be targeted towards practicing pathologists and pathologists in training.	Marian Rollins-Raval, MD, MPH, FCAP Geoffrey Wool, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Hemostasis Pathology	Marian Rollins-Raval, MD, MPH, FCAP	Geoffrey Wool, MD, PhD, FCAP				mar-val	geo-ool
Grow as a Leader	GAL1	Saturday, October 8, 2022, 1:30 PM - 2:30 PM \| In-Person Biopsies of Liver Mass Lesions: Let’s Master the Challenges and Pitfalls (Even on tiny Biopsy!) S2168 \| Hemostasis Pathology \| 1.50 CME Credits	S2168	Biopsies of Liver Mass Lesions: Let’s Master the Challenges and Pitfalls (Even on tiny Biopsy!)	1.50 CME Credits	Liver mass biopsy interpretation remains challenging for practicing pathologists, even for those with experience or a fellowship training in gastrointestinal/liver pathology. These lesions encompass a variety of benign and malignant hepatic neoplasms and metastases. Even within the category of primary hepatic neoplasms (hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma), new classifications/subtypes have emerged in recent years that have major implications in clinical practice. Metastatic lesions can not only closely mimic hepatocellular tumors, but they also sometimes come from an unknown primary. This requires a judicious IHC workup with a cost-effective approach, and an attempt to preserve tissues that might be needed for any subsequent molecular tests. Faculty will address practical approaches to a pathologic diagnosis of liver mass lesions, present an update on classifications/subtypes of liver tumors, and provide a guide to best practices in the application of IHC and other ancillary tests to the workup of hepatic metastases, particularly in the setting of limited biopsy material. This course is cosponsored by the Hans Popper Hepatopathology Society.	Eric Salazar, MD, PhD, FCAP Geoffrey Wool, MD, PhD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	02:30 PM		Saturday, October 8, 2022, 1:30 PM - 2:30 PM	Hemostasis Pathology	Eric Salazar, MD, PhD, FCAP	Geoffrey Wool, MD, PhD, FCAP				eri-zar	geo-ool
Keep Abreast of Innovation	KAI1	Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Practical approaches to Liver Mass Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls V2180 \| Hemostasis Pathology \| 1.50 CME Credits	V2180	Practical approaches to Liver Mass Lesions: A Case-Based Discussion With Emphasis in Differential Diagnosis and Pitfalls	1.50 CME Credits	Liver mass lesions encompass a variety of benign and malignant hepatic neoplasms, and metastases. Even within the category of primary hepatic neoplasms (hepatocellular adenoma, hepatocellular carcinoma, and cholangiocarcinoma), new classifications/subtypes have emerged in recent years that have major implications in clinical practice. Metastatic lesions can not only closely mimic hepatocellular tumors, but they also sometimes come from an unknown primary. This requires a judicious IHC workup with a cost-effective approach, and an attempt to preserve tissues that might be needed for any subsequent molecular tests. This two-hour virtual microscopy tutorial will demonstrate practical approaches to a pathologic diagnosis of liver mass lesions, present an update on classifications/subtypes of liver tumors, and provide a guide to best practices in the application of IHC and other ancillary tests to the workup of hepatic metastases, particularly in the setting of limited biopsy material. This course is cosponsored by the Hans Popper Hepatopathology Society.	Neil S. Harris, MD, FCAP Marian Rollins-Raval, MD, MPH, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Hemostasis Pathology	Neil S. Harris, MD, FCAP	Marian Rollins-Raval, MD, MPH, FCAP				nei-ris	mar-val
Grow as a Leader	GAL2	Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person Practical Immunohistochemistry (IHC) Approach for Small Tissue and Challenging Diagnostic Dilemmas S2157 \| Hepatopathology \| 1.50 CME Credits	S2157	Practical Immunohistochemistry (IHC) Approach for Small Tissue and Challenging Diagnostic Dilemmas	1.50 CME Credits	The advancement of precision medicine mandates pathologists to make accurate diagnoses and provide actionable recommendations based on scant tissue from sophisticated minimal invasive procedures. To apply IHC becomes essential, yet to preserve tissue for potential molecular analysis is also imperative. A systemic and data-proven best-practice approach is required to effectively execute this balancing act. The faculty will teach practical steps involving tissue triage and showcase smart IHC which entails specific markers, small panels, and stepwise workup. The focus of this course will be on commonly encountered challenging diagnostic dilemmas of general surgical pathology such as morphologically undifferentiated neoplasms and carcinomas of unknown primary origin. This course is intended for pathology trainees and practicing pathologists.	Maryam K. Pezhouh, MD, MSc, FCAP Meredith E. Pittman, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Hepatopathology	Maryam K. Pezhouh, MD, MSc, FCAP	Meredith E. Pittman, MD, FCAP				mar-ouh	mer-man
Keep Abreast of Innovation	KAI1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual To Improve is to Change: Tips and Tools for Quality Planning, Predictive Marker Monitoring, and Process Improvement in IHC S2282 \| Hepatopathology \| 1.50 CME Credits	S2282	To Improve is to Change: Tips and Tools for Quality Planning, Predictive Marker Monitoring, and Process Improvement in IHC	1.50 CME Credits	New monitoring and regulatory requirements for IHC laboratories performing predictive marker testing provide an opportunity for IHC laboratory directors to generate a comprehensive IHC laboratory quality plan. The faculty will review new PT survey monitoring requirements and discuss a standard approach to creating an IHC laboratory quality plan. The faculty will use selected cases based on the experience of the CAP IHC Subcommittee and past proficiency testing challenges to highlight process improvement principles that can be applied to current and future monitored assays.	Dhanpat Jain, MD, FCAP Xuchen Zhang, MD, PhD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Hepatopathology	Dhanpat Jain, MD, FCAP	Xuchen Zhang, MD, PhD, FCAP				dha-ain	xuc-ang
		Monday, October 10, 2022, 7:30 AM - 9:00 AM \| In-Person Uncultured: Infectious Diseases in Surgical Pathology S2136 \| Hepatopathology \| 1.50 CME Credits	S2136	Uncultured: Infectious Diseases in Surgical Pathology	1.50 CME Credits	Surgical pathologists can have a big impact upon diagnosing infectious diseases, particularly when cultures are not obtained, the agent is slow-growing not amenable to culture, or when colonization must be distinguished from infection. Armed with informed morphology and a few adjunctive tests, pathologists can learn to identify many agents to the species level. The faculty will review the morphologic features of several common and uncommon agents and elaborate on the available adjunctive tests.	Dhanpat Jain, MD, FCAP Xuchen Zhang, MD, PhD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	09:00 AM		Monday, October 10, 2022, 7:30 AM - 9:00 AM	Hepatopathology	Dhanpat Jain, MD, FCAP	Xuchen Zhang, MD, PhD, FCAP				dha-ain	xuc-ang
		Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person What’s Bugging the Gut: A Gastrointestinal Pathology and Microbiology Team Approach in Diagnosing Alimentary Tract Infections M2020 \| Immunohistochemistry \| 1.00 CME Credit	M2020	What’s Bugging the Gut: A Gastrointestinal Pathology and Microbiology Team Approach in Diagnosing Alimentary Tract Infections	1.00 CME Credit	The goal of this course is to facilitate a practical, case-based discussion of gastrointestinal infections that raise differential diagnostic challenges in surgical pathology. The faculty’s review focuses on the histological features of easy-to-miss infections and highlights the role of clinical laboratory testing in pathogen diagnosis through an integrated anatomic and clinical pathology team approach. This course will enhance attendees’ ability to look for and correctly identify gut infections. The course is intended for practicing surgical pathologists as well as clinical laboratory professionals with a goal to prepare attendees for an active role in multidisciplinary care.	Zong-Ming "Eric" Chen, MD, PhD, FCAP Anja C. Roden, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Immunohistochemistry	Zong-Ming "Eric" Chen, MD, PhD, FCAP	Anja C. Roden, MD, FCAP				zon-hen	anj-den
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person Glassless and Paperless: Everything You Are Wondering About a 100% Primary Diagnosis Digital Workflow S2284 \| Immunohistochemistry \| 1.50 CME Credits	S2284	Glassless and Paperless: Everything You Are Wondering About a 100% Primary Diagnosis Digital Workflow	1.50 CME Credits	Pathologists are facing a once in a lifetime disruption, which is the transition to a digital workflow. Much has been said about the countless benefits of entering the digital realm and how it will enhance pathologists’ practice. While some colleagues are experiencing this change with excitement, others are experiencing some anxiety, and some are in total denial. Human beings are creatures of habits, and pathologists are no exception. Thus a future with no microscope, no glass slides, and no paperwork can seem so stressful that it blocks the view of all the benefits that come after this transition. The presenting faculty will describe and demonstrate step by step how this transition can been done and how they not only survived, but are thriving in an uncluttered environment free of glass and paperwork. This workshop is for practicing pathologists at any stage in their careers.	Andrew Bellizzi, MD, FCAP Recording complete - St Emily Meserve, MD, MPH, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Immunohistochemistry	Andrew Bellizzi, MD, FCAP	Recording complete - St	Emily Meserve, MD, MPH, FCAP			and-zzi	rec-- s	emi-rve
Keep Abreast of Innovation	KAI1	Saturday, October 8, 2022, 1:30 PM - 3:00 PM \| In-Person Practical, Real-World Applications of Machine Learning in Pathology S2251 \| Infectious Disease Pathology \| 1.50 CME Credits	S2251	Practical, Real-World Applications of Machine Learning in Pathology	1.50 CME Credits	The potential of machine learning in pathology has stimulated substantial speculation in recent years. The deployment of machine learning applications in routine practice has now begun, yielding practical experience and best practices that can be shared. Machine learning in pathology remains a new domain in which there are challenges in matching the tool to the task, deploying machine learning tools successfully, and eliciting optimal ongoing performance. The faculty will introduce digital pathology for machine learning. They will review case-based examples of machine learning in anatomic pathology and laboratory medicine to illustrate opportunities and best practices for pathologists in the current landscape of machine learning systems.	Daniel Mais, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	01:30 PM	10/08/2022 01:30 PM	03:00 PM		Saturday, October 8, 2022, 1:30 PM - 3:00 PM	Infectious Disease Pathology	Daniel Mais, MD, FCAP					dan-ais
		Tuesday, October 11, 2022, 11:00:00 AM - 12:00 PM \| In-Person, Virtual Artificial Intelligence and Anatomical Pathology: What Every Practicing Pathologist Should Know S2288 \| Infectious Disease Pathology \| 1.50 CME Credits	S2288	Artificial Intelligence and Anatomical Pathology: What Every Practicing Pathologist Should Know	1.50 CME Credits	With recent advances in machine and deep learning, the integration of artificial intelligence (AI) into routine pathology practice is becoming a reality. Properly designed AI-enabled tools can potentially enhance a pathologist's job in many ways. In anatomical pathology, this could involve screening cases, automating tedious tasks, standardizing biomarker scoring, offering diagnostic assurance, novel prognostication, and much more. The faculty will provide an introduction to AI concepts and terminologies, review currently available products for anatomic pathologists, and explore deployment considerations in a practice setting. To provide a better understanding of AI principles, participants will be given an opportunity to train a machine learning algorithm using open-source (free) machine learning software (please bring a laptop running Windows/Mac OS/Linux to participate).	Alina Iuga, MD, FCAP Christina M. Wojewoda, MD, FCAP Maryam J. Zenali, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00:00 AM - 12:00 PM	Infectious Disease Pathology	Alina Iuga, MD, FCAP	Christina M. Wojewoda, MD, FCAP	Maryam J. Zenali, MD, FCAP			ali-uga	chr-oda	mar-ali
Get a Strong Start	GASS4	Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person Beyond Normal Limits: Uplifting Inclusivity Within Laboratory Medicine P2200 \| Informatics \| 1.25 CME Credits	P2200	Beyond Normal Limits: Uplifting Inclusivity Within Laboratory Medicine	1.25 CME Credits	The scientific plenary will focus on tangible changes laboratorians are able to make to help achieve health equity. Join our faculty for a discussion on health disparities and the connection with laboratory medicine. The discussion will cover deriving inclusive reference intervals representative of gender and race diversity, evaluate the clinical laboratory as a key stakeholder in propagating change, and elaborate on the responsibility pathologists and medical scientists have in mitigating negative implications of scientific “isms.” This session will also identify critical laboratory medicine changes to help eliminate health disparities. After this session, you will have an increased awareness of how reference ranges may contribute to inequality in health care and recognize your role in creating equity-centered change. Topics to be covered: Breaking Barriers to Gender-Inclusive Laboratory Medicine, Dina N. Greene, PhD, DABCC The NKF-ASN Task Force Recommendation on the Inclusion of Race in Diagnosing and Treating Kidney Disease, a Path Towards Health Equity, Cynthia Delgado, MD Toward Equity-Centered Science – Our Call to Action, Stephen P. Richmond, MD	Giovanni Lujan, MD, FCAP Anil V. Parwani, MD, PhD, MBA	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Informatics	Giovanni Lujan, MD, FCAP	Anil V. Parwani, MD, PhD, MBA				gio-jan	ani-ani
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Anatomic and Clinical Pathology Needs in Transgender Care S2275 \| Informatics \| 1.50 CME Credits	S2275	Anatomic and Clinical Pathology Needs in Transgender Care	1.50 CME Credits	Medical and surgical gender-affirmation therapies for transgender people have introduced a new spectrum to pathology practices. Sex hormones influence both anatomic and clinical pathology, which can complicate result interpretation for surgical specimens, chemistry, hematology, and microbiology. Our team has established transgender-specific reference intervals and performed in-depth analyses of surgical pathology aspects received from transgender men and women. Some of the nuances may not even be related to hormone administration, but rather are iatrogenically induced in the course of surgical affirmation. This session will empower pathologists with the tools necessary for serving the transgender population and prepare attendees to address the needs of their clinical colleagues in this regard.	Matthew G. Hanna, MD, FCAP James Harrison, MD, PhD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Informatics	Matthew G. Hanna, MD, FCAP	James Harrison, MD, PhD, FCAP				mat-nna	jam-son
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person Nailed It: How to Select and Track Meaningful Metrics in Your Lab M2260 \| Informatics \| 1.00 CME Credit	M2260	Nailed It: How to Select and Track Meaningful Metrics in Your Lab	1.00 CME Credit	Are you stuck in a rut measuring the same metrics in your lab year after year? Do you long for a more effective way to display and analyze your metrics? If you answered “yes,” please join us as we review the characteristics of meaningful metrics and different ways to display and report your data. This active course will allow you to practice defining, analyzing, and reporting metrics within your lab and to your organization in small peer groups. This course is geared toward new-in-practice or new-to-leadership roles, such as section director/technical supervisor, but open to all who enjoy quality assurance and subscribe to continuous improvement.	Jerome Y. Cheng, MD Liron Pantanowitz, MD, MHA, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Informatics	Jerome Y. Cheng, MD	Liron Pantanowitz, MD, MHA, FCAP				jer-eng	lir-itz
Grow as a Leader	GAL3	Sunday, October 9, 2022, 1:00 PM - 2:15 PM \| In-Person, Virtual Sweating Through PPE: Make Professional Practice Evaluation Less of a Workout R2209 \| Laboratory Medical Direction \| 1.00 CME Credit	R2209	Sweating Through PPE: Make Professional Practice Evaluation Less of a Workout	1.00 CME Credit	Join the experts for lunch! Discuss our struggles when creating and conducting meaningful professional practice evaluations (PPE) of pathologists and scientists in our lab. Realize it is okay to be anxious and be open to sharing our experiences and what-not-to-dos. If you’ve wondered, “What and how much should we evaluate?” and “Should the evaluation of a new-in-practice pathologist differ from a mid-career or senior pathologist?” to meet accreditation requirements, then this round table is for you! Attendees will walk away from this session with tips and tools for constructing a meaningful and balanced PPE program for their practice, including those for initial (focused), ongoing, and remedial evaluations.	Cynthia Delgado, MD Dina N. Greene, PhD, DABCC Stephen P. Richmond, MD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	01:00 PM	10/09/2022 01:00 PM	02:15 PM		Sunday, October 9, 2022, 1:00 PM - 2:15 PM	Laboratory Medical Direction	Cynthia Delgado, MD	Dina N. Greene, PhD, DABCC	Stephen P. Richmond, MD			cyn-ado	din-ene	ste-ond
Get a Strong Start	GASS1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Lemonade out of Lemons: Adjustments to Difficult Inspection Encounters M2250 \| Laboratory Medical Direction \| 1.00 CME Credit	M2250	Lemonade out of Lemons: Adjustments to Difficult Inspection Encounters	1.00 CME Credit	Would you say your last laboratory inspection was a lemon? Are you still carrying the wounds? In this session, the faculty will present difficult inspection scenarios and offer insights, recommendations, and strategies for navigating these difficult inspections. More importantly, the faculty will facilitate the discussion of sharing techniques designed to avoid adverse situations during future inspections. The faculty will also provide practical information from the collective experience of team leaders and laboratory directors focused on optimizing the inspection experience. Attendees will find communication techniques, such as effective listening and separating the people from the problem, invaluable in their everyday dealing with laboratory professionals, clinicians, administrators, and patients. This course is designed to benefit both the experienced and novice team leaders and lab directors.	Dina N. Greene, PhD, DABCC Mahmoud A. Khalifa, MD, PhD	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Laboratory Medical Direction	Dina N. Greene, PhD, DABCC	Mahmoud A. Khalifa, MD, PhD				din-ene	mah-ifa
Broaden Your Influence	BYI	Monday, October 10, 2022, 7:30 AM - 8:30 AM \| In-Person Succession Planning...Because Life Happens M2287 \| Laboratory Medical Direction \| 1.00 CME Credit	M2287	Succession Planning...Because Life Happens	1.00 CME Credit	Succession planning is a critical tool in securing leadership continuity, recruitment, staff retention, and overall job enrichment and satisfaction. In the laboratory industry, succession planning is often treated as an after-thought or not considered at all in the business and human resources strategic planning. In this course, the faculty will help define this critically important activity and provide participants at all levels of their career, especially those interested in leadership growth, with the tools needed to succeed in the establishment, implementation, and communication of a comprehensive corporate succession plan.	Jesse L. Kresak, MD, FCAP Ericka J. Olgaard, DO, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	07:30 AM	10/10/2022 07:30 AM	08:30 AM		Monday, October 10, 2022, 7:30 AM - 8:30 AM	Laboratory Medical Direction	Jesse L. Kresak, MD, FCAP	Ericka J. Olgaard, DO, FCAP				jes-sak	eri-ard
		Monday, October 10, 2022, 11:30 AM - 12:30 PM \| In-Person Unmasking the Post-Pandemic Pathologist: How to Succeed More While Working LESS M2229 \| Laboratory Medical Direction \| 1.00 CME Credit	M2229	Unmasking the Post-Pandemic Pathologist: How to Succeed More While Working LESS	1.00 CME Credit	Drivers of burnout heightened in the pandemic with 30% of health care workers considering leaving medicine, more than 50% feeling burned out, and 60% feeling harmed by the stress. We do not have to wait for medicine to change to feel better. We can feel better now by learning enduring coaching skills that can lead to immediate relief no matter the crisis. A randomized clinical trial published in JAMA (2019) demonstrated that professional coaching reduced emotional exhaustion by 20%, decreased burnout by 17%, and improved quality of life and resilience. In this course, the audience will learn practical self-coaching tools that can be put in place today to feel better now. This interactive course allows learners to apply the coaching tools to real-life vignettes on the most common issues facing the post-pandemic physician: feeling overwhelmed, time scarcity, feeling devalued, and dealing with difficult people. Learners will be empowered with practical strategies to achieve more by working LESS.	Jesse L. Kresak, MD, FCAP Ericka J. Olgaard, DO, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	11:30 AM	10/10/2022 11:30 AM	12:30 PM		Monday, October 10, 2022, 11:30 AM - 12:30 PM	Laboratory Medical Direction	Jesse L. Kresak, MD, FCAP	Ericka J. Olgaard, DO, FCAP				jes-sak	eri-ard
Grow as a Leader	GAL1	Monday, October 10, 2022, 2:30 PM - 3:30 PM \| In-Person How to Create More Success by Working LESS: Small Group Coaching to Empower You R2206 \| Laboratory Medical Direction \| 1.00 CME Credit	R2206	How to Create More Success by Working LESS: Small Group Coaching to Empower You	1.00 CME Credit	Join the experts for lunch! Exchange information about enduring coaching skills and share solutions in a relaxed setting with your peers. Learn to improve your ability to identify solutions to challenging scenarios through interactive sessions.	Chad D. Galderisi, DO, FCAP Shane David Basil Smith, MD	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	03:30 PM		Monday, October 10, 2022, 2:30 PM - 3:30 PM	Laboratory Medical Direction	Chad D. Galderisi, DO, FCAP	Shane David Basil Smith, MD				cha-isi	sha-ith
Broaden Your Influence	BYI	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Coping With Labor Shortages – Key Solutions to Create Change S2202 \| Leadership \| 1.50 CME Credit	S2202	Coping With Labor Shortages – Key Solutions to Create Change	1.50 CME Credit	Labor shortages of both pathologists and a wide range of laboratory staff are becoming a commonplace occurrence in laboratories. Labor shortages create direct adverse effects upon laboratory teams and laboratory service levels. Both society-wide recent trends in labor dynamics and certain health care-specific labor dynamics, are now impacting most laboratories. In this session, there will be discussion of creative approaches for strengthening staff retention and addressing labor shortages. These approaches will include low-cost, commonsense changes that can be readily implemented in your practice. Strategies for collaboration between physicians and hospital administration will also be highlighted. Attendees will engage in small group discussions to collaborate on ideas for change and improvement.	Karim E. Sirgi MD, MBA, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Leadership	Karim E. Sirgi MD, MBA, FCAP					kar- md
Grow as a Leader	GAL4	Monday, October 10, 2022, 9:30 AM - 10:30 AM \| In-Person Train How You Will Practice: Strategies for Becoming a Great New-in-Practice Pathologist S2026 \| Leadership \| 1.50 CME Credits	S2026	Train How You Will Practice: Strategies for Becoming a Great New-in-Practice Pathologist	1.50 CME Credits	The transition from junior member to “new-in-practice pathologist” can be a time of stress and great change. This workshop specifically targets CAP junior members, with a goal of achieving successful independent practice, focusing on five specific areas: 1) determining the proper type of workplace for career goals (academic versus private, and group structure); 2) building skills to keep up with real-life case volume; 3) developing interpersonal skills needed for practice success; 4) establishing management and leadership skills; and 5) developing resilience in taking on new responsibilities with receptiveness to on-the-job training. The faculty will utilize small group team-based learning to aid trainees in establishing practices and habits for career success. The interactive learning will be led by new-in-practice faculty mediators from diverse practice settings, ranging from private practice to academic settings.	Christina A. Arnold, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	09:30 AM	10/10/2022 09:30 AM	10:30 AM		Monday, October 10, 2022, 9:30 AM - 10:30 AM	Leadership	Christina A. Arnold, MD, FCAP					chr-old
Get a Strong Start	GASS1	Monday, October 10, 2022, 11:30 AM - 12:30 PM \| In-Person Make Change Happen: Don’t Let It Happen to You! M2224 \| Leadership \| 1.00 CME Credit	M2224	Make Change Happen: Don’t Let It Happen to You!	1.00 CME Credit	The current state of health care is mandating consolidation and integration of practices and laboratories and requiring pathologists to change organizational structures, test menus, and practice patterns to provide value and support. The scope and rapidity of these changes have been heightened in the setting of COVID, are unsettling and disruptive to physicians and staff, and can lead to workplace conflicts and unusually large numbers of resignations. The faculty do not anticipate that this will slow down in the near future. It is important for pathologists who will lead and be part of these changes to be cognizant of the impact of change and how they might manage and facilitate the process to minimize disruption and maximize outcomes. The faculty will discuss the challenges and solutions that others have implemented and will provide guidance to smooth the way to harmony.	Christina A. Arnold, MD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	11:30 AM	10/10/2022 11:30 AM	12:30 PM		Monday, October 10, 2022, 11:30 AM - 12:30 PM	Leadership	Christina A. Arnold, MD, FCAP					chr-old
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person, Virtual Setting Career Direction: Using Personal Leadership to Ignite the Flame and Keep it Going M2025 \| Leadership \| 1.00 CME Credit	M2025	Setting Career Direction: Using Personal Leadership to Ignite the Flame and Keep it Going	1.00 CME Credit	Your ship may have set sail, but is your career headed in the right direction? It is never too early or too late to set career direction and consider your professional legacy. In this course, the faculty will explore the concepts of meaning in work and values and how they relate to physician engagement and burnout. Come prepared to do some self-reflection! You will learn practical personal leadership strategies that set direction for your career. You will identify your great work—the work that makes you feel energized, define professional values, and discover your passions. This work sets the stage for a fulfilling career. Everyone can use these strategies, especially leaders and mentors, as they guide others in their journeys as pathologists.	Jennifer Fralick Christina S. Kong, MD, FCAP	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Leadership	Jennifer Fralick	Christina S. Kong, MD, FCAP				jen-lic	chr-ong
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person What is Your Why, and How Do You Do It: Identifying the Spark and Strategies To Keep the Flame Going R2223 \| Leadership \| 1.00 CME Credit	R2223	What is Your Why, and How Do You Do It: Identifying the Spark and Strategies To Keep the Flame Going	1.00 CME Credit	Join the experts for lunch! To be fulfilled as pathologists we need to understand our why, but have you ever contemplated your why? In this round table, we will explore our experience with understanding our why. Then, we will consider how we make time for our great work by sharing strategies and identifying solutions to challenges and barriers that keep us from our great work.	Juanita J. Evans, MD, FCAP Lauren King, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Leadership	Juanita J. Evans, MD, FCAP	Lauren King, MD, FCAP				jua-ans	lau-ing
		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM \| In-Person Neighborhoods Matter: Identifying Spatial Biomarkers in the Tumor Microenvironment M2208 \| Leadership \| 1.00 CME Credit	M2208	Neighborhoods Matter: Identifying Spatial Biomarkers in the Tumor Microenvironment	1.00 CME Credit	Tumors are composed of many cell types, and for some tumors, the most dominant cell type is not the malignant cell. Immunotherapy has demonstrated that clinically relevant molecular properties of a tumor are a function of interactions among the varying cell types in the tumor microenvironment, and not exclusively intrinsic to the malignant cells. Advances in highly multiplexed imaging are enabling single cell resolution of cell type heterogeneity of the tumor microenvironment in a spatial context. The faculty will review state of the art technologies in multiplexed in situ imaging, methods for computational analysis of multiplexed in situ images, and identification of spatial biomarkers.	Moira P. Larsen, MD, MBA, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	11:00 AM	10/11/2022 11:00 AM	12:00 PM		Tuesday, October 11, 2022, 11:00 AM - 12:00 PM	Leadership	Moira P. Larsen, MD, MBA, FCAP					moi-sen
Keep Abreast of Innovation	KAI2	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Understanding NGS and Interpreting Reports for Oncologic Pathology S2037 \| Leadership \| 1.50 CME Credits	S2037	Understanding NGS and Interpreting Reports for Oncologic Pathology	1.50 CME Credits	In this course, the faculty will provide a detailed description of informatics resources and databases used for tertiary data analysis, including interpretation and reporting of germline and somatic next-generation sequencing (NGS) assays. These resources include external data sources such as population, disease, and functional databases as well as internal variant databases maintained by the testing laboratory. The faculty will also discuss guidelines by the Association for Molecular Pathology and American College of Medical Genetics and Genomics to aid interpretation. As the size of NGS assays expand and big data analysis experiences a bottleneck at interpretation, the potential to use machine learning for improved variant filtration and ranking is being explored. Finally, the faculty will also discuss the impact of informatics in clinical decision making and the importance of training pathologists in using these resources appropriately. This course is cosponsored by the Association for Molecular Pathology.	Sarah M. Bean, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Leadership	Sarah M. Bean, MD, FCAP					sar-ean
		Sunday, October 9, 2022, 11:30 AM - 12:30 PM \| In-Person Gene Editing: A Primer for Practicing Pathologists M2114 \| Leadership \| 1.00 CME Credit	M2114	Gene Editing: A Primer for Practicing Pathologists	1.00 CME Credit	Gene-editing technology is being investigated in the clinical setting for treatment of inherited diseases, infectious diseases, and cancer. In addition to the scientific and medical issues related to gene-editing technology, there are ethical, financial, and regulatory issues that also must be considered. As gene-editing-based therapies expand into the clinical setting, pathologists must be educated on the topic. This course serves to both educate pathologists on gene-editing technologies and serve as a point of initial discussions in areas of gene-editing science, clinical therapy, and regulatory issues associated with gene-editing-based therapies, as these therapies are eventually introduced into clinical practice.	Sarah M. Bean, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	11:30 AM	10/09/2022 11:30 AM	12:30 PM		Sunday, October 9, 2022, 11:30 AM - 12:30 PM	Leadership	Sarah M. Bean, MD, FCAP					sar-ean
		Saturday, October 8, 2022, 7:30 AM - 8:30 AM \| In-Person, Virtual Genomic Pathology101: An Interactive Workshop S2027 \| Microbiology \| 1.50 CME Credits	S2027	Genomic Pathology101: An Interactive Workshop	1.50 CME Credits	Genomic testing is being integrated into pathology practice. From selecting the appropriate samples for testing to integrating findings into clinical reports, all pathologists need to understand genomic assays. The faculty will review introductory principles related to testing of tumor tissue including selection of samples and interpretation of results including the potential for detecting relevant germline variants. Using a case-based, interactive approach, participants will work in teams to answer clinically relevant questions integrating actual patient testing reports and utilizing online genomic pathology tools. If available, participants should bring a tablet or laptop (preferred). The faculty will provide directly applicable knowledge and skills for pathologists at all levels and practice settings. Members of the Training Residents in Genomics (TRIG) Working group committee at the Association of Pathology Chairs, experts in molecular pathology, medical education, and genetic counseling have developed this session.	Sylvia K. Plevritis, PhD	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	08:30 AM		Saturday, October 8, 2022, 7:30 AM - 8:30 AM	Microbiology	Sylvia K. Plevritis, PhD					syl-tis
Keep Abreast of Innovation	KAI2	Saturday, October 8, 2022, 7:30 AM - 9:00 AM \| In-Person OMG! MSI, MMR IHC, NGS, or TMB for Checkpoint Inhibitor Treatment Screening: An Overview of the CAP Guideline on Mismatch Repair and Microsatellite Instability Testing S2166 \| Molecular Genetics \| 1.50 CME Credits	S2166	OMG! MSI, MMR IHC, NGS, or TMB for Checkpoint Inhibitor Treatment Screening: An Overview of the CAP Guideline on Mismatch Repair and Microsatellite Instability Testing	1.50 CME Credits	Checkpoint inhibitors are associated with durable (more than 12 months) treatment responses in patients with advanced cancers. This therapeutic approach is also associated with severe toxicities and side effects. The accurate identification of patients most likely to respond to this approach is therefore crucial in the clinical laboratory. In 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the immune checkpoint inhibitor, pembrolizumab, for patients with any advanced solid tumor malignancy that is MSI high or MMR deficient. The FDA did not specify which specific assay should be used. Faculty will summarize the benefits and limitations of different laboratory assays, including IHC, PCR-based microsatellite instability, microsatellite instability derived from next-generation sequencing, and tumor mutation burden derived from next-generation sequencing. Some of these assays have tumor-specific performance characteristics. Faculty will discuss the evidence-based recommendations from the CAP MMR/MSI guideline, including areas the committee identified as requiring further study.	Vera Paulson, MD, PhD Cecilia Yeung, MD, FCAP	In-Person	Saturday, October 8, 2022	10/08/2022	07:30 AM	10/08/2022 07:30 AM	09:00 AM		Saturday, October 8, 2022, 7:30 AM - 9:00 AM	Molecular Genetics	Vera Paulson, MD, PhD	Cecilia Yeung, MD, FCAP				ver-son	cec-ung
Grow as a Leader	GAL3	Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Selecting the Right Tool for the Job: Practical Considerations for Application of Molecular Diagnostics Methods in Surgical Pathology S2165 \| Molecular Genetics \| 1.50 CME Credits	S2165	Selecting the Right Tool for the Job: Practical Considerations for Application of Molecular Diagnostics Methods in Surgical Pathology	1.50 CME Credits	Multiple technologies exist to evaluate molecular alterations across tumors. They can overlap in their ability to provide information about diagnostic, therapeutic, and prognostic strategies in oncology. Selecting the most appropriate testing modality may be challenging, and understanding the indications and limitations of different molecular tests in clinical practice is critical to interpretation and appropriate patient care. This course will provide an overview of commonly used and emerging molecular techniques, capabilities and indications for interrogating different types of genetic alterations, compare advantages and limitations, and discuss when they may be complementary to one another. These concepts will be reinforced with examples of molecular analysis from a variety of solid tumors. Faculty will also discuss applications of emerging molecular testing approaches and strategies for interpretation and reporting of molecular results.	Allison M. Cushman-Vokoun, MD, PhD, FCAP Wayne W. Grody, MD,PhD	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Molecular Genetics	Allison M. Cushman-Vokoun, MD, PhD, FCAP	Wayne W. Grody, MD,PhD				all-oun	way-ody
Get a Strong Start	GASS3	Saturday, October 8, 2022, 9:30 AM - 10:30 AM \| In-Person, Virtual Detection of Alzheimer's Disease Pathology in the Living Patient: What Combination of Plasma Biomarkers Works Best? M2207 \| Molecular Oncology \| 1.00 CME Credit	M2207	Detection of Alzheimer's Disease Pathology in the Living Patient: What Combination of Plasma Biomarkers Works Best?	1.00 CME Credit	Alzheimer’s disease (AD) is an evolving medical nightmare with no end in sight. Learning to detect and treat this disease early is vital to the lifespan of the patient. During this session, the faculty will discuss plasma biomarker tests that are proven to be helpful in the detection of amyloid pathology and tau pathology. In addition, published studies examining the accuracy of detecting AD using plasma biomarker tests in individuals who are mildly cognitively impaired following clinical evaluation will be covered. This session is based on extensive expertise in the development, validation, and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies.	Brent T. Tan, MD, PhD, FCAP	In-Person, Virtual	Saturday, October 8, 2022	10/08/2022	09:30 AM	10/08/2022 09:30 AM	10:30 AM		Saturday, October 8, 2022, 9:30 AM - 10:30 AM	Molecular Oncology	Brent T. Tan, MD, PhD, FCAP					bre-tan
		Sunday, October 9, 2022, 7:30 AM - 9:00 AM \| In-Person How is my Payment Determined for Pathology Services? M2171 \| Molecular Oncology \| 1.00 CME Credit	M2171	How is my Payment Determined for Pathology Services?	1.00 CME Credit	Learn about concepts of current procedural terminology (CPT) coding and payment for services on the Medicare Physician Fee Schedule (PFS). In this highly interactive course, faculty will provide a historical introduction and overview of how current coding and billing practices were developed, and how the Centers for Medicare & Medicaid Services (CMS) values codes on the PFS. They will discuss how CPT codes are modified and the steps involved. Faculty will also cover aspects of payment policy (eg, National Correct Coding Initiative) and the role of existing process in the new value-based payment system. As a result of attending this course, participants will better comprehend the changing payment and regulatory environment, anticipate future trends, and better adapt their practice to current reimbursement trends.	Richard L. Haspel, MD, PhD, FCAP Phillip Michaels, MD, FCAP Nikoletta Sidiropoulos, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	07:30 AM	10/09/2022 07:30 AM	09:00 AM		Sunday, October 9, 2022, 7:30 AM - 9:00 AM	Molecular Oncology	Richard L. Haspel, MD, PhD, FCAP	Phillip Michaels, MD, FCAP	Nikoletta Sidiropoulos, MD, FCAP			ric-pel	phi-els	nik-los
		Monday, October 10, 2022, 2:30 PM - 4:00 PM \| In-Person Are You Working Harder and Going Broke: Tools to Drive Practice Profitability S2292 \| Molecular Oncology \| 1.50 CME Credits	S2292	Are You Working Harder and Going Broke: Tools to Drive Practice Profitability	1.50 CME Credits	The lifeblood of any practice revolves around its ability to collect for services provided and know the true cost of a lab test. Revenue Cycle Management guides the audience through correct data capture with accessioning to the final billing and collection from payors. Attendees will compute contractual adjustments, collection and bad debt rates, and other key metrics from a practice’s financial data. Then compare this to industry standards, which will help them to recognize and thwart trends that will negatively impact their practice. The faculty will use case studies to illustrate the calculation laboratory expenses. Additionally, they will use precise data on direct and indirect costs to tabulate the cost per specific lab test.	Russell R. Broaddus, MD, PhD, FCAP	In-Person	Monday, October 10, 2022	10/10/2022	02:30 PM	10/10/2022 02:30 PM	04:00 PM		Monday, October 10, 2022, 2:30 PM - 4:00 PM	Molecular Oncology	Russell R. Broaddus, MD, PhD, FCAP					rus-dus
		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM \| In-Person The American Board of Pathology: 85 Years of Service to the Public and the Profession P2201 \| Molecular Oncology \| 1.00 CME Credit	P2201	The American Board of Pathology: 85 Years of Service to the Public and the Profession	1.00 CME Credit	Pathology emerged as a specialty in the late 1800s as the value to patient care gained greater appreciation and respect. Pathologists were not considered “equal” in medical practice by their clinical colleagues; however, in 1926 pathologists received significant recognition when the American College of Surgeons revised its standards to require that laboratories be under the direction of MD physicians with special training in pathology and that “all tissue removed at operations shall be examined in the laboratory and reports rendered.” Recognition of pathologists as physicians and pathology as a medical specialty was reinforced in 1935 when a joint committee of the AMA Section on Pathology and the ASCP agreed that a Board of Pathology should be established. In 1936, the ABPath was incorporated in Michigan and approval was granted by the ABMS and the AMA Council on Medical Education. On July 19, 1936, the ABPath met for the first time in Chicago. The growth in specialty medicine and certification boards were the result of advancements in medical science, leading to improvements in patient care. Before the creation of board certification, there was no way to assure the public or the profession that a physician claiming to be a specialist had the requisite skills. Board certification demonstrates that a physician has: 1) completed an extended period of rigorous training and assessment of the knowledge, skills, and professionalism required to practice in a specialty; and 2) passed a secure, comprehensive examination of knowledge and skills. Consistent with rapid changes in medicine and societal expectations, ABPath began issuing time-limited certification in 2006. Diplomates maintain certification by meeting requirements for professionalism, life-long learning, and self-assessment, including longitudinal assessment with ABPath CertLink®, and health and health care improvement activities.	Larissa V. Furtado, MD, FCAP Laura J. Tafe, MD, FCAP	In-Person	Tuesday, October 11, 2022	10/11/2022	07:30 AM	10/11/2022 07:30 AM	09:00 AM		Tuesday, October 11, 2022, 7:30 AM - 9:00 AM	Molecular Oncology	Larissa V. Furtado, MD, FCAP	Laura J. Tafe, MD, FCAP				lar-ado	lau-afe
		Tuesday, October 11, 2022, 1:00 PM - 2:00 PM \| In-Person, Virtual Demonstrating Your Value and Protecting Your Reimbursement in Evolving Quality Payment Models (On-Demand) M2177 \| Neuropathology \| 1.00 CME Credit	M2177	Demonstrating Your Value and Protecting Your Reimbursement in Evolving Quality Payment Models (On-Demand)	1.00 CME Credit	Value-based payment models continue to evolve to include considerations for quality of care, cost, and population health through a set of evidence-based metrics. While demonstrating the value of laboratory medicine to the health system, pathologists must also find quantitative ways to demonstrate their value in newer payment models. Pathologists must report on measures of quality, utilization, and cost, depending on the program or payer. For example, within the Centers of Medicare and Medicaid (CMS) Quality Payment Program, there are two participation pathways that impact an individual’s or group’s Medicare payments. The faculty will provide information to pathologists on how to demonstrate their impact on overall quality and cost to the organization through various quality measures to maximize reimbursement in these payment programs. The faculty will also present an interactive portion to facilitate discussions about the challenges and opportunities related to developing and implementing quality measures for accountability and quality payment program purposes.	Leslie M. Shaw, PhD	In-Person, Virtual	Tuesday, October 11, 2022	10/11/2022	01:00 PM	10/11/2022 01:00 PM	02:00 PM		Tuesday, October 11, 2022, 1:00 PM - 2:00 PM	Neuropathology	Leslie M. Shaw, PhD					les-haw
		Sunday, October 9, 2022, 9:30 AM - 10:30 AM \| In-Person Early Detection of Lung Cancer: Radiology-Pathology Correlation M2212 \| Practice Finance \| 1.00 CME Credit	M2212	Early Detection of Lung Cancer: Radiology-Pathology Correlation	1.00 CME Credit	Recent literature shows that low-dose CT screening has significantly increased the detection of stage I lung cancer and reduced lung cancer mortality. This finding has led to the increased tissue sampling of smaller nodules detected by radiology, leading to several challenges encountered on microscopic analysis. With the World Health Organization (WHO) fifth edition of Thoracic Tumors and the Internatinoal Association for the Study of Lung Cancer Pathology Committee recommendations, accurate histologic typing and triaging of the smaller biopsy samples have become increasingly complex. In this course, the faculty will present the radiological characteristics of lung nodules <2 cm along with the pathology correlation. In addition, faculty will offer guidance using the most recent recommendations provided by the WHO classification especially in small biopsies.	Jonathan Myles, MD, FCAP Mark S. Synovec, MD, FCAP	In-Person	Sunday, October 9, 2022	10/09/2022	09:30 AM	10/09/2022 09:30 AM	10:30 AM		Sunday, October 9, 2022, 9:30 AM - 10:30 AM	Practice Finance	Jonathan Myles, MD, FCAP	Mark S. Synovec, MD, FCAP				jon-les	mar-vec
Grow as a Leader	GAL1	Sunday, October 9, 2022, 2:30 PM - 4:00 PM \| In-Person, Virtual Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing M2183 \| Practice Finance \| 1.00 CME Credit	M2183	Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing	1.00 CME Credit	Most lung cancer patients are diagnosed at an advanced stage by minimally invasive techniques that include small biopsies and cytology specimens. Potential challenges for diagnosis and biomarker testing can arise in these limited volume specimens. Therefore, judicious triaging in an effort to maximize the information one can obtain on these small specimens is important. With rapid advances in predictive and prognostic biomarker testing in lung cancer, pathologists are at the forefront of triaging these small specimens for diagnosis as well as performing and interpreting clinically needed biomarker testing. Hence, an understanding of the best practices to ensure adequate collection and handling of small specimens is critical. This course is designed for practicing pathologists, molecular laboratory personnel, and pathology trainees. The faculty will address various challenges in lung cancer diagnosis and the ever-expanding list of biomarker testing targets for small biopsy and cytology specimens, as well as discuss strategies to improve specimen collection and handling with a focus on therapeutic implications.	Chiraag N. Gangahar, MD, FCAP Susan B. Kern, MD, FCAP	In-Person, Virtual	Sunday, October 9, 2022	10/09/2022	02:30 PM	10/09/2022 02:30 PM	04:00 PM		Sunday, October 9, 2022, 2:30 PM - 4:00 PM	Practice Finance	Chiraag N. Gangahar, MD, FCAP	Susan B. Kern, MD, FCAP				chi-har	sus-ern
		Monday, October 10, 2022, 1:00 PM - 2:00 PM \| In-Person, Virtual Challenges in Diagnosis and Biomarker Testing of Lung Cancer Using Cytology and Small Biopsy Specimens V2296 \| Process and Outcome Improvement \| 1.50 CME Credits	V2296	Challenges in Diagnosis and Biomarker Testing of Lung Cancer Using Cytology and Small Biopsy Specimens	1.50 CME Credits	This video microscopy will expand upon the companion course, Updates on the Use of Cytology and Small Biopsy Specimens for Lung Cancer Diagnosis and Biomarker Testing, on updates for the use of cytology and small biopsy specimens for lung cancer diagnosis and biomarker testing. The faculty will identify potential diagnosis and biomarker testing challenges that could arise with limited samples. Pathologists need to be at the forefront of rapid advances in lung cancer diagnosis and predictive biomarker testing.	Rebecca L. Johnson, MD, FCAP	In-Person, Virtual	Monday, October 10, 2022	10/10/2022	01:00 PM	10/10/2022 01:00 PM	02:00 PM		Monday, October 10,

Paths